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Intellectual disability (ID) is categorised by a significant reduction in cognitive function 
and adaptive abilities that begin in childhood. ID is part of a heterogeneous group of 
neurodevelopmental conditions associated with impairment in developmental domains 
and a cause of particularly adverse socioeconomic impact worldwide. There have been 
many recent advances in identifying causative genetic mutations in previously 
unexplained ID cases. With these advances comes an increasing demand for 
understanding mechanisms underpinning these pathogenic pathways. In this PhD thesis, 
I have studied rare monogenic novel neurodevelopmental disorders associated with ID. 
The objective of the thesis was to model a subset of mutations associated with novel 
neurodevelopmental disorders in mice to demonstrate a causal link between mutation 
and phenotype and to further understand the mechanisms by which these mutations 
result in human neurodevelopmental disorders. In order to achieve this, I adopted a 
multi-phase approach. Firstly, I designed a phenotyping platform, by combining 
behavioural and cognitive tests with morphometric brain analysis and genome-wide 
transcriptional analysis. I then used this approach to study KPTN-related syndrome, a 
novel developmental disorder that to date has not been characterised in mice, 
successfully recapitulating the main phenotypes described in the patients. Moreover, I 
gained further insight into the underlying pathogenic mechanisms associated with the 
disorder, opening the possibility of a therapy that could treat some aspects of cognitive 
and morphological impairments identified in the patients with KPTN-related syndrome. 
Lastly, I determined whether such an approach could be scaled-up to study multiple novel 
neurodevelopmental disorders, each with a mutation associated with a haploinsufficient 
novel neurodevelopmental disorder. I identified specific phenotypes for each of the four 
mouse lines under investigation, providing a platform for comparison between several 
developmental disorders. These refinements contributed to a larger five-year project 
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Chapter 1.  Introduction to intellectual disability 
1.1 Preface 
In my PhD thesis, I have studied rare monogenic novel neurodevelopmental disorders 
associated with intellectual disability (ID). There have been many recent advances in 
identifying causative genetic mutations in previously unexplained intellectual disability 
cases. However, there is still much to learn about the affected genes and the associated 
pathogenic pathways. In the context of this thesis, I consider as novel disorders those that 
have been identified after the start of my PhD, from 2014 onwards. 
In this introductory Chapter, I provide a brief background of ID, focusing on genetic causes. I 
then provide an account of the advancements in genetic diagnosis in recent years and how 
they have shaped our understanding of the causes of ID. Finally, I outline some similarities 
and differences in brain ontology between rodents and humans, which are relevant for 
modelling human disorders with affected brain development in rodents.  
I introduce mouse modelling of ID in Chapter 3, describe the use of mouse models to study 
rare recessive inherited mutations in Chapter 4 and de novo dominant mutations in Chapter 
5. Chapter 6 contains a concluding discussion on the main findings of the thesis and outlines 
future areas of research.   
 
1.2 Neurodevelopmental disorders and intellectual disability 
Neurodevelopmental disorders (DD) are a heterogeneous group of conditions characterised 
by impairment in developmental domains, such as cognitive, language, social, and motor, 
and are associated with a complex set of endophenotypes (Levitt et al., 2004). The shared 
onset of pathologies in these disorders occurs during the period of maturation and 
development, which includes both prenatal and postnatal stages (Zoghbi, 2003). The most 
commonly diagnosed neurodevelopmental disorders, based on the Diagnostic and Statistical 
Manual of Mental Disorders Fifth Edition (DSM-5), include autism spectrum disorder (ASD), 
Chapter 1  
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attention deficit hyperactivity disorder (ADHD), and intellectual disability (ID) (American 
Psychiatric Association, 2013). ID, or developmental cognitive impairment, is a 
heterogeneous group of neurodevelopmental disorders categorised by a significant 
reduction in cognitive function and adaptive abilities that begin in childhood (Ropers, 2010; 
Salvador-Carulla & Bertelli, 2008). The term adaptive ability implies the capacity to carry out 
daily activities appropriate to the individual’s age group. 
ID is commonly assessed using IQ tests, such as the Wechsler Intelligence Scale for Children 
(WISC) or Adults (WAIS), adjusted for age and cultural background. Individuals with IQ 
scores of 70 or less (2 or more standard deviations below the general population mean 
score of 100) are diagnosed with ID (Ropers, 2010; Vissers et al., 2016). Based on DSM-5, ID 
was classified into four severity categories depending on the IQ score of the individual: mild, 
moderate, severe, and profound. However, studies often use a simplified classification of 
mild (IQ 50-70) and severe (IQ<50) ID (Chelly et al., 2001; Kaufman et al., 2010). Moreover, 
the updated 5th DSM edition has moved away from the specific IQ score categorisation, 
keeping the classifications but placing more emphasis on adaptive function (American 
Psychiatric Association, 2013).  The reliable diagnosis of ID in children younger than six years 
old is more difficult. Therefore the term global developmental delay (GDD) is used instead.  
GDD is diagnosed when children fail to meet expected developmental milestones. 
Importantly, while many children diagnosed with GDD later meet ID criteria, they are 
diagnostically distinct (Numis and Sankar, 2016).  
ID patients have an increased risk of developing comorbidities, with an estimated 30% of ID 
patients also having behavioural and psychiatric conditions (Cooper et al., 2007; Einfeld and 
Tonge, 1996; White et al., 2005). Due to the presence of other clinical features or 
comorbidities, ID can be further divided into syndromic (S-ID) and nonsyndromic (NS-ID) 
(American Psychiatric Association, 2013). The purist definition of NS-ID is when ID is the sole 
clinical feature. However, it is often difficult to identify other features in ID patients due to 
masking by the cognitive impairment or the subtlety of the other features. This often blurs 
the distinction between the NS- and S-ID. Moreover, the causes of these two subgroups 
often overlap, for example, certain genes associated with NS-ID have also been linked to S-
ID cases (Kaufman et al., 2010). Since NS-ID has ID as its only manifestation, many studies 
Chapter 1  
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have focused on studying NS-ID as means of understanding processes involving learning and 
memory and cognition in general (Kaufman et al., 2010). 
 
1.3 ID demographics  
ID has a worldwide occurrence of 1-2%, with a higher prevalence of ID reported in lower 
socioeconomic groups and developing countries, and is diagnosed more frequently in males 
(Boyle et al., 2011; Van Naarden Braun et al., 2015; Maulik et al., 2011; Durkin, 2012). The 
former discrepancies are mainly explained by environmental factors, while the latter sex 
bias may in part be explained by the X-linked causes of ID (Boyle et al., 2011; Emerson, 
2007). Due to its worldwide prevalence and chronic nature, ID is a significant socioeconomic 
burden and is listed by the International Classification of Diseases (ICD10) as the most costly 
of all diagnoses (Honeycutt et al., 2003; Polder et al. 2002). The average lifetime cost per 
person with ID is $1-2 million in Europe and the United States, with an estimated total 
lifetime cost of $51.2 billion in the US for people born in 2000 (Honeycutt et al., 2003).  
The occurrence of severe ID is relatively stable in the population (0.3–0.5%) worldwide, 
while the reported prevalence of mild ID is higher but more variable, as it is influenced by 
external factors such as access to education and healthcare and is less clear-cut to identify 
(Chelly et al., 2001; Kaufman et al., 2010). Severe ID is often associated with dysmorphic 
features and a higher rate of behavioural abnormalities, which is why it is typically identified 
earlier in childhood than mild ID, which may not be diagnosed until school age (Kaufman et 
al., 2010). ID can either be non-progressive or worsen with age, due to comorbidities and 
challenges of transitioning into adulthood, or improve due to early intervention (Jeste, 
2015).  
1.4 Common causes of ID  
ID and other neurodevelopmental disorders are caused by various environmental and 
genetic factors that affect the development of the nervous system (pre-, peri-, and 
postnatally). ID is the most frequent reason for genetic service referral, but it is important to 
consider both genetic and nongenetic etiologies when performing clinical evaluations 
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(Ehninger et al., 2008; Numis and Sankar, 2016). The environmental factors that cause ID 
include traumatic brain injury, prenatal and postnatal complications such as hypoxemia, 
maternal and childhood infections, exposure to toxic substances (pre or postnatally), 
nutritional deficits, and radiation (Kaufman et al., 2010; Modabbernia et al., 2016). The 
genetic causes are also varied and account for 25-50% of ID cases, proportionally increasing 
with severity (Ehninger et al., 2008). ID has a variable effect on reproductive fitness 
depending on the severity level, which in turn affects the genetic architecture of different ID 
forms. For this reason, severe genetic forms of ID are mainly sporadic (Ehninger et al., 
2008). 
Genetic forms of ID involve chromosomal aneusomies and structural abnormalities, X-
chromosome linked defects and monogenic diseases. Autosomal and X-chromosome 
aneuploidies are typically associated with ID, such as Down syndrome, or trisomy 21, which 
is the most frequent form of ID (Rauch et al., 2006). Overall, chromosomal abnormalities are 
a common cause of ID, accounting for around 15% of diagnosed cases (Michelson et al., 
2011). Since the 1990s, chromosome X has been a focus of attempts to elucidate genetic 
defects linked with ID. This led to the identification of fragile X mental retardation 1 (FMR1) 
gene as the cause of the most common inherited form of ID, fragile X syndrome (Coffee et 
al., 2009; Pieretti et al., 1991; Verkerk et al., 1991). With over 100 identified ID genes linked 
to the X chromosome, the discovery of X-linked ID genes is now approaching a plateau, but 
many more autosomal ID genes remain to be discovered (Lubs et al., 2012; Vissers et al., 
2016). Current genomic approaches have enabled the identification of previously 
overlooked but highly frequently mutated ID genes ARID1B and DDX3X, each accounting for 
more than 1% of ID patients (Blok et al., 2015; Santen et al., 2012).   
Advancements in genomic microarray technologies enabled the discovery of pathogenic 
genomic microdeletions and duplications associated with ID. These copy number variants 
(CNVs) were previously not resolved by routine chromosome analysis (Albertson and Pinkel, 
2003; Grayton et al., 2012; Wagenstaller et al., 2007). The human genome contains around 
12% of CNV, which contribute to the variation in individual genomes and not all of which are 
pathogenic (Iafrate et al., 2004; Redon et al., 2006). However, many de novo autosomal 
variants and X-linked CNVs have now been identified as causative of many ID-associated 
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disorders, as well as being predisposing factors for neuropsychiatric conditions (Itsara et al., 
2009; Mefford et al., 2009).  While autosomal-recessive ID forms are not as prevalent in 
outbred populations, they are the major cause of ID in populations with high rates of 
consanguinity (de Ligt et al., 2012; Musante and Ropers, 2014). Consanguineous marriage is 
defined in a clinical genetic setting as a marriage between two closely related individuals 
(second cousins or closer), with an inbreeding coefficient (F) equal or higher than 0.0156 
(Hamamy, 2012). F is a measure of the proportion of the loci with identical gene copies from 
both parents that the offspring from a consanguineous union is expected to inherit.  Such 
families are common in countries belonging to the so-called ‘consanguinity belt’ which 
comprises regions from Morocco to India, with Pakistan having a particularly high 
prevalence. Indeed 62.7% of marriages in Pakistan are consanguineous, around 80% of 
which are between first cousins (Hussain and Bittles, 1998). Children from consanguineous 
unions have an increased risk of autosomal recessive disorders compared to that of the 
general population’s risk (Hamamy et al., 2011). In non-consanguineous populations, the 
recessive variants associated with ID are most frequently sporadic and include cases with 
compound heterozygous mutations (Schuurs-Hoeijmakers et al., 2012; Ten Kate et al., 
2010).  
 
1.5 Genetic diagnosis, past and present, and rare ID cases 
The advancements in our knowledge of genetic causes of ID have been driven by 
advancements in the tools available for genetic diagnosis. Initially, genetic diagnosis relied 
on karyotyping to detect gross chromosome abnormalities, beginning with the discovery of 
trisomy 21 as the cause of Down’s syndrome in 1959 (Lejeune et al., 1959). In the 1970s 
conventional karyotyping became a routine test and allowed for conclusive genetic 
diagnosis in up to 6% of ID cases (Vissers et al., 2016). The advancements in cytogenetic 
chromosome banding technologies and the identification of X chromosome markers 
increased the efficiency of detection of chromosomal abnormalities, leading to the 
identification of genetic causes in multiple ID-associated syndromes such as Prader–Willi 
syndrome (deletion of 15q11-q13) (Butler et al., 1986; Lubs and Ruddle, 1970). The next 
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step forward in diagnostic yield came with the introduction of Sanger sequencing in the 
1970s and the development of targeted fluorescence in situ hybridisation (FISH) in the 
1980s, which together increased the diagnostic yield to 6-10% (Vissers et al., 2016).  
In the 1990s, the shift from radiolabelling to chromogenic Sanger sequencing increased the 
identification of monogenic ID cases. The research at the time largely focused on identifying 
ID causing genes on the X-chromosome due to sex ratio bias and ease of pedigree analysis 
(Tarpey et al., 2009). An example of two success stories of the period included the 
identification of FMR1 in fragile X syndrome and MECP2 in Rett’s syndrome (Amir et al., 
1999; Pieretti et al., 1991; Verkerk et al., 1991). Collectively, X-linked ID genes explain 10% 
of ID in males (Lubs et al., 2012).  
Until the introduction of genomic microarrays at the beginning of this century, the research 
into autosomal causes of ID was lagging behind X-linked causes. Genomic microarrays 
enabled a better resolution and higher diagnostic yield, replacing the former strategies in 
the clinic (Miller et al., 2010). Two routinely used chromosome microarrays were 
comparative genomic hybridisation (CGH) and single-nucleotide-polymorphism (SNP) 
genotyping arrays, which increased the diagnostic yield to 12-23% (Gilissen et al. 2014). For 
recessive forms of ID, homozygosity mapping and high-density SNP microarrays, with 
follow-up Sanger sequencing of candidate genes, facilitated accurate and rapid detection of 
further recessive autosomal causes of ID (Schuurs-Hoeijmakers et al., 2011).  
Sanger sequencing has been used extensively in the last three decades and was used to 
produce the first complete human genome sequence (Collins and McKusick, 2001; Kelavkar, 
2001; Venter et al., 2001). However, the technology has relatively low throughput. The 
introduction of next-generation sequencing (NGS) technologies in the mid-2000s, 
revolutionised the field by providing powerful high-throughput tools for successful 
detection of causative autosomal de novo and recessive variants in unexplained ID cases. 
This increased diagnostic yield to over 30%, with 55–70% in severe ID cases (de Ligt et al, 
2012; Gilissen et al., 2014; Rauch et al., 2012; Vissers et al., 2010; Worthey et al., 2011; Yang 
et al., 2013). Whole-exome and whole-genome sequencing has been used to sequence 
patient–parent trios, successfully identifying causal variants in patients with extreme 
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genetic and phenotypic heterogeneity (Fitzgerald et al., 2015; Gilissen et al., 2014; McRae et 
al., 2017; Rauch et al., 2012; Wright et al., 2015; Vissers et al., 2010).  
Due to the genome-wide approach, NGS technologies can now be applied as a diagnostic 
tool in the absence of clinical phenotyping. Therefore these technologies are well suited for 
discovery of causative single nucleotide de novo variants in individual patients where 
parental DNA is available for comparison, accelerating the discovery of rare as well as 
hypomorphic and less-penetrant variants.  Moreover, with the reduction in sequencing time 
and cost, NGS has now been successfully implemented in a clinical diagnostic setting (Bick et 
al., 2017; de Ligt et al., 2012; Monroe et al., 2016; Rauch et al., 2012; Worthey et al., 2011). 
Overall, there has been a drastic increase in gene discovery in ID-associated disorders over 
time (Fig.1.1). Around 700 genes have now been linked to disorders where ID is the major or 
only feature, with a total number of identified ID genes predicted to exceed 1,000 in the 
next decade (Lubs et al., 2012; Vissers et al., 2016).  




Figure 1.1 Overview of the gene discovery for intellectual disability over time, separated by types 
of inheritance.  Red dashed line represents the introduction of genomic microarrays, while the 
orange dashed line represents the introduction of next-generation sequencing technologies. Figure 
reproduced from Vissers et al., 2016.  
 
1.6 Brain ontology  
The development of the human brain requires a very intricate and tightly regulated set of 
processes, with a plethora of cells proliferating, differentiating, migrating and integrating 
into cohesive circuitry, giving rise to a complex structure with around 85 billion neurons 
(Azevedo et al., 2009). The human brain total volume reaches 1,700mL in adulthood and is 
composed of 80% parenchyma, which is predominantly neurons and glial cells, 10% blood, 
and 10% cerebrospinal fluid (Williams et al., 2008). Glial cells, including oligodendrocytes, 
astrocytes, ependymal cells, and microglia, are 10-15 times more abundant in the brain than 
neurons (Williams and Herrup, 1988). It is therefore not surprising that the complex 
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processes of brain development are highly sensitive to errors and that neurodevelopmental 
disorders have been identified that are associated with each stage of brain development 
(Walsh and Engle, 2010).  
An increased focus on the genetics of neurodevelopment disorders has facilitated an 
understanding of the underlying genes and pathways critical for normal brain development 
(Ehninger et al., 2008; Hu et al., 2014). The consequences of aberrant development 
processes have a wide range of associated phenotypes. For example, aberrant neuronal 
migration is associated with lissencephaly (a brain malformation with a thickening of the 
cortex), defects in neuronal progenitor proliferation is associated with microcephaly 
(significant reduction in head circumference), and aberrant connectivity in the brain has 
been linked to autism (Courchesne, 1997; Forman et al., 2005; Yang et al., 2012). Moreover, 
identical mutations in the same gene can cause different phenotypes due to the 
hypomorphic or less penetrant nature of the variant, as is the case with mutation in 
POMGNT1, which causes muscle-eye-brain disease, but of variable phenotypic severity even 
in related individuals (Diesen et al., 2004; Teber et al., 2008).   
The milestones of brain development have been shown to be conserved between humans 
and rodents, but the processes occur along different timelines: humans have a longer 
period of brain development, which is thought to be associated with the development of a 
larger cortex and a longer postnatal period for fine-tuning and shaping of the brain circuitry 
(Clancy et al., 2000; Clancy et al., 2007; Rice and Barone, 2000; Semple et al., 2013) (Fig.1.2). 
The association between specific behaviours and the development of brain structures and 
circuits are comparable between humans and rodents (Rice and Barone, 2000). Because 
many disorders arise due to defects in the ontogeny of developmental processes and brain 
structures, it is critical when modelling the human developmental conditions in mice to be 
cognizant of differences and similarities in the brain ontogeny between the two species.  
The peak of brain growth and gliogenesis occurs at 36-40 weeks of gestation in humans, 
around the time of birth, and in postnatal days P7-10 in rodents (Bockhorst et al., 2008; 
Catalani et al., 2002; Kriegstein and Alvarez-Buylla, 2009) (Fig.1.2). Cortical neurogenesis, 
the process by which new cortex neurons are made, starts during gestation in both rodents 
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and humans, and can continue up to 2.5 years in humans (although mainly happens during 
gestation) and up to postnatal day (P) 15 in rodents (Babikian et al., 2010; Prins and Hovda, 
2003). Neurogenesis in the hippocampus in both species continues into adulthood, but at a 
much lower rate than during development (Hill et al., 2015; Kitamura and Inokuchi, 2014). 
The brain reaches 90-95% of adult weight by 2-3 years old in children and P20-21 in rodents, 
which is also the time for the peak of myelination (Keshavan et al., 2002). Grey matter, 
consisting of neuronal cell bodies and dendrites and glial cells, initially increase from birth 
and then begins to reduce, with synaptic density reaching a plateau at 12-18 years in 
humans and P34-49 in rodents (Huttenlocher, 1979; Lidow et al., 1991). At this stage, the 
activity-dependent circuitry is being refined. Of note, the timing of changes in grey matter 
volumes tends to be region-specific. For example, grey matter in the frontal lobe reaches 
maximum volume in humans at 11-12 years of age, while the temporal lobe reaches 
maximum size later, at 16-17 years of age (Bansal et al., 2008; Sowell et al., 1999). White 
matter, composed primarily of myelinated axons that connect various grey matter regions, 
follows a different growth trajectory to grey matter, with ongoing myelination and increase 
in white matter volume happening beyond 20 years of age in humans and P60 in mice (Lebel 
and Beaulieu, 2011). 
Due to the cross-species alignment in key brain developmental milestones, with comparable 
brain growth trajectories, rodents have been used extensively as model organisms for 
understanding these developmental processes. In Chapter 2, I will describe the use of 
rodents in the modelling of intellectual disability.  
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Figure 1.2 Brain ontology in humans and mice, including developmental milestones and growth of 
the brain over time. A. Brain growth in humans (solid line) and mice (dotted line), represented by 
the percentage of adult brain weight gain over time (in month units for humans and day units for 
mice). The peak brain growth spurt for humans is around the time of birth (36-40 prenatal weeks), 
while for mice the peak is around postnatal day 7-10. B. Human brain ontology over time with key 
conserved developmental processes: neurogenesis (green) occurs predominantly during prenatal 
stages but may continue up to 2.5 years (postnatal), gliogenesis (blue) peaks around 36-40 prenatal 
weeks, synaptogenesis (orange) peaks around 2 years of age, myelination (purple) is an on-going 
process that happens beyond 20 years of age. C. Equivalent developmental processes in the mouse: 
neurogenesis (green) starts around prenatal day 9.5 and the majority of neurogenesis is completed 
by postnatal day 15, gliogenesis (blue) peaks around postnatal days 7-10, critical period of 
synaptogenesis (orange) occurs during the first three postnatal weeks, peaking during second 
postnatal week, myelination (purple) is an on-going process that happens beyond postnatal day 
20. Of note, the timings outlined above are not exact, as they vary between different brain regions. 
Figure adapted from Klintsova et al., 2013 and Semple et al., 2013. 
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1.7 PhD objective and aims  
The primary objective of my PhD was to model a subset of loss-of-function mutations in 
mice, associated with novel neurodevelopmental disorders, identified in patients from large 
collaborative genetic projects, Deciphering Developmental Disorders (DDD) and Windows of 
Hope (WOH). This was done in order to firstly, demonstrate a causal link between mutation 
and phenotype, and secondly, to further understand the mechanisms by which these 
mutations result in human neurodevelopmental disorders. The mutations I modelled 
include homozygous and compound heterozygous recessive mutations (WOH dataset) and 
de novo dominant heterozygous mutations (DDD dataset).  
I adopted a multi-phase approach to study these novel developmental disorders associated 
with ID. To successfully model human disorders in mice, it is necessary to develop a robust 
approach to testing cognitive and behavioural deficits in the mouse models. I therefore first 
designed a cognitive and behavioural phenotyping strategy for modelling DDs and ID in mice 
(described in Chapter 2). I then employed these behavioural and cognitive strategies, as well 
as morphometric and molecular paradigms, to study one such novel disorder, KPTN-related 
syndrome, in-depth (described in Chapter 3). After that, I determined whether such an 
approach could be scaled up to study multiple novel neurodevelopmental disorders. For 
this, I employed the most robust techniques from the Kptn work to design a behavioural and 
cognitive screening paradigm and employed this to test four further mouse models, each 
with a loss-of-function mutation in a candidate DDD gene (described in Chapter 5). Finally, 
in the concluding discussion of my findings, in Chapter 5, I outline potential future avenues 
of research opened up by this work and the broader implications of the state of the field of 




Chapter 2. Materials and methods 
2.1 Mutant alleles 
All the mouse models were generated at the Wellcome Trust Sanger Institute. The tm1a and 
tm1b alleles contain a splice acceptor (SA), IRES:LacZ:Puro promoter-driven reporter 
cassette, followed by a polyadenylation site (pA) inserted upstream of the critical exon. The 
‘knockout-first’ allele (tm1a) generated by insertion of an IRES:lacZ trapping cassette and a 
floxed promoter-driven neo cassette into an intron of the gene of interest, disrupting gene 
function at the mRNA level by interfering with transcription downstream of the cassette site 
(Skarnes et al., 2011; Testa et al., 2004; White et al., 2013). Tm1a also has the potential to 
be converted to a conditional allele (tm1c) restoring gene activity (Skarnes et al., 2011). 
Tm1b allele was generated by flanking of the critical exon by LoxP sites. In the presence of 
Cre recombinase, the LoxP sites recombine leading to the excision of the critical exon. 
Deletion of this critical exon results in a frameshift and predicted absence of the protein 
product. Zmynd11em1(IMPC)Wtsi model harbouring frame shifting exon-deletion null allele was 
generated using the CRISPR/Cas9 system (Fig.2.1). Mouse models were kept on 
C57BL/6NTac background, apart from Kptntm1a(EUCOMM)Wtsi which was on a mixed C57BL/6B 
background (C57BL/6Brd-Tyr<c-Brd>;C57BL/6Dnk;C57BL/6N;C57BL/6NTac).  








Figure 2.1 Schematic representation of the mutant alleles. (A) Arid1btm1b(EUCOMM)Wtsi and (B) 
Setd1atm1b(EUCOMM)Wtsi are tm1b alleles; (C) Setd5 tm1a(EUCOMM)Wtsi and (D) Kptntm1a(EUCOMM)Wtsi are tm1a; 
(E)  Zmynd11em1(IMPC)Wtsi is CRISPR/Cas9 frame shifting exon-deletion 
 
2.2 Animal husbandry 
Animal husbandry was greatly facilitated by the collaboration of the WTSI Research Support 
Facility staff. The colony managers at the Sanger Institute provided support on colony 
maintenance. Housing and breeding of mice and experimental procedures were carried out 
under the authority of UK Home Office project and personal licenses. All procedures were 




Trust Sanger Institute and the UK Home Office Animals (Scientific Procedures) Act of 1986, 
under UK Home Office PPL 80/2472.  
Standard rodent chow and tap water were available ad libitum, with the exception of the 
touchscreen experiment that required mild food restriction. All test animals were housed 2-
5 mice per cage in mixed-genotype cages, except where stated otherwise and were 
maintained on a 12:12 light-dark cycle with lights on at 7:00 AM, and at ∼20°C and 55% 
humidity. Testing was done during light-hours.  
 
2.3 Mouse behavioural paradigms 
In all assays, the mice were tracked by detection of the mouse’s centre and nose point using 
overhead infrared video cameras and a user-independent automated video tracking 
software Ethovision XT 8.5 (Noldus Information Technology, Wageningen, The Netherlands).  
All experiments were carried out on mice aged 10-22 weeks. The mice were handled for 2-3 
days before the onset of testing. When assays were piloted, wildtype mice of C57BL/6NTac 
genetic background were tested, unless otherwise stated. All mice were habituated to the 
behavioural room in their home cages for ≥ 30 minutes under the same light condition as 
the test. Males were tested unless stated otherwise.  
Determining how many animals should be used in a study is an important factor in 
experimental study design. Sample size calculations reduce the probability of not detecting 
a statistically significant difference between groups even if it truly exists, while minimising 
the unnecessary use of animals (Chow et al., 2008; Kadam and Bhalerao, 2010). The factors 
that influence the estimated sample size are the power, the significance level, the effect size 
of scientific interest and inter-individual variability (Chow et al., 2008; Kadam and Bhalerao, 
2010). The power, which is the probability of finding an effect the study aimed to find, was 
kept at 80% in all calculations. The significance level, the probability that the observed 
differences are likely to be due to chance, was always set at type I error of 5% (P = 0.05). 
The mean and the standard deviation (the variation within a group) were taken from the 




5 when there was no pilot data. Estimated sample size was calculated by either comparing 
the mean (μ) to a reference value that represented ‘no preference’ and thus ‘no learning’; 
or comparing two means from two groups (μ and μB), where the effect size, which is the 
minimum difference between two groups that is clinically significant, was decided based on 
previously published studies. Two-tailed Student’s t-test was used. Power analysis was done 
using online software (Chow et al., 2008). 
I received help in doing some of the assays by members of Team 29 and 156 at the Sanger 
Institute. Genotyping was performed by a specialist team (led by Dr. Ed Ryder), Mouse 
Genetics Programme, using a standard qPCR 
 
2.3.1  Open field 
Mice have an innate tendency to explore novel environments (Seibenhener and Wooten, 
2015). When placed in an open field, measurements such as distance covered, time spent 
moving, and velocity travelled can be used to assess the overall activity and locomotion of 
the mice (Seibenhener and Wooten, 2015). A period of movement was defined when the 
mouse reached a velocity of 2 cm/s over two frames; a period of non-movement was 
defined when velocity was lower than 1.75 cm/s over two frames. Open field can also be 
used to test anxiety-like behaviour, by exploiting the conflicting tendencies of mice to 
spontaneously explore a novel environment and to avoid brightly lit open spaces 
(Kulesskaya and Voikar, 2014).  
In all open field trials, mice were placed in the left corner of the open field arena. Two 
animals were tested in parallel in two separate open fields (74 cm x 74 cm). A centre zone 
was designated with equidistant borders to the open field walls (8 cm) (Fig.2.2). The arenas 







Figure 2.2 Open field arena with the centre and border areas outlined. The arena was divided using 
Ethovision tracking software into north west (NW), north east (NE), south west (SW), and south east 
(SE) and further subdivided into centre vs. border areas (comprising of the following quadrants - left 
top (LT), middle top (MT), right top (RT), left middle (LM), right middle (RM), left bottom (LB), middle 
bottom (MB), right bottom (RB)). The time spent by a mouse in these areas was calculated by the 
automated tracking system and the border quadrants are summed to get the final value for time 
spent in the borders. The arena size was calibrated in Ethovision to match the dimensions of the 
open field (75cm x 75cm).  
 
2.3.1.1 Mice 
In Chapter 4, I tested the mice in the open field under dim (1-3lux), in order to capture the 
general activity and locomotion of mice in a less stressful environment (dim light). The 
duration of each trial was 10 minutes. n=12 male Kptn-/- and n=13 wildtype littermate 
controls were tested in one day, within light-hours.  In Chapter 5, the mice were tested in an 
open field under bright-light (200-300lux) for 15 minutes and the time spent at the borders 
of the arena close to the wall was also analysed in relation to the amount of time spent in 




(wildtype: n=15, mutant: n=15), Arid1b (wildtype: n=12, mutant: n=11), Setd5 (wildtype: 
n=24, mutant: n=12), Zmynd11 (wildtype: n=14, mutant: n=12). 
 
2.3.2  Light/dark box  
Light/dark box assay was used to test for anxiety-related behaviours. The light/dark assay 
exploit the conflicting tendencies of mice to spontaneously explore a novel environment 
and to avoid brightly lit open spaces (Hascoet and Bourin, 2003; Crawley and Goodwin, 
1980). The light/dark box comprises of a brightly-lit light zone (two-thirds of the total area) 
and a dark zone (one-third of the total area).  
The assay was conducted in the dark. After 30 minutes of habituation to the room in their 
home cages, mice were separated into new cages (with clean bedding, food pellets, fun 
tunnel, and some dirty bedding to reduce fighting between the males), two mice per cage. 
Light/dark box was placed into an open field arena, positioned with the help of acrylic lid 
and empty cage to ensure the light/dark box was in the same location in the open field 
arena between experiments (Fig.2.3). The light zone had two spotlights facing down directly 
into the compartment, illuminating the whole of the ‘light’ compartment as evenly as 
possible (lux 300-400). The dark zone was sheltered from the light by a top lid and a door at 
the opening between the two compartments. The mouse was placed in the centre of the 
dark compartment. The door was released at the start of the trial. Trial duration was 10 
minutes, and two mice were tested in parallel. The time spent in each of the compartments, 
as well as the frequency of the transition between zones, were recorded. Preference score 







Figure 2.3 Light/dark box set-up. Image of two open fields with light/dark boxes inside. Each 
light/dark arenas contains a dark zone and light zone. The arena size was calibrated in Ethovision to 
match the dimensions of the open field (75cm x 75cm). 
 
2.3.2.1 Mice 
Light/dark assay exploits the tendency of mice to prefer the dark zone over the light zone, 
with mice experiencing higher levels of anxiety exploring the light zone significantly less, 
spending longer in the dark zone and making fewer transitions into the light zone (Blundell 
et al., 2009; Shum et al., 2005). To calculate the estimated sample size needed to detect a 
difference in mean time spent in the dark zone, the following was used: mean time spent in 
the dark μ = 67.96 (%; wildtype data from Chapter 5), SD= 15.77, effect size = 18-24 (%; 
chosen based on published studies (Blundell et al., 2009; Shum et al., 2005)). The estimated 
sample size was n=7-12 (accounting for an effect size of 18% or 25%: with lower n calculated 
from higher effect size).  
Mice that did not transition into the light zone at all during the duration of the assay thus 
not exploring both areas, were excluded due to the possibility that the preference is due to 
lack of exploration. 
In Chapter 4, n=14 Kptn-/- mice and n=13 wildtype littermate controls were tested, and one 




and remained the dark zone the whole time. In Chapter 5, only two out of the four mouse 
lines were tested: Setd1a mice (n=14 wildtypes and n=11 mutants; none were excluded 
from the final analysis) and Zmynd11 mice (n=14 wildtypes and n=12 mutants; n=2 WT and 
n=1 mutant were excluded due to 0 transitions to light zone). 
 
2.3.3  Object discrimination  
Novel object recognition (NOR) assay relies on rodent’s innate preference for investigating 
the novel over the familiar object (Ennaceur and Delacour, 1988). Longer investigation of 
the unfamiliar object by the animal is indicative of an acquired memory for the familiar 
object.  The NOR pilots (described in Chapter 3) were done under a modified protocol from 
Ennaceur and Delacour (1988) and Tuscher et al. (2015). A modified version of the NOR, 
object displacement (OD),  is a spatial memory task that exploits the natural tendency of 
rodents to explore their environment and show a preference to investigate a moved object 
when compared to a static object (Anderson and O'Mara, 2004; Ricceri et al., 2000; Tuscher 
et al., 2015). OD pilot described in Chapter 3 was based on a protocol from personal 
correspondence with Dr Lukas von Ziegler at the Laboratory of Neuroepigenetics, Brain 
Research Institute, University of Zurich.  
In order to test mice for spatial and non–spatial memory in a time-efficient manner, I 
designed a three-day paradigm combining OD and NOR assays (Fig.2.4B). In this paradigm, 
the OD assay was used as both an independent test for spatial memory and as the training 






Figure 2.4 Object discrimination paradigm set-up. A. An image of the objects used for the paradigm 
– vial (left on the image) and light bulb (right on the image). B. The object discrimination schematics: 
(i) Object displacement (OD) acts as both a spatial test, with training phase (two identical objects 
placed in the north and south side of the open field) and testing phase (one of the object is moved 
from north west to north east), and as a novel object recognition (NOR) training, followed by (ii) 
NOR testing 24 hours later, with two objects (vial and light bulb) displayed at the same time on west 




The mice were tested under dimmed lights (40 lux). Each open field was divided into four 
smaller arenas. A spatial queue, horizontal stripes (white tape) on the central wall (running 
north to south), was provided in each arena. Eight mice were tested in parallel. Each trial 
lasted 10 min. During Day 2 and Day 3, the time the mouse spent investigating the objects 
was recorded, by tracking the nose point (rather than centre point) as it came into contact 
with the zone around the objects.   
 
2.3.3.1  Day 1 (habituation to the arena) 
Mice were randomly assigned an arena, put into the centre of the arenas facing the striped 
wall, and allowed to habituate to the empty arena for 10 minutes. At the end of the 10 
minutes, mice were put back into their home cages and returned to their holding room.  
 
2.3.3.2  Day 2 (OD /NOR training) 
2.3.3.2.1  OD training 
Mice were placed into the same arenas as Day 1 and presented with either two identical 
small vials or two identical small light bulbs on the west side (NW and SW quadrants of the 
arena) (Fig.2.4A,Bi). The objects were counterbalanced within each run and between 
genotypes.  After 10 minutes, mice were placed back in their home cage and left in the 
experimental room undisturbed for 1-2 hours. 
2.3.3.2.2  OD testing 
Mice were placed back to the same arenas containing the same object set as in training, but 
SW object was moved to SE (Fig.2.4Bi). At the end of the trial, the mice were put back into 





2.3.3.2.3 Day 3 (novel object testing phase) 
After 24 hours the mice were brought back to the testing room, and after 30 min of 
habituation (in their cages) to the room, were placed in their previously allocated arenas. 
The arenas contained a vial and a light bulb, placed near the middle of the west and east 
walls of the arena (Fig.2.4Bii). For each object set, one object was the familiar one from Day 
2, and the other was unfamiliar. The objects were counterbalanced for novelty (based on 
Day 2).  
 
2.3.3.3  Mice  
Object displacement paradigm exploits the natural tendency of rodent to prefer novelty in 
their environment, by investigating moved or novel objects more (Anderson and O'Mara, 
2004; Ennaceur and Delacour, 1988; Ricceri et al., 2000; Tuscher et al., 2015). In order to 
calculate the estimated sample size needed to detect a preference for a moved object, the 
following was used: mean μ= 61.01 (% preference of investigating the moved object rather 
than the stationary object (wildtype pilot; Chapter 3)), SD=13.53, reference value = 50 (%; 
‘no preference’ for either of the objects). The calculated sample size was n=12.  
Mice that did not meet the pre-determined exclusion criterion of <10 seconds total 
investigation of objects in a 10-minute assay were removed from the analysis and 
subsequent phases of the assay (Arqué et al., 2008; Leger et al., 2013).   
For the Kptn cohort (Chapter 4), out of initial n=12 for both genotypes, one wildtype and 
one Kptn-/- were excluded from the Day 1 (OD acquisition phase), four wildtypes and two 
mutants were excluded from the Day 2 (OD testing phase) due to their low overall 
investigation (<10sec), therefore the total number of mice in the OD analysis was wildtype 
n=7 and Kptn-/- n=9.  One wildtype was excluded from Day 3 (NOR testing) due to low overall 





2.3.4  Social recognition 
Social recognition assay exploits the innate preference of mice to investigate novel 
conspecifics and tests olfactory-mediated memory (Ferguson et al., 2001; Guan et al., 1993; 
Kogan et al., 2000; Winslow and Insel, 2004). It has previously been shown that 
performance in this assay is dependent on neuroanatomical structures such as the olfactory 
bulb, amygdala, and hippocampus (Ferguson et al., 2001; Guan et al., 1993; Kogan et al., 
2000; Winslow and Insel, 2004). I used the social recognition protocol used in the lab 
previously (Dias et al., 2016; Sanchez-Andrade et al., 2005). The assay comprises two days: 
Day 1 is memory acquisition and Day 2 is 24 h memory retention test (Fig.2.5).  
Testing was conducted under red light. All trials were recorded (but not tracked) by 
Ethovision and manually scored. Testing arenas comprised of six empty cages (removed of 
bedding and enrichment materials), placed in the open field and separated with dividers so 
that the test animals could not see each other. Twelve animals were tested in parallel in two 
open fields and twelve arenas in total. Test animals were habituated to the room (and red 
light) for half an hour in their home cages and were then habituated to the arenas for 10 
minutes before the start of the testing.  
Due to technical difficulties, females from the Kptn cohort were tested in Chapter 4. In 
Chapter 5, only males were tested for all the mouse lines under the investigation.   
 
2.3.4.1 Stimuli 
Mice used as stimuli were matched to test animals according to their weight, size, and 
gender, and will be henceforth referred to as stimuli. Stimuli for Day 1 trial 1-4 were of 
different genetic background to those used for trial 5. For trial 5, in Chapter 4 (Kptn cohort), 
C57BL/6NTac stimuli were used. For all other lines (Chapter 5) stimuli with 129 background 
were used in trial 5.  
To ensure familiar and unfamiliar stimuli pair for each test animals could be distinguished 
cage mates were never used. For Kptn cohort familiar-unfamiliar stimuli pair were from 




all other lines (except Arid1b) C57BL/6J and C57BL/6J(50.0%)CBA/Ca(50.0%) mice were used 
as stimuli. The stimuli were counterbalanced for novelty.  
For each trial, the same stimulus was used for 3 test animals to reduce the number of 
animals needing to be anaesthetised. Stimulus animals were subject to non-terminal 
anaesthesia with ketamine/xylazine (intraperitoneal injection 1 g/0.1 g per kg of body 
weight) and were recovered with atipamezole (subcutaneous injection 0.5 mg) in a home 
cage with a warm water bottle.  
 
 
Figure 2.5 Images depicting test animal and stimuli on Day 1 and Day 2 of social recognition. A. Day 
1 - the test animal investigates one stimulus (A) for four trials. B. Day 2 - the test animal is presented 





2.3.4.2  Day 1 (memory acquisition) 
A conspecific anaesthetised mouse (stimulus A) was placed on top of a clean petri dish and 
placed in the centre of the test arena for 1 minute (Fig.2.5A). This was repeated four times, 
with inter-trial intervals of 10 minutes. On the fifth trial a novel stimulus (B) was presented 
instead of stimulus A. Time investigating the stimulus (when the test mouse actively sniffed 
and interacted with the stimulus) was recorded manually, blind to genotype. Mice were 
then returned to their home cages and returned to their holding room for 24 hours. 
 
2.3.4.3  Day 2 (memory retention test) 
After a 24 hours, the test mice were put back in their allocated testing arenas and re-
exposed to the familiar stimulus animal (A) used on Day 1 (Trial 1-4) trials at the same time 
as an unfamiliar stimulus animal (C). The stimuli were placed on Petri dishes and placed on 
opposite sides of the arena for 2 minutes. The time the test animal spent with stimuli was 
recorded, and the difference in investigation time between familiar and unfamiliar stimuli 
was compared per genotype using multiple t-tests with multiple comparison corrections.  
 
2.3.4.4 Mice 
Social recognition assay exploits the natural tendency of mice to investigate an unfamiliar vs 
a familiar conspecific (stimuli) (Ferguson et al., 2001; Guan et al., 1993; Kogan et al., 2000; 
Winslow and Insel, 2004). To calculate the estimated sample size needed to detect a 
preference for the unfamiliar stimuli, the following was used: mean μ=63.48 (% preference 
for unfamiliar; wildtype pilot data not shown), SD= 14.15, reference value = 50 (%; ‘no 
preference’ for either stimulus). The estimated sample size was n=9. 
Mice were excluded if their overall investigation time was <10 seconds on trial 1 or if they 
did not investigate one of the stimuli during Day 2. The mice used in Chapter 4 (Kptn cohort; 
female only): started with n=12 per genotype. One wildtype and four mutants were 




The mice used in Chapter 5 (male only): Setd1a cohort - wildtype n=9 and Setd1a+/- n=10; 
Setd5 cohort – on Day 1 wildtype n=15, Setd5+/- n=10, excluded 1 wildtype on Day 2; 
Zmynd11 cohort – wildtype n=14, Zmynd11+/- n=10, excluded 1 mutant on Day 2; Arid1b 
cohort - wildtype n=6, Arid1b+/- n=7. 
 
2.3.5  Sociability 
Sociability is an olfactory-mediated social assay reliant on the natural affinity of wildtype 
mice to prefer interaction with a novel conspecific over a novel inanimate object (Moy et al., 
2004; Silverman et al., 2010). The three chamber paradigm, which is widely used as a test 
for ASD-like phenotypes in rodent models, consists of one chamber with a holder containing 
a stimulus mouse, the central second chamber that is empty, and the third chamber with a 
holder containing an object (Moy et al., 2004; Silverman et al., 2010). The sociability 
protocol used in Chapter 5 has been previously established in our laboratory (Dias et al., 
2016), and was modified here to account for the preference of mice for novel objects. 
Therefore, instead of habituating the mice to empty chambers first, I habituated the mice to 
chambers containing empty holders.  
The test was conducted under dimmed lights (40lux) in an open field divided into four 
quadrants. One of the quadrants was sealed off, the remaining three chambers (L shape 
configuration) had openings through which mice could transition between chambers 
(Fig.2.6). The mouse zone was defined as the area around the holder containing a mouse 
stimulus, while the object zone was defined as the area around the holder containing an 
object (Fig.2.6). Awake stimuli (size and sex-matched) were of 129 background due to their 
reported relative hypo-activity predisposition when compared to some other inbred 
background strains (and care was taken to use novel mice since 129 mice were also used as 
stimuli in social recognition) (O’Leary et al., 2011). Stimuli could freely move inside the 
holder. The holes in the utensil holder allowed for the test animals to see and sniff the 
stimuli.  
The time the test mouse spent in object and mouse zones, as well as in the mouse and 




Ethovision (Fig.2.6). The mice were initially placed in the central chamber and allowed to 
explore all the chambers freely for 10 minutes (habituation phase). The mice were then 
ushered back to the centre and the doors were closed. A stimulus mouse was placed in one 
utensil holder while an object, a small plastic bottle, was placed in the other utensil holder. 
The doors were then released and the test mouse was allowed to freely explore all 
chambers for another 10 minutes. Preference for mouse zone was calculated as a 




Figure 2.6 Schematic representation of the three-chamber sociability set up. The set up contains a 
centre, mouse, and object chambers with defined mouse and object zones around the holders 
containing a mouse and an object respectively.   
 
2.3.5.1 Mice 
Sociability assay is reliant on the natural affinity of wildtype mice to prefer a conspecific 
(stimuli) over an inanimate object, therefore spending longer in the mouse zone (Moy et al., 
2004; Silverman et al., 2010). To calculate the estimated cohort size needed to detect 




for mouse zone; wildtype data from Chapter 5), SD= 0.1375, reference value =0.5 (chance), 
5% type I error rate, 80% power. The calculated cohort size was n=9. 
Mice were excluded if their overall investigation time was <10 seconds or if they did not 
investigate one of the stimuli at all. In Chapter 5 the following number of mice were used. 
Arid1b cohort: wildtype n=12, Arid1b mutant n=10; Setd5 cohort: wildtype n=11, Setd5 
mutant n=10; Setd1a cohort: wildtype n=14, Setd1a mutant n=15.  
 
2.3.6  Pairwise discrimination 
Automated touchscreen technology is a platform for assessing cognitive function in rodents 
(Bussey et al., 2012; Morton et al., 2006).  Pairwise visual discrimination (PD) assay is one of 
the cognitive tasks that can be assessed using this platform. PD is an operant conditioning 
task that tests reward-based associative perceptual memory and learning (Bubser et al., 
2014; Horner et al., 2013). The protocol used in Chapter 4 was adapted from previous 
studies and Campden instruction manual for PD task (for mouse touch screen systems and 
ABET II) (Brigman et al., 2007; Horner et al., 2013; Morton et al., 2006). The piloting of this 
assay is described in Chapter 3.  
Because the assay is dependent on appetitive reward, the mice were food restricted to 
achieve a gradual reduction of 10-15% of the initial body weight, and this weight was 
maintained throughout training and testing (Table 1). The weight of the mice was measured 





Table 1 Food restriction guidelines. 













Before testing was carried out, the mice underwent several pre-testing procedural training 
phases, also known as schedules, where they learned how to select an image by nose-poking 
the screen, initiate a new trial and collect the reward (Horner et al., 2013) (Fig.2.7). Each 
phase had its own set of predefined criteria that dictated whether the mouse was ready to 
pass to the next phase of training (Fig.2.7). The training phase required the mice to learn the 
correct instrumental responses. Only once the mouse passed all these stages by satisfying 
the relevant criteria, could it progress to the PD task.  
The training started with habituation of the mouse to the chambers (habituation 1) and 
learning how to collect the reward (habituation 2). The mouse was then presented with one 
image, appearing one at a time on one of the screens in a pseudo-randomised order (‘initial 
touch’ phase). After the image was displayed for 30 seconds, the mouse received a reward 
independent of whether it nose-poked the image or not. The mouse was encouraged to 
nose-poke the image (stimulus) on the screen by receiving three times more reward without 
the 30 seconds delay if it did. A new trial would start when the reward was collected. In the 
next training phase, the mouse had to nose-poking the image in order to receive a reward, 
as well as collect this reward to progress to the new trial (‘must touch’ training phase).  In 
‘must initiate’ training phase, the mouse had to do all the requirements of the previous 
phases, as well as initiate the start of that day’s training session by receiving a free delivery 
of food which it had to collect from the reward tray, after which the first trial would start. 
For all the above training phases (from initial touch to must initiate) the mice had to 
complete 30 trials in 60 minutes to progress. The final training phase ensured the mouse 
had learned to associate correct nose-poking with a reward, by ‘punishing’ the wrong nose-
pokes (poking the part of the screen without an image). If the mouse nose-poked wrongly, it 
received a time-out period of 5 seconds and the lights were inverted (all testing occurred in 
the dark). To complete the ‘Punishment’ training phase the mice had to complete 30 trials in 





Figure 2.7 Pairwise discrimination flowchart. Blue boxes depict training phases (habituation, initial 
touch, must touch, must initiate, punish incorrect) and the purple box depicts pairwise 
discrimination testing phase. The criteria that needed to be achieved for the mice to progress to the 
next phase is shown in orange. 
 
In the PD test phase, the pairwise discrimination task, the mice were presented with a 
choice of two novel simultaneously appearing images: the conditioned stimulus (CS+) 
associated with a reward and CS- that was not rewarded (Fig.2.8A). The mouse had to 




two consecutive days in order to complete the PD task. The performance in this task was 
assessed by the number of sessions it took for the mouse to meet the criteria.  If the mouse 
nose-poked CS- image instead of CS+, it was punished with a time-out, followed by a 
correction trial, where the images kept appearing in the same position on the screens until 
CS+ was selected. The correction trials did not count toward the total session trial number 
or the final score (the percentage of trials selected correctly). The correction trials were 
designed to counteract potential side and stimulus biases, aid with learning, and ensure that 
mice got a certain number of rewards per session regardless of their performance in the 
non-correction trials.  
 
 
Figure 2.8 Pairwise discrimination set-up. A. A schematic representation of the pairwise 
discrimination task, in which the mouse is exposed to two novel images instantaneously and needs 
to pick the CS+ (the image that is pre-assigned to be linked to a reward) to get a strawberry 
milkshake reward. B-D. Image sets that have been used in the literature for pairwise discrimination. 
Image set B was discontinued due to reported image bias (correspondence with Campden 
Instruments Product Specialist). Image C was used in Pilot 1, while image D was used in Pilot 2 





There were an additional set of pre-determined rules that were set during the piloting of 
this task (discussed in Chapter 3): 
1. Because of the weekend break in testing, no new schedules were tested on Monday; 
all schedules from Friday were repeated. This was to take into account potential 
memory deficits in the mutant mice and have all animals re-baselined on Monday 
before continuing onto the next phase.   
2. If however, the mouse did not pass criteria again on Monday – they repeated the 
schedule until they passed the criteria before proceeding to a new training phase.  
3. In phases where the criteria had to be met two days in a row, if the mouse did Day 1 
of criteria on the Friday but did not pass the criteria on Monday – they would need 
to pass the criteria two days in a row again to proceed.  
 
2.3.6.1 Mice 
All the mice were progressed through the assay on an individual basis. Mice were tested in 
the same testing box each time throughout all the sessions. There was a total of four boxes, 
allowing for four mice to be tested in parallel. Once each mouse reached the criteria in the 
PD task phase they were no longer tested. In order to represent the percentage of correct 
trials over sessions in PD task, for those mice that completed the PD task earlier, the criteria 
mean (correct trial percentage over the last two days) was calculated, and this number was 
included into the overall mean for the subsequent sessions. Therefore, when the 
percentage of trials was plotted against sessions, each session had an equal number of mice, 
even though some mice finished the assay faster than other. The number of days taken to 
reach criteria was plotted separately. There was a pre-defined 25 days cut-off point 
(described in Chapter 3, section 3.2.4), after which if mice did not complete the criteria, they 
were excluded.  
The days needed to reach the PD test criteria are indicative of learning and memory abilities 




detect difference in days to reach criteria between two groups, the following was used: 
mean of days necessary to reach criteria μ = 14.6 (days; wildtype pilot data, Chapter 3), 
SD=7.09 and effect size = 6-8 (days; chosen based on published studies (Copping et al., 2017; 
Yang et al., 2015)). The estimated cohort size that would be necessary to detect a significant 
difference in the means with a smaller effect size of 6 days was n=22. A larger effect size of 
8, would require n=13 animals.  
In Chapter 4, due to breeding constraints, a cohort of n=12 per genotype was put through 
training, however only n=10 wildtype and n=8 Kptn-/- were progressed onto the pairwise 
discrimination task (two wildtypes and four mutants were excluded because they did not 
reach criteria within 25 day cut-off).  
 
2.3.7  Barnes maze 
Barnes maze is a spatial test that is a dry alternative of the Morris water maze and relies on 
the inherent tendency of mice to want to escape an aversive environment (Harrison et al., 
2006; Harrison et al., 2009; Koopmans et al., 2003). Mice placed on a brightly lit open table 
surface with 20 holes around the periphery must repeatedly locate an escape box beneath 
one of the holes, the target, with the aid of spatial cues (Harrison et al., 2006; Harrison et 
al., 2009; Koopmans et al., 2003). Barnes maze had the dimensions of 120cm diameter, 
20x5cm holes and 4 goal box locations (Fig.2.9). External cues of different shapes and sizes 
were placed around the walls of the room, to help the mouse navigate. The mice were 
tested in the dark with overhead lights facing the Barnes maze tables, under maximum 
illumination.  
Three days before the first session, cages were cleaned and an escape box was placed in the 
centre of the clean home cage. Mice were placed into the box and allowed to climb out of it. 






Figure 2.9 Schematic of the Barnes maze table set-up. Predefined areas around the 20 holes (H1-
20), triangular segments from the hole towards the centre (S1-20), and the central circular area 
(Centre) are outlined. 
 
The mice were tested sequentially and in the same order on every day, with two mice 
tested in parallel on two tables. Fifteen minutes before testing, mice were singly housed in 
new cages with bedding, food, and fun tunnel, and a handful of old bedding from the home 
cage of the mouse.  
Before the first trial on Day 1, the mice were habituated to the escape box in the 
introduction trial (Table 2). The mouse was placed into the escape box and the opening of 
the box was blocked for 20 seconds, after which the mouse was free to climb out of it and 
explore for the remainder of the one minute. After one minute, if the mouse was not in the 




trained for two days to locate the target hole, four trials per day (Table 2; Fig.2.10A,B). Trials 
ended either after four minutes or when the mouse went inside the escape box. Learning 
was assessed by measuring primary latency to reach the target and a total number of errors 
recorded before the mice went inside the escape box. After two days of training, the escape 
box was removed and the percentage of time spent around the target hole relative to other 
holes was calculated during the 24h probe trial (Table 2; Fig.2.10A). After this trial, the 
location of the target hole was changed (Fig.2.10C) and the mice were re-trained to locate 
the new target (for three days) (Table 2; Fig.2.10A). Training N2 started directly after the 
24h probe trial and consisted of only two training trials on Day 3, followed by four trials per 
for two more days (Day 4-5) (Table 2; Fig.2.10A). On Day 8, 72 hours after the last training, 
the escape box was removed and the mice were tested for memory retention of the target 
location in the 72h probe trial (Table 2; Fig.2.10A-C). It was important to train the mice after 
the initial 24h probe and to re-baseline before the subsequent 72h probe, to counteract the 






Figure 2.10 Barnes maze set up. A. Experimental design consisting of training with one target 
location (training 1) for two days (Day 1-2; four trials per day; blue bars), followed by a 24h probe 
trial (green bar) and then training with a different target location (training 2) for two days (Day 3-5; 
four trials; black bars) followed by a 72h probe trial (green bar); B. Target hole locations during 





Table 2 Barnes maze schedule over eight days. 






1 1 Training 1 4 
minutes 
 
1 2 Training 1 4 
minutes 
  
1 3 Training 1 4 
minutes 
  
1 4 Training 1 4 
minutes 
  
2 1 Training 1 4 
minutes 
  
2 2 Training 1 4 
minutes 
  
2 3 Training 1 4 
minutes 
  
2 4 Training 1 4 
minutes 
  
3 1 24h Probe 4 
minutes 
No Goal Box 




minutes changed  
3 3 Training 2 4 
minutes 
  
4 1 Training 2 4 
minutes 
  
4 2 Training 2 4 
minutes 
  
4 3 Training 2 4 
minutes 
  
4 4 Training 2 4 
minutes 
  
5 1 Training 2 4 
minutes 
  
5 2 Training 2 4 
minutes 
  
5 3 Training 2 4 
minutes 
  
5 4 Training 2 4 
minutes 
  
8 1 72h Probe 4 
minutes 






The percentage of time mice spent at the target hole comparative to other holes when the 
escape box is removed during probe trial is indicative of memory retention (Harrison et al., 
2006; Harrison et al., 2009; Koopmans et al., 2003). The estimated cohort size needed to 
detect a preference in time spent at the target hole was calculated using the following: 
mean μ =12.845 (% time at the target; wildtype data Chapter), reference value = 5 (% time; 
‘no preference’ for any hole), SD=8.11. The estimated cohort size n=9.  
Kptn (n=16 wildtype, n=11 Kptn mutants), Setd1a (n=15 wildtype, n=12 Setd1a mutants), 
and Arid1b (n=16 wildtype, n=12 Arid1b mutants) cohorts underwent both Training 1 and 2. 
Setd5 (n=12 both genotypes) cohort underwent only Training N1 and 24h probe.  The 
inclusion Training N2 and the 72h probe came after Setd5 mouse line had already been 
tested, and due to breeding issues with this line, it was not possible to repeat the assay to 
test for the 72h probe. Zmynd11 mice did not undergo Training N2, but rather were re-
trained briefly (two training trials) with the same target location immediately after 24h 
probe and then tested for 72h memory retention during the 72h probe. This made Zmynd11 
(n=12 both genotypes) data not directly comparable to the other lines tested, but allowed 
to test a shorter Barnes maze protocol for future studies.  
 
2.3.8  Statistics 
The statistical analyses, including Student’s t-test, Welch's t-test, two-way ANOVA, and one-
way ANOVA were done using GraphPad Prism 6 software. The error bars on all the graphs 
represent the standard error of the mean (SEM).  Where the assumption of normality was 
rejected by the D’Agostino-Pearson test the non-parametric Mann-Whitney U test was used 





2.4 MRI voxel-based morphometry of mouse brains 
For brain morphometric analysis (Chapter 4), 23-week old adult male and female mice (n=8 
per gender) were terminally anaesthetised by intraperitoneal injection of 0.1mL 
pentobarbitone sodium. After the mice were no longer responsive, 20 mL of cold PBS was 
injected into the left ventricle of the exposed heart at low speed, followed by 20 ml of 4% 
PFA, either by hand (20-50 ml syringe) or using a perfusion pump. After the transcardial 
perfusion, skulls were collected and stored in formalin solution at 40C until they were ready 
to be imaged, at which point the skulls were transferred to PBS.  
MRI (Magnetic Resonance Imaging) imaging and analysis were performed by Dr. Stephen J. 
Sawiak of the Wolfson Brain Imaging Centre, University of Cambridge, using previously 
published methodology (Sawiak et al., 2013). Brains were scanned using a Bruker 
PharmaScan 47/16 system at 4.7T with a manufacturer-provided birdcage transmit-receive 
coil. The imaging protocol was fast spin echo (scan parameters: repetition time 2000 ms, 
effective echo time 16 ms, echo train length 4, bandwidth 32 kHz, matrix 256×192×128, field 
of view 1.79×1.34×0.90 cm3, resolution 70 µm isotropic with two averages). MRI Tensor-
based morphometry brains were segmented into tissue types: grey matter, white matter, 
cerebrospinal fluid and ‘other’. This was followed by voxel-based quantification of brain 
volume. Voxel-based morphometry is an automated process of analysing morphological 
differences between images of brains by performing voxel-wise statistics (Ashburner and 
Friston, 2000). The images are registered into the same stereotactic space and segmented 
into images of usually four tissue types: grey matter, white matter, cerebrospinal fluid and 
‘other’. This technique has been previously shown to successfully detect even subtle 
differences in Huntington’s disease mouse model brain (Sawiak et al., 2013). To control the 
type I error rate due to multiple comparisons, an adjusted p-value was used for a false-





2.5 X-ray cephalometrics 
Skull X-ray imaging was performed on live 14-week old (± 4 days) age-matched littermates 
and Kptn-/- mutants (n=7 per genotype) (Chapter 4). Digital X-ray images were acquired using 
the Faxitron system MX20 scanner (Faxitron X-ray Corporation) in collaboration with the 
Mouse Genetics Programme (MGP) staff. Mice were anaesthetised for the procedure 
(intraperitoneal injection of weight adjusted ketamine/xylazine anaesthetic solution) and 
recovered with atipamezole at experiment terminus. 
 
2.6 Histomorphometric analysis (P0 and adult brains) 
For the histomorphological study (Chapter 4), adult mice aged 16 weeks (n=8 per genotype 
and sex) were perfused in the same way as described in section 2.4, the brain was removed 
from the skull and post-fixed in formalin for 48 hours, after which it was kept in PBS. For the 
P0 brains, male mice were culled at birth using schedule 1, brains were removed from skull 
and post-fixed for 12 days before being transferred into PBS.  
The morphometric analyses were performed by Dr. Binnaz Yalcin and lab members at the 
Institute of Genetics and Molecular and Cellular Biology, France using a previously published 
method (Mikhaleva et al., 2016).  Brains were paraffin embedded and 5µm sectioned were 
collected and analysed. Seventy-eight brain parameters across 20 distinct brain regions 
were analysed for neuroanatomical defects in mutant mice relative to littermate controls 
(Table 3).  This consisted of a systematic quantification of the same three coronal brain 
regions, namely the Section 1 (Bregma +0.98mm), Section 2 (Bregma -1.34mm) and Section 
3 (Bregma -5.80mm), down to cell level resolution and blind to the genotype (Table 3). To 
minimize environmental and genetic variation, mice were separately analysed according to 
their gender.  
Focusing on two cortical regions (motor and somatosensory) of adult male mice, cell count, 
regional area, cell size, solidity and circularity were quantified at each cortical layer (layer I 




Proliferation was measured in 16 weeks old mice by staining for a cell proliferation marker 
Ki67 using 3 sections throughout the rostro-caudal extent of the dentate gyrus. The sections 
were probed using 1:1000 rabbit polyclonal anti-Ki67 (Vector labs, VPK451). For Nissl 
staining, slides were incubated with 0.1% cresyl violet acetate solution in a 56°C water bath.  
For brain morphology analysis of P0 mouse brains, a quantification approach, equivalent to 
that used for adults, of 53 parameters of size and surface at Bregma +2.19mm (Section 1, 
Table 4) and +3.51mm (Section 2) (equivalent to adult section 1 and 2) was used for male P0 
mice (n=8 wildtype littermate controls, n=9 Kptn-/-) (Table 4).   
Sections were scanned using Slide scanner (Hamamatsu, NanoZoomer 2.0HT, C9600 series) 
and accessories (racks and NanoZoomer digital pathology, version 2.5.64 software) at 20x 
magnification and analysed using ImageJ (78 measurements) or manually quantified (Ki67 
positive cell count).  
 
Table 3 List of parameters for adult coronal analysis. 
Section analysed Parameter Units 
Section 1 (Bregma +0.98mm) Total brain area cm2 
Lateral ventricle, left hemisphere cm2 
Lateral ventricle, right hemisphere cm2 
Cingulate cortex, left hemisphere cm2 
Cingulate cortex, right hemisphere cm2 
Genu of the corpus callosum cm2 
Caudate putamen, left hemisphere cm2 




Anterior commissure, left hemisphere cm2 
Anterior commissure, right hemisphere cm2 
Piriform cortex, left hemisphere cm2 
Piriform cortex, right hemisphere cm2 
Cingulate cortex, width, left hemisphere cm 
Cingulate cortex, width, right hemisphere cm 
Cingulate cortex, height cm 
Genu of the corpus callosum, width, top cm 
Genu of the corpus callosum, width, bottom cm 
Genu of the corpus callosum, height cm 
Primary motor cortex, left hemisphere cm 
Primary motor cortex, right hemisphere cm 
Secondary somatosensory cortex, left 
hemisphere 
cm 
Secondary somatosensory cortex, right 
hemisphere 
cm 
Section 2 (Bregma -1.34mm) Total brain area cm2 
Lateral ventricle, left hemisphere cm2 
Lateral ventricle, right hemisphere cm2 
Dorsal third ventricle cm2 





Retrosplenial granular cortex, c region, right 
hemisphere 
cm2 
Corpus callosum cm2 
Dorsal hippocampal commissure cm2 
Hippocampus cm2 
Amygdaloid nucleus, left hemisphere cm2 
Amygdaloid nucleus, right hemisphere cm2 
Piriform cortex, left hemisphere cm2 
Piriform cortex, right hemisphere cm2 
Mammillothalamic tract, left hemisphere cm2 
Mammillothalamic tract, right hemisphere cm2 
Internal capsule, left hemisphere cm2 
Internal capsule, right hemisphere cm2 
Optic tract, left hemisphere cm2 
Optic tract, right hemisphere cm2 
Fimbria of the hippocampus, left hemisphere cm2 
Fimbria of the hippocampus, right hemisphere cm2 
Habenular nucleus, left hemisphere cm2 
Habenular nucleus, right hemisphere cm2 




Hypothalamus, left hemisphere cm2 
Hypothalamus, right hemisphere cm2 
Retrosplenial granular cortex, c region, width, 
left hemisphere 
cm 
Retrosplenial granular cortex, c region, width, 
rigtht hemisphere 
cm 
Retrosplenial granular cortex, c region, height cm 
Corpus callosum, width cm 
Corpus callosum, height cm 
Total internal length of pyramidal cells cm 
Dentate gyrus, left hemisphere cm 
Dentate gyrus, right hemisphere cm 
Molecular layer of the hippocampus, left 
hemisphere 
cm 
Molecular layer of the hippocampus, right 
hemisphere 
cm 
Radiatum layer of the hippocampus, left 
hemisphere 
cm 
Radiatum layer of the hippocampus, right 
hemisphere 
cm 
Oriens layer of the hippocampus, left 
hemisphere 
cm 





Primary motor cortex, left hemisphere cm 
Primary motor cortex, right hemisphere cm 
Secondary somatosensory cortex, left 
hemisphere 
cm 
Secondary somatosensory cortex, right 
hemisphere 
cm 
Section 3 (Bregma -5.80mm) Number of folia  
Total brain area cm2 
Fourth ventricle cm2 
Pons cm2 
Pyramidal tract, left cm2 
Pyramidal tract, right cm2 
Genu of the facial nerve, left cm2 
Genu of the facial nerve, right cm2 
Cochlear nucleus, left cm2 
Cochlear nucleus, right cm2 
Lateral cerebellar nucleus, left cm2 
Lateral cerebellar nucleus, right cm2 






Interposed cerebellar nucleus, anterior part, 
right 
cm2 






Table 4 List of parameters for P0 coronal analysis. 
Section analysed Parameter Units 
Section 1 (Bregma 2.19mm) 
 
Total Brain Area cm² 
Area of Lateral Ventricle_Left cm² 
Area of Lateral Ventricle_Right cm² 
Area of Cingulate Cortex_Left cm² 
Area of Cingulate Cortex_Right cm² 
Width of Cingulate Cortex_Left cm 
Width of Cingulate Cortex_Right cm 
Height of Cingulate Cortex cm 
Area of Genu of Corpus Callosum cm² 
Width of genu of Corpus Callosum cm 
Height of genu of Corpus Callosum cm 
Area of Caudate Putamen_Left cm² 
Area of Caudate Putamen_Right cm² 
Area of anterior commissure_Left cm² 
Area of anterior commissure_Right cm² 
Height of Motor cortex_Left cm 




Height of Somatosensory cortex_Left cm 
Height of Somatosensory cortex_Right cm 
Section 2 (Bregma 3.51mm) Total Brain Area cm² 
Area of Lateral ventricule_Left cm² 
Area of Lateral ventricule_Right cm² 
Area of Dorsal 3rd ventricule cm² 
Area of 3rd ventricle cm² 
Area of Retrosplenial Granular cortex_Left cm² 
Area of Retrosplenial Granular cortex_Right cm² 
Width of Retrosplenial Granular cortex_Left cm 
Width of Retrosplenial Granular cortex_Right cm 
Height of Retrosplenial Granular cortex cm 
Area of the splenium of the corpus callosum cm² 
Width of the splenium of the corpus callosum cm 
Height of the splenium of the corpus callosum cm 
Area of Hippocampus_Left cm² 
Area of Hippocampus_Right cm² 
Total internal length of Pyramidal layer_Left cm 
Total internal length of Pyramidal layer_Right cm 




Area of the internal capsule_Right cm² 
Area of the fimbria_Left cm² 
Area of the fimbria_Right cm² 
Area of the Amygdala_Left cm² 
Area of the Amygdala_Right cm² 
Area of the Hypothalamic nucleus_Left cm² 
Area of the Hypothalamic nucleus_Right cm² 
Area of the Habenula_Left cm² 
Area of the Habenula_Right cm² 
Area of the Thalamus cm² 
Height of Motor cortex_Left cm 
Height of Motor cortex_Right cm 
Height of Primary Somatosensory cortex_Left cm 
Height of Primary Somatosensory cortex_Right cm 
Height of Secondary Somatosensory cortex_Left cm 
Height of Secondary Somatosensory cortex_Right cm 
 
 
2.7  RNA sequencing analysis 
2.7.1  RNA tissue extraction 
Tissue was homogenised in buffer RLT plus (Qiagen, 1053393) with β-mercaptoethanol 




beads and operated at 50Hz for 2 minutes. Samples (n=6 per genotype) were pre-treated on 
gDNA eliminator columns and then extracted on RNeasy Plus columns as per manufacturer’s 
protocol (Qiagen, Venlo, Netherlands), and were immediately snap frozen on dry ice and 
stored at -80C. An aliquot of each sample was quantified using 2100 Bioanalyzer (Agilent 
Technologies). 
  
2.7.2  Library preparation  
Library preparation and sequencing was performed by the WTSI DNA Pipelines Illumina Low-
Throughput Team. Multiplexed libraries were prepared for sequencing using Illumina RNA 
Library Preparation Kits as per manufacturer’s protocol. Paired end sequencing was 
performed on the Illumina HiSeq 2000 or V4 generating 75bp reads. 
 
2.7.3  Alignment, mapping and differential gene expression 
STAR version 2.5.2b was used to align sequenced reads to the altered version of the mouse 
reference genome and map the reads.  
The following parameters were used: 
fastq_convert = 1, star = 1, mem_cram = 2000, queue_cram = normal, mem_fastq = 18000, 
queue_fastq = long, mem_star = 36000, queue_star = long, mismatch = 4 
The count data was used as input for differential gene expression analysis using R (version 
3.2.2) DESeq2 package (versions 1.17.16). DESeq2 is a conservative model for differential 
expression analysis that employs a Benjamini-Hochberg procedure to control for multiple 
testing, returning an adjusted p-value (padj) for the differential gene expression. DESeq2 
returns an estimation of Log2 fold change, a regularised log transformation which reduces 
the false positive rate for genes with low counts and high dispersion. MA plots were used to 
visualize the expression differences between genotypes, by transforming the data onto M 
(log ratio) and A (mean average) scales and plotting these values. The Log2 fold changes 




fold change of normalised read counts). DESeq2 cut-off of BHadjusted p-value<0.05 was 
used for all analyses.  For differential gene expression analysis in DESeq2, transcript counts 
mapped to the mitochondrial genome were excluded 
For the identification of functionally enriched terms in the differentially expressed genes, I 
performed Gene ontology (GO) and KEGG pathway enrichment analyses using the grpofiler 
online suite (http://biit.cs.ut.ee/gprofiler/index.cgi). A threshold of 5% FDR and an 
enrichment significance threshold of P<0.05 (hypergeometric test with Benjamini-Hochberg 
False Discovery rate correction for multiple testing) was used. In all analyses, a background 
comprised of only the expressed genes in the tissue studied (genes where the adjusted p-


















Chapter 3. Cognitive assay development 
3.1 Introduction 
3.1.1  Mouse modelling of intellectual disability 
The mammalian central nervous system (CNS) contains a large number of cell types, with a 
unique combination of gene expression repertoires, which are necessary for cognitive 
function (Lein et al., 2007). As outlined in Chapter 1, due to the complexity and intricacy of 
the system, minimal changes to the genetic programming of the brain can lead to a diverse 
set of conditions ranging from neurodevelopmental to neurodegenerative disorders (Hu et 
al., 2014).  
Mus musculus has been extensively used as a model organism to identify causal links 
between mutations and disease phenotypes, characterise candidate genes, provide insight 
into the associated disease mechanisms, and inform treatment. Mice are commonly used 
for modelling human disease for several reasons. Firstly, approximately 99% of mouse genes 
have human orthologues, and on average 85% of protein-coding regions are identical in 
both species (Chinwalla et al., 2002). Secondly, due to the availability of a high-quality 
reference genome and sophisticated genetic tools, the mouse genome can be manipulated 
and analysed with relative ease (Weyden et al., 2011).  And lastly, the similarity of 
neurobiological pathways and their behavioural outputs in mice and humans, allows for 
parallels to be made with human conditions (Bucan and Abel, 2002).  
As outlined in Chapter 1, genetic alterations are among the leading causes of intellectual 
disability (ID), disrupting the functionality of the nervous system and development of 
cognitive function (Ehninger et al., 2008; Fitzgerald et al., 2016; Wright et al., 2015). 
Genetically modified mice have been extensively used to study the pathologies associated 
with ID, which also sheds light on the pathways involved in normal cognition (Bakker et al., 
1994; Dias et al., 2016; Celen et al., 2017; Mircsof et al., 2015). Testing the mice in a battery 
of behavioural and cognitive assays and employing multiple tasks for each behavioural 
domain of interest can allow for the detection of subtle cognitive and behavioural defects 




human disorder, they may offer a valuable tool to study the molecular basis of, and aberrant 
pathways are leading to, the pathologies (Guy et al., 2001; Gogliotti et al., 2017).  When 
characterising the mouse model, before undertaking assays of complex behaviour, it is 
critical to first measure general health parameters, as well as the sensory and motor 
functions of the mice, to avoid possible misinterpretation of the subsequent results 
(Spencer et al., 1995; Strekalova et al., 2005).  Moreover, because mouse behaviour is 
sensitive to environmental changes and prior experiences, to ensure reproducibility the 
order in which the mice are tested should be consistent and the environmental conditions, 
such as external noise, housing conditions, handling regime, and time of testing must be 
controlled (Chesler et al., 2002; McIlwain et al., 2001; Ramos et al., 1997). Moreover, the 
genetic background strain of the test animals should be considered and controlled. Inbred 
strains contain fixed polymorphisms, some of which result in neurobehavioural differences 
between strains that affect their performance in behavioural and cognitive assays 
(Homanics et al., 1999; Keane et al., 2011).  For example, 129 inbred strains have been 
reported to be less active than C57BL/6 strains in explorative assays, display increased 
anxiety-like behaviour and, depending on the sub-strain tested, there is conflicting data on 
their learning and memory abilities (Abramov et al., 2008). FVB/N mice are visually 
impaired, due to the rd mutation that causes retinal degeneration, making them 
inappropriate for assays that rely on visual cues, such as the Barnes maze (O’Leary et al., 
2011). Therefore, to maximise the chances of detecting a phenotype associated with a 
mutated candidate gene, it is important to avoid modelling in strains with extreme traits, 
due to ceiling or floor effects that may mask the phenotypic consequences of the mutation. 
C57BL/6 strains have average performance in many behavioural paradigms. Moreover, 
testing mice of a common genetic background, such as C57BL/6 strains, facilitates the 
comparison of results across different laboratories (Bothe et al., 2005; Crawley et al., 2008). 
In this thesis work, all the mouse models characterised were of C57BL/6 background.  
Some conditions, for example, those with complex inheritance patterns and multiple 
interacting genes are more challenging to replicate efficiently in mouse models (Watase and 
Zoghbi, 2003). In contrast, studies modelling highly penetrant monogenic disorders, such 




sphingomyelinase enzyme activity, have successfully recapitulated the main endophynotes 
of the disorders, manifested as changes in behavioural and cognitive capacity, in the mice 
(Horinouchi et al., 1995; Otterbach and Stoffel, 1995). In this thesis work, I focused on 
modelling complex traits and monogenic disorders.  
 
3.1.2  The approach and aims  
My first objective was to established and refine a series of behavioural assays tailored for 
the identification of phenotypes associated with neurodevelopmental disorders. In this 
thesis work, I focused on assessing cognition through learning and memory paradigms, as 
they can be used to test multiple cognitive domains, including associative learning, spatial 
and non-spatial learning, short-term and long-term memory (Sweatt, 2004; 
Nithianantharajah and Grant, 2013).  Out of the behavioural assays (outlined in Table 5) 
used extensively in our laboratory at the start of my PhD, only two were cognitive tests - 
Barnes maze (testing spatial memory and learning) and social recognition (testing olfactory 
memory) (Dias et al., 2016; Huckins et al., 2013; Sánchez-Andrade et al., 2005). I, therefore, 
set out to expand the cognitive assay repertoire to include novel object recognition (NOR) - 
assessing non-spatial memory, object displacement (OD) - assessing spatial memory, and 
pairwise visual discrimination (PD) - assessing association-based learning, to enable the 
detection of a dynamic range of deficits, associated with neurodevelopmental disorders, in a 




Table 5 Behavioural and cognitive assay usage status in our team at the start of my PhD. 
Assay name Testing Existing status in the lab 
Open field Locomotion and activity Used extensively 
Light/dark Anxiety-like behaviour Recently optimised 
Social recognition Olfactory memory Used extensively 
Novel object recognition Recognition memory Not established 
Object displacement Spatial memory Not established 
Barnes maze Spatial memory Recently optimised 
Pairwise discrimination Associative learning Not established 
Sociability Social interaction Recently optimised 
 
 
In this Chapter, I will discuss the optimisation of the assays highlighted in bold (Table 5), 
outlining the series of undertaken pilots, which aided in the development of a testing 
strategy I subsequently used in Chapter 4 and 5.  
 
3.1.3  Novel object recognition and object displacement assays  
Recognition memory relies on the ability to identify a previously encountered item as 
familiar and is dependent on the functioning of the medial temporal lobe of the brain, which 
consists of neuroanatomical structures, including the hippocampus and the adjacent 
parahippocampal regions, including the perirhinal and entorhinal cortices (Squire et al., 
2007).  Novel object recognition (NOR) assay, initially outlined in 1988, was designed to test 
recognition memory similarly to visual paired-comparison task used in clinical 




preference for investigating novel over the familiar object (Ennaceur and Delacour, 1988). 
Longer investigation of the unfamiliar object by the test animal is indicative of an acquired 
memory for the familiar object.  
The parahippocampal regions of the temporal lobe (in particular the perirhinal cortex) and 
the prefrontal cortex (PFC) have been implicated to have a critical role in the NOR task 
(Banks et al., 2012; Bussey et al., 1999). While the role of perirhinal cortex in NOR has been 
well established, the importance of the hippocampus in NOR is disputed (Broadbent et al., 
2004; Forwood et al., 2005; Gilbert and Kesner, 2003; Hammond et al., 2004; Kim et al., 
2014; Yi et al., 2016). The inconsistency of NOR results between different groups may be 
due to the variability in the testing method across studies (training procedures, arena size, 
and type of objects) or the differences in the type or extensiveness of hippocampal lesions. 
There is a body of work which has shown the involvement of the hippocampus in NOR when 
it is tested in a complex environment with spatial and contextual cues (Balderas et al., 2008; 
Forwood et al., 2005; Nemanic et al., 2004). This suggests that the hippocampus may be 
involved in the retrieval of contextual information, while the other regions of the temporal 
lobe are required for consolidation of familiarity of the objects. Furthermore, there is 
increasing evidence of functional overlap between various regions in the brain, implying the 
roles between brain regions are not as delineated as previously thought (Vann and Albasser, 
2011).  
A modified version of the NOR assay, object displacement (OD), was developed to assess 
spatial memory in rodents (Ennaceur et al., 1997). OD task exploits the natural tendency of 
rodents to explore their environment and the preference to investigate a moved object 
when compared to a static object (Tuscher et al., 2015). While the NOR assay tests the 
memory for the identity of the object, the OD task assesses the memory for the location of 
the object. It is, therefore, unlike NOR, a spatial memory task, and relies primarily on the 
hippocampus (Anderson and O'Mara, 2004; Ricceri et al., 2000). As with NOR, multiple 
testing strategies exist for this assay (Fernandez and Garner, 2007; Dere et al., 2005; Larkin 





3.1.4  Pairwise visual discrimination task  
Automated touchscreen technology is becoming an increasingly popular platform for 
assessing cognitive function in rodents (Bussey et al., 2012; Morton et al., 2006). Although 
relatively less ethological than some traditional methods, touchscreen technology exploits 
the natural tendency of rodents to investigate novelty and learn the consequence of 
exploring particular stimuli (Horner et al., 2013a; Horner et al., 2013b). The touchscreen 
tasks have a great level of translational potential, as they operate similarly to the Cambridge 
neuropsychological test automated battery (CANTAB) methods used to test patients (Bussey 
et al., 2008; Nithianantharajah et al., 2015; Robbins et al., 1994). Moreover, multiple 
cognitive tests, such as autoshaping, visual discrimination, and visuomotor conditional 
learning can be run using the same apparatus in a standardised and relatively high-
throughput manner (Horner et al., 2013; Oomen et al., 2013).  
Pairwise visual discrimination (PD) assay is one of the cognitive tasks that can be assessed 
using the touchscreen platform and is an operant conditioning task that tests reward-based 
associative perceptual memory and learning (Bubser et al., 2014; Horner et al., 2013). It is a 
hippocampus-independent task and is reliant on neuroanatomical structures such as the 
dorsal striatum, which mediates the formation of reinforced stimulus-response associations 
(Brigman et al., 2013; Chudasama and Robbins, 2003; Izquierdo et al., 2013). Of note, PD 
requires intact motor and visual abilities for the rodent to navigate inside the chamber, 
collect the reward, respond to the stimuli on the screen when necessary, and discriminate 
between two visual stimuli. Mouse strains have been shown to perform differently on this 
the task (Graybeal et al., 2014). For example, FVB/N mice cannot be used due to their visual 
impairment (O’Leary et al., 2011). 
 
3.2 Results  
3.2.1  NOR assay  
Since NOR assay relies on the ability of mice to differentiate between objects, the choice of 




used, and often this varies not only between studies but between test animals in the same 
study, making it difficult to reproduce results (Tuscher et al., 2015). I therefore first 
investigated which objects would generate the most reproducible results, aiming to use the 
same set of objects for all the mice. Objects were chosen based on similar size, but different 
textures and shapes, to allow for easier discrimination (Fig.3.1).  
 
 
Figure 3.1 Novel object recognition set-up in the two pilot studies. In both pilot studies, the mice 
were habituated to two identical (sample) objects, presented with the familiar (sample) object and 
an unfamiliar (novel) objects after 1-hour interval. A. In the first pilot study, the sample object was a 
300mL Coca-Cola can and the novel object was a glass slide washstand; B. In the second pilot, the 
sample object was a 300mL Coca-Cola can and the novel object was a water bottle, used in mouse 
caging, without the lid.  
 
The first object pair tested was a Coca-Cola can and glass slide washstand (Fig.3.1A). Both 
objects can be easily purchased, are a similar size, but different textures and colours. To 




mice were presented with both objects and the time taken to investigate both objects were 
recorded. The mice investigated the glass stand on average significantly longer than the 
Coca-cola can (P=0.0391; Wilcoxon matched-pairs signed rank test) (Fig. 3.2A). Due to this 
inherent bias, the mice were tested with a different object set - water bottle and a Coca-
Cola can (Fig.3.1B). There was no significant inherent preference for either of the objects (P= 
P=0.25, Wilcoxon matched-pairs signed rank test) and this pair was thus picked for the NOR 
assay (Fig.3.1B; Fig. 3.2B). The Coca-cola can data failed D'Agostino & Pearson omnibus 






Figure 3.2 Novel object recognition inherent preference test. The time spent investigating either of 
the two objects from the pair was plotted. A. Naïve wildtype adult mice (n=8) spent significantly 
longer investigating the glass stand relative to the Coca-cola can (P=0.0391*). B. There was no 
inherent bias detected for either of the objects (P=0.25). Values are plotted as mean ± SEM. 
 
Once the object set was picked, a new cohort of mice (n=9) was put through NOR training 




hour later, in the testing phase, the mice were exposed to two objects: water bottle 
(familiar sample object) and Coca-cola can (novel object) for 5 minutes and the time spent 
investigating both objects was recorded (Fig.3.1B). The preference for the unfamiliar object 
was calculated as a proportion of the total investigation time. No significant difference was 
observed in the wildtype mice in the time mice spent near either of the objects (P=0.9328, 
t=0.08704 df=8, two-tailed paired Student’s t-test), implying that the mice were unable to 
distinguish between the two objects (Fig.3.3).  
 
 
Figure 3.3 Novel object recognition pilot. The plot shows the percentage of time wildtype mice 
(n=9) spent investigating the familiar sample object (plotted in green) and unfamiliar novel object 
(plotted in orange).  There was no significant increase in the percentage of time spent with a novel 
object (P= 0.9328). Values are plotted as mean ± SEM. 
 
 
3.2.2  OD assay  
Three identical Lego objects were used for the OD pilot, based on a personal 
correspondence with Dr Lukas von Ziegler at the Laboratory of Neuroepigenetics, Brain 
Research Institute, University of Zurich. In the training phase, the mice were habituated to 




identical Lego objects. In the testing phase, the mice were re-exposed to the three Lego 
objects 24 hours later, but one of the objects was moved to a different location in the arena 
(Fig.3.4). The time spent investigating both objects was recorded.   
 
 
Figure 3.4 Schematic representation of the object displacement protocol. One of the identical 
objects (Object 3*) moved between the training and testing phases (24 hours apart).   
Object 1 






Figure 3.5 Object displacement pilot with Lego objects. The plot shows the percentage of time mice 
(wildtypes, n=12) spent investigating  Object 3* as a proportion of overall investigation time during 
training (Day 1) and testing (Day 2) phase. There was a significant difference in time spent 
investigating the moved object (Object 3*) during testing when compared to the initial investigation 
during the training phase (P=0.0347*). A significant difference from chance or no preference (33%; 
represented by dotted line) and was detected only during testing (training: P = 0.54; testing: P= 
0.026). Values are plotted as mean ± SEM. 
 
The time spent investigating the moved object (Object 3*) was calculated as a proportion of 
the total investigation time. A significant difference from the reference value of 33% (one 
out of the three objects, and implying no preference for any of the objects) for Object 3* 
was detected only during testing (training: P = 0.54, t=0.6364 df=11; testing: P= 0.026, 
t=2.574 df=11; One sample t-test) (Fig.3.5). There was a significant increase in the 
investigation of Object 3* between training and testing phase (mean difference: 15.27sec, 
P=0.035, t=2.408 df=11, paired two-tailed Student’s t-test), indicating that the wildtypes 





3.2.3  Object discrimination paradigm 
I next investigated whether the NOR and OD assays could be used not only sequentially in 
order to assess both spatial and non–spatial memory, but in addition whether OD assay 
could be used as NOR acquisition training. For this, I modified both NOR and OD protocols 
(Chapter 2, section 2.3.3).  
13 male naïve wildtype mice were presented with an object pair (vial and light bulb) and the 
time they spent investigating both of the objects was recorded (Chapter 2, section 2.3.3). No 
inherent preference for either of the objects was detected (P= 0.9238, t=0.09771 df=12, 
paired Student’s t-test) (Fig.3.6A). Due to the lack of object bias, a new set of wildtype mice 
(n=14) were tested using the object discrimination paradigm (which involved OD assay, 
followed by NOR assay as outlined in Chapter 2, section 2.3.3, Fig.2.4A). The results showed 
an increase in time spent with the moved object at OD test phase (P= 0.0061, t=3.046 df=13, 
one-sample Student’s t-test), as well as an increase in the time spent with the novel object, 
24h later, during NOR testing (P<0.0001, t=6.073 df=12, one-sample Student’s t-test) 
(Fig.3.6C). One mouse was eliminated from NOR analysis because it did not meet the pre-
determined exclusion criteria (Chapter 2, section 2.3.3). 
Overall, the wildtype mice were able to discriminate between moved vs stationary objects, 
as well as showing a preference for the novel object. These results suggest that using the 
vial-light bulb object pair, object discrimination can be used to assess both spatial memory 
deficits (OD phase) and recognition memory (NOR phase) in mutant mice.




Figure 3.6 Object discrimination testing. A. The time naïve wildtype mice spent investigating two 
objects (vial and light bulb) is plotted. No difference in investigation time of the object was detected 
(P= 0.9238). B. The results of object displacement testing phase plotted as a proportion (%) of total 
time spent with the moved object. The mice (n=14) investigated the moved object significantly 
longer (P=0.0094) than expected by 50% chance (dotted line). C. The results of novel object 
recognition testing phase plotted as the proportion (%) of total time spent with the novel object. The 
mice (n=13) investigated the novel object significantly longer (P<0.0001) than expected by 50% 
chance (dotted line). Values are plotted as mean ± SEM. 




3.2.4  PD assay  
I had two aims when establishing this assay at the Sanger Institute. Firstly, I wanted to add 
to my battery of memory and learning tests an assay that is hippocampus-independent, to 
have the ability to capture a broader range of cognitive deficits (Chapter 4).  Secondly, due 
to its translational potential and automated design, I wanted to assess whether this type of 
assay could be used in a cognitive screen (Chapter 5). The latter posed certain limitations to 
the protocol design - no testing on the weekend and time limitation for the duration of the 
assay. To take into account the weekend break in testing, I established a set of stringent PD 
rules before the start of the pilot. Due to the time constraint imposed on the assay, the aim 
was to identify, based on the outcomes of the piloting, a fixed time after which the 
experiment would be stopped even if not all the animals completed the criteria. 
 
3.2.4.2  Pilot Number 1 
The first pilot I carried out was with C57BL/6J mice (n=12). Mice were housed in groups of 
four and advanced through training phases as a group (Chapter 2, section 2.3.6). This 
entailed not moving any mice onto the next training phase until all the mice passed the set 
criteria, allowing for synchrony of assessment. At the start of a new training phase, there 
was a reduction in the number of trials completed in 60 minutes (Fig.3.7A). However, as the 
mice did more sessions and learned the required set of skills to complete the task, they 
increased the number of trials, eventually reaching the criteria for that training phase 
(Fig.3.7A). Two mice out of 12 did not complete criteria in the Punishment phase and were 
excluded from subsequent sessions. The rest of the mice (N=10) were moved onto PD 
testing.  
In PD testing, the mice were exposed to two images (image 1 and 2), counterbalanced for 
which image was assigned as CS+ (Chapter 2, Section 2.3.6, Figure 3.7). It took 12 sessions 
for all the mice to reach criteria of 30 trials in 60 minutes with 80% of trials done correctly 
over two consecutive days, with a correct trial defined as a trial where the CS+ image was 
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nose-poked (Fig.3.7B). The time taken to complete the trials decreased significantly as the 
mice increased their accuracy (measured as % of trials done correctly) (Fig.3.7C.). The 
number of correction trials was inversely correlated with the accuracy of performance 
(number of trials done correctly) (significant interaction: F (11, 198) = 23.02, P<0.0001, two-
way ANOVA) (Fig.3.7D).  
To test for the effect of weekend breaks on the performance of the mice in PD task, I 
analysed the number trials completed (Fig.3.7A) and speed of completion (Fig.3.7E) after a 
two-day break between Session 3 and 4 (labelled as Session 17 and 18 in Fig.3.7A) and after 
a three-day break between Session 8 and 9 (labelled as Session 22 and 23 in Fig.3.7A). There 
was no significant difference in the trials completed after two- or three-day break in PD task 
(Session 3 vs 4: P >0.9999, Session 8 vs 9: P=0.9138, post-hoc analysis after one-way 
ANOVA), nor did the time taken to complete the trials differ (Session 3 vs 4: P= 0.7958, 
Session 8 vs 9: 0.3464, post-hoc analysis after one-way ANOVA).  
When the performance was analysed based on two groups, depending on what image was 
assigned as CS+ (group 1: all the mice that had image 1 as CS+, group 2: image 2 as CS+) 
there was an overall difference in performance between groups (significant interaction: F 
(11, 84) = 3.096, P=0.0016, group difference: F (1, 84) = 19.05, P<0.0001, two-way ANOVA). 
There was no difference in the percentage of trials done correctly per CS+ group in session 
1, however, in session 3 and 4 the group with image 2 as CS+ had significantly higher 
percentage of trials done correctly, implying a potential image bias (session 3: P ≤ 0.001; 
session 4: P ≤ 0.0001, post hoc analysis after a two-way ANOVA) (Fig.3.7F). 
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Figure 3.7 Pairwise discrimination Pilot N1 results. A. The number of trials completed by mice over 
all the session, throughout the whole assay (training phases and PD test phase included). Each 
session is equivalent to one day of training/testing, and are serially numbered. The session ended 
once the mouse either did 30 trials or 60 minutes elapsed (the time available). Mice were moved to 
the next phase once all the mice in the cohort completed the criteria for that phase. As the mice 
progressed through a phase (had more sessions doing the same task), their performance improved 
(more trials were completed in 60 minutes). As the mice started a new phase, the number of trials 
completed decreased in the first sessions for that phase compared to the last sessions of the 
previous training phase. Initial training phase took one session (Session N1), Must touch phase took 
three sessions (Session N2-4), Must initiate phase took two sessions (Session N5-6), Punishment of 
incorrect phase (Session N7-14), and pairwise discrimination (PD) testing phase (Session 15-26). In 
PD testing, there was no difference in trials completed between session 17 and 18 (two-day break 
between sessions) (P >0.9999) and session 22 and 23 (three-day break in between sessions) 
(P=0.9138). The dotted line at 30 indicates the maximum trials that can be done per session. B. 
Percentage of correct trials (when CS+ image was nose-poked) out of the total trials done per 
session. The dotted line represents the criteria of 80% correct trials (24 out of 30) C. The time 
(minutes) that it took for mice to complete each PD testing session. The maximum time (60 minutes) 
is shown with a dotted line. D. The number of correction trials (in red) and correct trials (in green) 
done in each PD session. As the number of correct trials increase, the number of correction trials 
(trials that follow nose-poking CS- image) decrease. The maximum number of non-correction trials is 
30, whereas there is no limit on the number of correction trials. The dotted line represents the 
criteria of 24 correct trials out of 30 (80% correct). E. Trial per time ratio plotted per session, with 
anything below 0.5 implying the criteria of 30 trials in 60 minutes was not reached. The mice had to 
get above 0.5, as well as get 80% of the 30 trials correct to complete the task successfully. The 0.5 
cut-off is annotated with a red line. There was difference in trials per time ratio between session 3 
and 4 (two-day break between these sessions; thin arrow) (P=0.7958) and session 8 and 9 (three-day 
break in between those sessions; thick arrow) (P=0.3464). F. The percentage of correct trials done 
per session was plotted separately for the two CS+ groups (depending on which image was assigned 
as CS+: image 1 (in purple) or image 2 (in peach)). On the first session, there was no difference in the 
percentage of correct trials per CS+ group, and both groups had around 50% chance (dotted line). In 
session 3 and 4, the group with image 2 as CS+ had a significantly higher percentage of trials done 
correctly (session 3: P ≤ 0.001***; session 4: P ≤ 0.0001****). The second dotted line represents the 
criteria of 80% correct trials. Values are plotted as mean ± SEM. 




3.2.4.3  Pilot Number 2 
Based on results from Pilot 1, I further optimised the protocol to address several limitations:  
1. The mice tested in Pilot N1 were C57BL/6J background, whereas all mutant mice to 
be tested (Chapter 4 and 5) are of C57BL/6N background. I therefore tested 
C57BL/6N next. 
2. Even though group advancement of the mice is easier to coordinate and analyse, 
due to the variability in the completion of each phase, there is a risk of over-training 
some of the mice. One proposed way of eliminating this is resting those animals that 
completed criteria and running the entire cohort with a refresher session to re-
baseline the mice to the same level, once the whole group has completed criteria 
(Horner et al., 2013). However, another possible regime of training is advancing all 
the mice individually. This avoids overtraining but does not allow the group to be 
synchronised. I applied that latter option in my second pilot. 
3. After a personal communication with Dr Stacey Rizzo, Jackson Laboratory, I added 
two further changes to the protocol. Firstly, mice were now singly housed for the 
duration of the assay. This allowed for better control of their food intake, as well as 
reduced any confounding effects of hierarchical structures in the home cages on 
their behaviour and task performance. Secondly, I ensured that each mouse had an 
allocated touchscreen chamber, and the mouse consistently was tested in this 
chamber throughout all the sessions. This was to eliminate the effect of any possible 
differences there may be between chambers.   
4. Due to a potential image bias observed in Pilot N1, I changed image set to the plane 
and spider image set (Chapter 2, section 2.3.6, Fig.2.8D).  
The mice (n=12) advanced through the training phases in a comparable manner to the first 
pilot (Fig.3.8).  
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During PD testing, the mice (n=10) initially got 50% of trials correct on session 1 (which 
indicates no preference for either of the images) and increased their performance by 
increasing the percentage of correct trials done (Fig.3.9A,C), while decreasing the time 
taken to complete each session (Fig.3.9B), reaching criteria in an average of 14.6 sessions 
(Fig.3.8, Fig.3.9A). Based on the average number of days (one day = one session) taken for 
mice to reach criteria in the two pilots (Pilot 1 = 12 days, Pilot 2 = 15 days) and existing data 
from other studies (personal communication with Dr Stacey Rizzo, Jackson Laboratory; 
Copping et al., 2017; Yang et al., 2015), I set 25 days of PD task as the maximum cut-off 
point for future studies. Two mice had to be excluded from Pilot 2 analysis because they did 
not reach criteria after 25 sessions. 
Because each mouse progressed individually to the next phase and there was no group 
synchrony, once each mouse reached PD criteria, the average percentage of correct trials of 
the two criteria days was calculated. This was then plotted alongside mice that have yet not 
completed the trials until all mice reached criteria or 25 sessions (Fig.3.9A). 
To assess whether there was an image bias when using the new image pair, I analysed the 
two image CS+ groups separately. There was no significant difference in the performance (% 
correct trials) between mice that were assigned image 1 as CS+ (n=6) and image 2 as CS+ 
(n=4) (significant interaction: 0.0392, image difference: F (1, 8) = 2.245, P= 0.1725, two-way 
ANOVA; no significant difference between images post hoc analysis after a two-way 
ANOVA), indicating a lack of image bias when spider and plane images were used (Fig.3.9D). 
The spider and plane images were therefore used subsequently as a default (Chapter 2, 
section 2.3.6, Fig.2.8D).    
To confirm the results are due to learning, after 25 sessions, the CS+ and CS- image values 
were swapped. Five further sessions were run in this manner (n=9), and as expected the 
mice dropped below 50% correct trials in the first session (session 3 in Fig.3.10), reaching 
the 50% correct at the fifth session (Session 7 in Fig.3.10).  
 
 





Figure 3.8 Days needed to complete each pairwise discrimination phase. Days (which were 
equivalent to sessions, because mice had a session a day) needed to reach criteria was plotted for all 
training phases (average number of days: Initial touch = 1, Must touch =1.4, Must initiate=1, Punish 
incorrect =4.6) and pairwise discrimination testing phase (PD = 14.6). Criteria for all training phases 
from Initial touch to Must initiate was 30 trials in 60 min. Criteria for Punish incorrect is 30 trials in 
60 min, 24 correct, for two consecutive days. PD requires for the mouse to complete 30 trials in 60 
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Figure 3.9 Pairwise discrimination Pilot N2 results. A. The percentage of correct trials (when CS+ 
image was nose-poked) out of the total trials done per session, plotted for all the sessions (1-25). 
The dotted line represents the criteria of 80% correct trials. B. The time (minutes) that it took for 
mice to complete each PD testing session. The maximum time (60 minutes) is shown with a dotted 
line. C. The number of correction trials (in red) and correct trials (in green) done in each PD session. 
As the number of correct trials increase, the number of correction trials (trials that follow nose-
poking CS- image) decrease. The maximum number of non-correction trials is 30, whereas there is 
no limit on the number of correction trials. The dotted line represents the criteria of 24 correct trials 
out of 30 (80% correct). The percentage of trials done correctly, over total number of trials in 60 
minutes was plotted over sessions. D. The percentage of trials done correctly out of total completed 
trials, divided into groups based on which image was CS+ (image 1 (in purple) or image 2 (in peach)). 
There was no significant between the performance (% correct trials done) in group 1, assigned image 
1 as CS+, and group 2, assigned image 2 as CS+ (P=0.1725). 50% (chance) and 80% correct trials 
(criteria) are represented with dotted lined. Values are plotted as mean ± SEM. 
 
 
Figure 3.10 Performance when CS+ and CS- images were reversed. Performance (n=9) in the last 
two sessions of PD task (Session N1-2) are shown (same as the last two sessions in Fig.3.9A), 
followed by Session N3-7, in which the images are swapped (CS- image becomes CS+ and vice versa). 
The percentage of correct trials drops on Session N3 accordingly (below 80% correct trials criteria 
annotated with a red dotted line) and slowly increases with more sessions, reaching just under 50% 
(black dotted line; representing chance) on the fifth session (Session N7). Values are plotted as mean 
± SEM. 
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3.3 Discussion  
3.3.1   Object discrimination paradigm 
The major challenge when optimising both novel object recognition (NOR) and object 
displacement (OD) assays was the choice of objects. It took several pilots to establish the 
best performing object set for both of the assays. Several key points emerged as the result 
of piloting. Firstly, mice have inherent biases towards investigating man-made objects, 
which is why inherent preference must be assessed before testing to avoid false positives 
and negatives. Dividing the cohort so that the objects are counterbalanced between animals 
(alternating which object is the familiar one) partially controls for these potential biases, but 
significant differences in innate preference can mask potential phenotypes.  Secondly, the 
chosen objects have to be sufficiently different from one another for the mice to be able to 
distinguish between them. Thirdly, even if there is no detectable inherent preference for 
either of the objects, this does not necessarily imply the mice are able to distinguish 
between the objects. For example, even though I did not detect an inherent preference for 
either of the initial objects used (Cola cola can and water bottle) in NOR, the mice did not 
show a preference for the unfamiliar object after training, indicating they were unable to 
distinguish between the objects. The mice successfully discriminated between the final set 
of objects, small glass vial and light bulb piloted in the object discrimination paradigm, 
resulting in the subsequent use of this object set (Chapter 4).  
Due to the similarity in set-up, I used OD not only as an independent spatial test, but also as 
the training phase for NOR. Importantly, the performance in NOR was not reliant on 
performance in OD, as both training and testing in OD served as memory acquisition training 
for NOR irrespective of whether the mice remembered the new location of the object. This 
combined paradigm, therefore, enables independent detection of deficits in spatial and 
non-spatial components of memory in an efficient manner, both in terms of utilizing only 
one set of objects for both tests and in terms of time efficiency. In order to use both assays 
using this paradigm, the OD interval time between training and testing was shortened to 1-
2h, which is a suggested optimal time interval by Murai et al. (2006), while the interval time 
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of NOR was extended to 24h, which has been used in other studies (Fernandez and Garner, 
2007). This design enabled testing shorter (1h) vs longer (24h) term memory. 
The mice did not have an object bias for either of the objects used (vial and light bulb) and 
were able to distinguish both between moved and stationary (in OD phase), by spending an 
average of 61% of total investigation time with the moved object, and between novel and 
familiar objects (in NOR phase), by spending on average 67% of total investigation time with 
the novel object. Of note, the pre-determined exclusion criterion (of <10 seconds of total 
investigation of objects in a 10-min assay) ensures that the animals analysed have explored 
both objects sufficiently during the acquisition phases. Moreover, removing the mice that 
are not motivated to explore the objects during testing phase reduces inter-individual 
variability and increases the accuracy of the results (Arqué et al., 2008; Leger et al., 2013).  
 
3.3.2   Pairwise discrimination   
Touchscreen technologies are an attractive system to test cognitive function in an 
automated manner that parallels the way patients are tested with CANTAB technology 
(Bussey et al., 2008; Luciana et al., 1997; Robbins et al., 2010). Moreover, the technology 
offers a wide range of available cognitive tasks, allowing testing specific brain regions and 
cognitive functions (Horner et al., 2013; Oomen et al., 2013). To date, touchscreen 
technology has not been used at the Sanger Institute. I, therefore, aimed to establish one of 
the touchscreen assays, pairwise discrimination (PD). This assay tests for associative 
perceptual learning and memory. Due to time constraints reversal of the CS+ and CS- images 
served only as a confirmation of associative learning in the PD task, and not as a reversal 
learning task. Reversal learning tests for cognitive and behavioural flexibility, and is 
associated with different brain regions (namely subregions of the PFC) than PD task (which 
is associated primarily with the dorsal striatum) (Chudasama et al., 2001; Chudasama and 
Robbins, 2005; Horner et al., 2013; Miller, 2000). It, therefore, would test different domains 
of cognitive function and should be considered on hypothesis-driven bases for specific 
mouse lines, as an additional assay.   
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I completed two pilots of pairwise discrimination (PD) task, using the results of the first pilot 
to change several parameters in the second one, further optimising the assay. In Pilot N2, 
the mice were individually advanced to the next phase in order to avoid overtraining. Mice 
with C57BL/6N background were used instead of C57BL/6J mice (Pilot N1), in order to test 
mice of the same background as mice under investigation in Chapter 4 and 5. This was 
important because of reported differences in performance in touchscreen learning based on 
genetic background (Graybeal et al., 2014).  
In order to keep better control of the food intake, maintaining full appetitive motivation, 
and avoid the confounding effects of hierarchical behaviours in home cages, for the second 
pilot I singly housed the mice throughout the course of the test rather than group housed 
them. Housing environment has been shown to affect rodent behaviour, with the reported 
increase in locomotor activity in singly housed mice, task- and strain-specific effects on 
stress levels, and detectable memory impairment in some cognitive tasks (Võikar et al., 
2004). Although touchscreen studies often use group housed animals, from personal 
correspondence with Dr Stacey Rizzo from Jackson Laboratory, who routinely uses singly 
housed animals, there are no observed deficits in the pairwise discrimination in singly 
housed wildtypes. Although a direct comparison cannot be made between the 
performances of the mice in the two pilots I have carried out, due to variability testing 
methodology, both sets of wildtypes completed training within the expected timeline, 
suggesting that housing conditions are not a critical factor for memory acquisition and 
learning in this task.  
My motivations for piloting pairwise discrimination (PD) assay were two-fold. Firstly, I 
wanted to assess whether PD could be used as part of a cognitive phenotyping screen for 
characterising a diversity of novel neurodevelopmental disorders (described further in 
Chapter 5). This phenotyping platform was designed to serve as a proof of principle and 
refinement platform of a large 5-year project at the Sanger Institute, aimed at characterising 
a diversity of novel neurodevelopmental disorders arising from mutations identified in the 
Decipher Developmental Disorders and Prenatal Assessment of Genomes and Exomes 
projects. In order for PD task to be included as part of this phenotyping screen, it had to fit 
into the time frames of the screen, which posed a major limitation, and have the sensitivity 
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for detecting subtle cognitive impairments. In both instances, the assay did not meet the 
relevant criteria to be included in the phenotyping screen (Chapter 5).  
The overall time taken for the mice to progress through the assay (training and testing) was 
over a month, which did not fit with the timelines of the phenotyping screen of four weeks 
of testing per mouse line (discussed in Chapter 5). The time taken to reach the learning 
criteria in the pilots was similar to, although on the upper end of, other reported the 
wildtype performance of 10-16 days in PD. Of note, the criteria for PD varies between 70-
85% correct trials between studies which may explain the shorter time frames in some of 
them (Brigman et al, 2008; Morton et al., 2006; Romberg et al., 2013; Yang et al., 2015). Due 
to weekend breaks in testing, it was critical to ensure these did not introduce an additional 
confounding effect on the performance of mice in the PD testing phase. The set of rules for 
the advancement of mice to the next phase after a weekend break increased however the 
absolute time of the assay, even though this was not reflected in the analysis of the time 
taken to reach criteria. Nevertheless, the stringency of the pre-set rules was especially 
important if the assay was to be used as part of the larger screen testing multiple mouse 
lines.   
In order to detect a significant difference in days (effect=6 days) to reach criteria, using Pilot 
2 wildtype data (Chapter 2, section 2.3.6), with 80% power and 5% type I error rate, the 
sample size would need to be n=22. For a smaller cohort of n=13, we would only have 
enough power (80% power, 5% type I error rate) to detect a larger difference (effect=8 
days); therefore lacking the sensitivity to detect subtle differences with a smaller cohort 
size. 
The second motivation for piloting PD assay was to include a hippocampus-independent test 
in the repertoire of available behavioural assays in our team. This was particularly relevant 
in assessing the hippocampal involvement in the loss-of-function Kptn mouse model in 
Chapter 4, where larger impairment effects were expected.  
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3.3.3   Concluding remarks 
Overall, the establishment and optimisation of the assays in this Chapter provide an 
important addition to the repertoire of already existing behavioural and cognitive assays in 
our team, to characterize a variety of mouse models (described in Chapter 4 and Chapter 5). 
The newly established assays provided opportunities to characterize the mice with a multi-
layered approach, ensuring a range of overlapping cognitive domains were tested. For 
example, object displacement, a spatial hippocampus-dependent task, can be used to 
confirm results from the Barnes maze.  Novel object recognition (NOR) task complements 
both pairwise discrimination and social recognition tasks for different reasons. On the one 
hand, NOR task assesses the memory of the mouse for the familiar object without the 
confounders of social interaction and olfactory learning. On the other hand, NOR is a non-
spatial task, which complements pairwise discrimination (PD) that explored non-
hippocampus dependent memory deficits, providing further information on brain regions 
associated with the neurodevelopmental condition under investigation. 
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Chapter 4. KPTN 
4.1  Introduction 
4.1.1  KPTN-related syndrome 
Windows of Hope (WOH) is a large population-based medical project set up to identify 
genetic causes of inherited conditions, including distinct uncharacterised developmental 
disabilities, focusing on the Anabaptist communities in the USA.  Due to the nature of these 
communities, most mutations identified through this project are recessive and 
consanguineously inherited. One finding from WOH was a group of nine patients, six males 
and three females, belonging to four nuclear families, with a distinct inherited undiagnosed 
developmental delay syndrome (Fig.4.1) (Baple et al., 2014). The most consistent 
phenotypes found in the patients include global developmental delay of variable severity, 
macrocephaly with frontal bossing, anxiety, stereotypies and repetitive speech. Additional 
features found in a subset of the patients include hyperactivity, recurrent pneumonia, 
splenomegaly, childhood hypotonia, and primary seizures.  
Macrocephaly refers to an abnormally large head, including scalp, cranial bone and 
intracranial contents and is diagnosed with occipital frontal circumference (OFC) 2 standard 
deviations (SD) above the mean, with severe macrocephaly defined as OFC 3+ SD above the 
mean (Rollins et al., 2010).  Macrocephaly can be present from birth or can be progressive. 
Absolute macrocephaly, often referred to simply as macrocephaly, is measured without 
taking the overall stature into account, while relative macrocephaly refers to OFC within 2 
SD, but measurements of stature above 2 SD (Rollins et al., 2010). Macrocephaly may be 
due to megalencephaly (enlargement of the brain parenchyma) or due to other conditions, 
such as cranial hyperostosis (thickening of the skull) and hydrocephalus (accumulation of 
fluid in the brain) (Williams et al., 2008). In this thesis, the term macrocephaly will be used 
to include megalencephaly.  
 





Figure 4.1 Amish family pedigree. Pedigree diagram showing the four nuclear families and the nine 
affected patients (in black), with circles representing females and squares representing males. The 
segregation of the two founder mutations is annotated as follows, c.776C>A variant denoted by X 
and c.714_731dup variant is denoted by Dup. Six out of nine probands are compound heterozygous 
for both mutations. Bottom left corner – two sibling patients with homozygous X/X mutation. Figure 
adapted from Baple et al., 2014. 
 
Exome sequencing in the nine probands revealed two founder loss-of-function recessive 
mutations in exon 8 of KPTN gene on chromosome 19 (Fig.4.2). One of the mutations, a 
nonsense c.776C>A sequence variant (annotated as X, Fig.4.1), causes a premature stop 
codon. The other mutation is an in-frame 18 bp duplication, c.714-731dup variant 
(annotated as Dup, Fig.4.1), producing either mislocalised or nonfunctional protein products 
(Fig.4.2) (Baple et al., 2014). Six out of the nine patients were compound heterozygous for 
both of the mutations (Fig.4.1). The patients who were homozygous (X/X) had a more 
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severe intellectual impairment and a higher incidence of seizures than the compound 
heterozygous patients. The authors propose that this may be due to Dup mutation retaining 
partial in vivo functionality (Baple et al., 2014).  
 
Figure 4.2 KPTN gene organisation and position of the two mutations in exon 8 (c.776C>A and 
c.714-731dup). c.776C>A variant is a nonsense mutation where cytosine is substituted for adenine. 
c.714-731dup is an in-frame 18 bp duplication mutation. Figure adapted from Baple et al., 2014 
 
Subsequently, two siblings from Estonia were identified with characteristics associated with 
the KPTN-related syndrome and one-nucleotide homozygous loss-of-function duplication in 
exon 7 of KPTN gene (Fig.4.3) (Pajusalu et al., 2015). Both siblings have moderate 
intellectual disability, progressive macrocephaly (OFC+ 4-5 SD), and anxiety. Out of the two 
siblings, the brother had more severe behavioural abnormalities and experienced two 
episodes of generalised seizures, whereas the sister has no remarkable behavioural 
abnormalities apart from anxiety, and never had seizures (Pajusalu et al., 2015).  





Figure 4.3 Appearance of the Estonian siblings with one-nucleotide duplication in exon 7 of KPTN. 
(Pajusalu et al., 2015) 
 
4.1.2  KPTN and actin cytoskeleton 
KPTN, also known as 2E4, is an actin-binding protein that is not well characterised. Initially 
isolated from blood platelets, with a possible role in actin dynamics of platelet activation, it 
was also found to be localised in sensory epithelium of embryonic inner ear with a 
suggested role in stereocilia formation (Bearer & Abraham, 1999; Bearer et al., 2000; Hong 
et al., 2004). Moreover, it mapped to DFNA4 nonsyndromic deafness locus and was 
therefore postulated to be a hearing loss candidate gene (Bearer & Abraham, 1999; Bearer 
et al., 2000; Chen et al., 1995; Hong et al., 2004). However, no mutations were subsequently 
detected in the coding region of the gene in deaf individuals (Zong et al., 2012). Consistent 
with this, no hearing deficits were identified in the Amish or the Estonian KPTN-syndrome 
cohorts.  
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Actin is an abundant highly conserved protein that polymerizes into filaments and is 
essential for many cellular properties and functions such as cellular motility, the structure 
and mechanical properties of the cytoplasmic matrix, ion channel activity in the plasma 
membrane, and for localizing neurotransmitter receptors (Allison et al., 1998; Kneussel & 
Betz, 2000; Lambrechts et al., 2004; Maximov et al., 1997; Polard and Cooper, 1986; Winder 
and Ayscough, 2005).  The actin cytoskeleton plays an important role in neuron migration 
and axonal projection during brain development, leading to the formation of highly complex 
neuronal networks necessary for higher cognitive brain functions (Rivière et al, 2012).  Cell 
motility and migration is crucial both during development and throughout the lifetime of 
the organism and must be tightly controlled (Lambrechts et al., 2004; Kessels et al., 2011). 
Actin-binding proteins are responsible for regulating the dynamic behaviour of the actin 
cytoskeleton, and mutations in genes encoding these may, therefore, lead to diseases 
(Lambrechts et al., 2004).  It has been shown that the modulation of the actin system 
through actin-binding proteins is impaired in the developing brain of individuals with 
Down’s Syndrome, and depolymerization of dynamic actin filaments can affect generation 
of memory in the hippocampus (Krucker et al., 2000; Weitzdoefer et al., 2002).  
Baple et al. demonstrated that KPTN is associated with dynamic actin cytoskeletal structures 
of neuronal cells necessary for dendritic arborization or spine formation (Baple et al., 2014). 
It was found to be enriched in neuronal growth cones at early developmental stages and at 
postsynapses of neurons during synaptogenesis, suggesting a role for KPTN in 
neuromorphogenesis (Baple et al., 2014).  Moreover, KPTN is expressed throughout the 
body and seems to be present in all cell types in the brain (Fig.4.4) (Uhlén et al., 2015; Zhang 
et al., 2014).  
 




Figure 4.4 KPTN RNA-Seq transcriptome. A. Relative KPTN expression, as FPKM (fragments per 
kilobase of transcript per million mapped reads), in glia, neurons, and vascular cells of the cerebral 
cortex. B. Diagram of the human tissue atlas, with some tissue groups, underlined with the same 
colour scheme as used for relative expression of KPTN in these tissues. C. The panel of tissues and 
their relative KPTN expression, as RPKM (reads per kilobase of transcript per Million mapped reads). 
Colour scheme: Brain (green), Bone marrow and immune system (grey), endocrine (purple), muscle 
tissue (pale red), lung (yellow), liver and gallbladder (lilac), pancreas (light green), gastrointestinal 
tract (dark blue), kidney and urinary bladder (orange), male tissues (light blue), female tissues (pink), 
skin (peach), adipose and soft tissue (turquoise). Figure adapted from The Human Gene Database, 
The Human Protein Atlas, and Zhang et al., 2014.   
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4.1.3   KPTN and mTOR signalling 
More recently KPTN has been implicated as an upstream regulator of the mTORC1 signalling 
pathway (Wolfson et al., 2017). mTOR, (formerly ‘mammalian’) mechanistic target of 
rapamycin, is a serine/threonine protein kinase that forms the catalytic subunit of two 
distinct protein complexes, known as mTOR Complex 1 (mTORC1) and 2 (mTORC2) (Crino, 
2011; Laplante & Sabatini, 2012; Saxton & Sabatini, 2017; Wolfson et al., 2017). mTORC1 
comprises three core components: mTOR, Raptor (regulatory protein associated with 
mTOR), and mLST8 (mammalian lethal with Sec13 protein 8) (Fig.4.5A). Raptor enables the 
recruitment of substrates to the complex and is necessary for the correct subcellular 
localization of mTORC1, while mLST8 associates with the catalytic domain and may play a 
role in stabilizing the kinase activation loop although its importance is still not fully 
understood (Frey et al., 2014; Hoeffer and Klann, 2010; Saxton & Sabatini, 2017). The 
complex also contains regulatory subunits PRAS40 (proline-rich Akt substrate of 40 kDa) and 
DEPTOR (DEP domain containing mTOR interacting protein) that inhibit Raptor (Fig.4.5A) 
(Peterson et al., 2009; Wang et al., 2007).  The mTORC2 contains mTOR, mLST8 and 
DEPTOR, but instead of Raptor has an unrelated protein Rictor (rapamycin-insensitive 
companion of mTOR) with an analogous function, and has additional regulatory subunits 
Protor1/2 (Protein observed with rictor-1 or 2) and mSin1 (mammalian stress-activated 
protein kinase interacting protein 1) (Fig.4.5B) (Frias et al., 2006; Guertin et al., 2006; 
Lamming et al., 2012). Rapamycin is a potent antagonist of mTOR, and rapamycin-FKBP12 
complexes directly bind and inhibit mTORC1, while mTORC2 is insensitive to its acute 
exposure (Crino, 2011; Laplante & Sabatini, 2012; Saxton & Sabatini, 2017; Wolfson et al., 
2017). However, despite this, prolonged rapamycin treatment does inhibit the mTORC2 
signalling, by hindering the incorporation of mTOR into new mTORC2 complexes (Phung et 
al., 2006; Sarbassov et al., 2006). 
 




Figure 4.5 mTORC1 and mTORC2 subunits. A. mTORC1, comprising of mTOR, positive regulators 
Raptor and mLST8, as well as negative regulators DEPTOR, PRAS40, and FKBP12 that forms a 
complex with rapamycin. B. mTORC2, comprising of positive regulators Rictor, mLST8, Protor 1/2, 
and mSin1, as well as negative regulators DEPTOR. Figure adapted from Saxton & Sabatini, 2017. 
 
mTOR signalling pathways are activated in response to environmental cues such as amino 
acid, oxygen, stress, and growth factor levels, as well as synaptic activity in the case of 
neurons (Fig.4.6) (Crino, 2011). Once activated, mTOR signalling regulates many important 
and distinct cellular processes (Fig.4.6). 
 mTORC1 signalling plays a central role in nutrient sensing, regulation cell cycle progression 
(through the regulation of protein, lipid, and nucleotide synthesis, as well as autophagy), 
and metabolism (by controlling the balance between anabolic and catabolic processes in 
response to environmental cues) (Fig.4.6)  (Kim et al., 2002; Kim et al, 2008; Laplante & 
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Sabatini, 2012). One of the most characterised functions of mTORC1 is the regulation of 
translation through multiple processes, including regulation of ribosomal biogenesis, 
through proteins such as S6 kinase 1 and 2 (S6K1/2) and eIF4E-binding proteins (4E-BPs), 
and regulation of activity of phosphatases that in turn regulate mTOR substrates, leading to 
a mTOR-dependent feedback loop (Mayer and Grummt, 2006). Of note, although 
extensively linked to translational regulation, mTORC1 signalling has also been shown to 
regulate gene transcription through modulating the activity of transcription regulators, and 
potentially other processes such as affecting RNA stability and degradation directly or 
regulating epigenetic mechanisms (Passtoors et al., 2012; Wang et al., 2011; Yokogami et 
al., 2000).  
mTORC2 signalling is important for cell survival and proliferation, ion transport, cell 
migration, metabolism, insulin/PI3K signalling, and cytoskeleton organisation (Fig.4.6) (Gu et 
al., 2011; Inoki et al., 2003; Jacinto et al., 2004 Yao et al., 2014). Therefore, not surprisingly, 
due to the pivotal roles of mTOR in many processes, aberrant mTOR signalling is associated 
with many diseases such as cancer, diabetes, neurodegenerative disorders, and neurological 
disorders such as epilepsy and autism (Crino, 2011; Saxton and Sebatini, 2017) (Fig.4.6).  
Proteins associated with both mTORC1 and mTORC2 pathway regulation, are expressed in 
progenitor cells of the ventricular zone during early brain development and in early neurons 
in the nascent cortical plate, and are important for regulating neuronal control of feeding, 
neural circuit formation, and overall brain development (Choi et al., 2008; Hentges et al., 
2001; Kwon et al., 2006; Nie et al., 2010; Tavazoie et al., 2005; Thomanetz et al., 2013). Both 
mTORC1 and mTORC2 signalling play a role in these neurological processes (Lipton and 
Sahin, 2014; Tee et al., 2016). Moreover, mTOR signalling is central to the regulation of long-
lasting synaptic plasticity, which is reliant on protein synthesis and is critical for the 
formation and storage of memories (Hoeffer and Klann, 2010).   
 




Figure 4.6 mTOR signalling and associated disorders. The upstream regulators of mTORC1 and 
mTORC2 pathways and the downstream pathways mTOR signalling regulates, as well as the roles 
mTOR signalling has in brain development. Bottom right (yellow box) – disorders associated with 
aberrant mTOR signalling. 




Interestingly, KPTN has been recently shown to be a part of KICSTOR protein complex, 
consisting of KPTN, ITFG2, C12orf66 and SZT2 (seizure threshold 2) (Wolfson et al., 2017).   
KICSTOR is required for inhibition of mTORC1 signalling in response to amino acid or glucose 
deprivation (Saxton and Sebatini, 2017; Wolfson et al., 2017). The proposed mechanism 
through which KPTN works involves a heterodimer of KPTN and ITFG2.  These then form a 
complex with the other two proteins (C12orf66 and SZT2) of the KICSTOR complex, with 
SZT2 being the link between the other three proteins (Fig.4.7). Amino acid levels, detected 
via intra-lysosomal and cytosolic sensing mechanism, activate Rag GTPases (obligate 
heterodimers) that are tethered to the lysosome membrane via a pentameric Ragulator 
complex. Rag GTPases bind Raptor and promote the translocation of mTORC1 to lysosome 
surface. Once at the surface mTORC1 acts via an ‘AND-gate’ mechanism - both Rag GTPases 
and Rheb (Ras-homolog expressed in brain) must be activated - to activate mTORC1 
signalling (Fig.4.7). In response to amino acid or glucose deficiency, KICSTOR localizes to 
lysosome surface and recruits GATOR 1 (GTPase activating protein for RAGA), which inhibits 
Rag GTPases.  Conversely, GATOR 2 inhibits GATOR 1 in response to cytosolic amino acid 
levels (Fig.4.7). Thus, KICSTOR acts as a negative regulator of the mTORC1 pathway. 
Complexes, such as TSC1-TSC2 (tuberous sclerosis complex) protein heterodimer, negatively 
regulate Rheb, integrating signals from cellular energy status and growth factor signalling 
(Fig.4.7).  
Loss-of-function of TSC1 or TSC2 causes unregulated mTOR activation, which in turn leads to 
tuberous sclerosis complex disease, associated with epileptic seizures (Crino, 2011).  
Importantly, mutations in KICSTOR components have been shown to result in neurological 
diseases. Homozygous and compound heterozygous mutations in SZT2 cause a distinct and 
severe early-onset autosomal-recessive epileptic encephalopathy, characterised by epilepsy, 
global developmental delay, brain abnormalities such as thick and short corpus callosum, 
and affected head size (Basel-Vanagaite et al., 2013; Tsuchida et al., 2017). In mice, loss-of-
function Szt2 mutants had epileptogenesis and an increase of mTORC1 signalling in the brain 
(Peng et al., 2017; Frankel et al., 2009). Mutations in KPTN, outlined above, further link the 
role of mTOR in neurological disorders.  




Figure 4.7 KICSTOR complex and mTORC1 signalling. Amino acid levels, detected via intra-lysosomal 
and cytosolic sensing mechanism, also activate Rag GTPases (obligate heterodimers). Rag GTPases 
are tethered to the lysosome membrane via a pentameric Ragulator complex. When activated Rag 
GTPases binds Raptor, which is part of the mTORC1, thus promoting the translocation of mTORC1 to 
lysosome surface, where it also interacts with Rheb (Ras-homolog expressed in brain). Both Rheb 
and Rag GTPases must be activated to activate the mTORC1 signalling pathways. KPTN forms a 
heterodimer with ITFG2, and these then form a complex with the other two proteins (C12orf66 and 
SZT2) of the KICSTOR complex, with SZT2 being the link between the other three proteins. In 
response to amino acid or glucose deficiency, KICSTOR localizes to lysosome surface, where it 
recruits GATOR 1 (GTPase activating protein for RAGA), which inhibits Rag GTPases. While GATOR 2 
acts as a negative inhibitor of GATOR 1, in response to cytosolic amino acid levels. Thus KICSTOR acts 
as a negative regulator of the mTORC1 pathway. TSC1-TSC2 (tuberous sclerosis complex) protein 
heterodimer, negatively regulate Rheb. Figure adapted from Saxton & Sabatini, 2017. 




4.1.3  The approach and aims  
My aim was to model the novel KPTN-related syndrome, using a Kptn mutant mouse line, to 
demonstrate a causal link between the loss-of-function mutations and phenotype.  Once a 
link was established, I aimed to use the validated animal model to study the mechanisms by 
which loss of KPTN protein results in the human developmental disorder. No study to date 
has modelled this syndrome in mice.  
My approach was first to test whether I could recapitulate the main patient phenotypes in 
the homozygous loss-of-function Kptn mice, to confirm this is an appropriate model for the 
disorder. To this end, I employed a set of morphometric, cognitive, behavioural, and 
molecular tests. Secondly, to identify the potential mechanisms underpinning this 
neurodevelopmental disorder, I carried out both hypothesis-driven developmental work, as 
well as genome-wide expression profiling in several brain regions. 
Because the most consistent phenotypes found in patients include macrocephaly, global 
developmental, and anxiety, I focused on testing these features first.  
 
4.2  Results 
4.2.1   Kptn-/- mouse model 
To study the syndrome associated with the loss-of-function mutations in KPTN in greater 
detail, I used an engineered loss-of-function Kptntm1a(EUCOMM)Wtsi “knockout first” model, 
generated by the Wellcome Trust Sanger Institute's Mouse Genetics Project (MGP) (White 
et al., 2013). To assess the extent of transcriptional knockdown in the Kptn mutant line, the 
gene expression in three tissues -  brown adipose, white adipose, and liver tissues - was 
assessed in 4 Kptntm1a/tm1a and 4 Kptn+/+ mice (Fig.4.8). The results indicate the tm1a allele 
has complete loss of expression for Kptn and is henceforth referred to as Kptn-/-.  





Figure 4.8 Kptntm1a(EUCOMM)Wtsi “knockout first” construct is a complete null. Expression profile of 
Kptn-/- (n=4) and wildtype (+/+; n=4) in A. brown adipose, B. white adipose, C. and liver tissues. The 
graphs are showing the relative quantity (RQ) of expression in each tissue from quantitative PCR. 
Values are plotted as mean ± SD.  
 
4.2.2   Morphometric brain analyses  
Since macrocephaly was observed in all the patients, in both the Amish and Estonian 
cohorts, I investigated whether the homozygous mice recapitulate this aspect of the human 
disorder. To investigate the skull and brain volumes, I employed several approaches, in 
collaboration with Stephen Sawiak (Magnetic resonance imaging (MRI), Binnaz Yalcin and 
Perrine Kretz (histological morphometrics), and with support of the Mouse Genetics Project 
(MGP) team (X-ray cephalometrics). 
 
4.2.2.1  Kptn mutants have a severe and global macrocephaly 
Using X-ray cephalometric analysis (Chapter 2, section 2.5), we detected an increase in skull 
perimeter and width and a decrease in skull length in Kptn-/- mice (perimeter P=0.0007, skull 
width P=9.7x10-6, skull length P=0.003, Fig.4.9). The results indicate that the mutant mice 
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are macrocephalic. The fact that the skull length was decreased, while other parameters 
were increased, also implies skull shape abnormalities.  
 
 
Figure 4.9 Kptn-/- mice are macrocephalic. Perimeter, skull width and skull length were measured 
with X-Ray cephalometrics in mutant (Kptn-/-) and wildtype (+/+) male mice (n=7 per genotype). 
There was a significant increase in the perimeter and width of the skull, and a decrease in the length 
(perimeter length P=0.0007, skull width P=9.7x10-6, skull length P=0.003). Values plotted as a box 
and whisker plot, with outliers plotted as individual points.  
 
To analyse brain volume directly, we performed Magnetic resonance imaging (MRI) imaging 
on post-mortem mouse brains (Chapter 2, section 2.4). Using MRI tensor-based 
morphometry followed by voxel-based quantification of brain volume, we detected 
intracranial volume increase in the homozygous Kptn mice of both genders when compared 
to controls (Male: P= 0.0009, t=4.526 df=11, two-tailed Student’s t-test; Female: P= 0.0001, 
t=5.226 df=14, two-tailed Student’s t-test). Since Kptn-/- mice have larger brains, removing 
the effect of overall brain volume also removes the Kptn effects. I, therefore, did not adjust 
for overall brain volume. Without regressing out the overall volume, there were detectable 
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effects at every part of the brain (significant at p<0.05 family-wise error rate corrected). We, 
therefore, set a more stringent threshold (p < 0.01 family-wise error corrected), so that only 
the most significant areas are highlighted Fig.4.10.  
 
 
Figure 4.10 Kptn-/- mice are macrocephalic. A. Representative coronal histology section (Nissl 
staining) of Kptn-/- and control (+/+) brain respectively, qualitatively showing the mutant mice have 
larger brain than controls. B. 3D reconstruction MRI image of Kptn-/- brain; regions highlighted in red 
are significantly larger in mutant mice than in controls (with a threshold of significance at p < 0.01 
family-wise error corrected). C. Total intracranial brain volume, from MRI, of male mutant (Kptn-/-; 
red; n=7) and control mice (+/+; blue; n=6), showing an enlargement in intracranial volume the Kptn 
mutant mice (P= 0.0009***) D. Total intracranial brain volume, from MRI, of female mutant (Kptn-/-; 
red) and control mice (+/+; blue) (n=8 per genotype), showing an enlargement in intracranial volume 
the Kptn mutant mice (P= 0.0001***).  Values are plotted as mean ± SEM.  
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The global increase in brain volume was confirmed by histological volumetric analysis 
(Chapter 2, section 2.6). The representative coronal histology section of Kptn-/- and control 
brains visually illustrates the mutant mice have enlarged brains (Fig.4.10A). For a more 
thorough quantitative approach to analyse the neuroanatomical defects in Kptn-/- mice, we 
used a robust method of assessment of 78 brain parameters across 20 distinct brain regions, 
developed by my collaborators (Mikhaleva et al., 2016). This consisted of a systematic 
quantification of the same three coronal brain regions down to cell level resolution and 
blind to the genotype (Fig.4.11; Chapter 2, section 2.6; Table 3).  
In males (n=8 per genotype; Fig.4.11A) the total brain area was significantly increased across 
the three coronal sections (section 1: +14.4%, P=0.0007; section 2: +9.1%, P=0.00008; 
section 3: +10.2%, P=0.00002) concomitantly with enlarged cortical regions including the 
cingulate cortex (+10.8%, P=0.03), motor cortex (section 1: +6.2%, P=0.01; section 2: 
+10.3%, P=0.0008), somatosensory cortex (section 1: +10.3%, P=0.008; section 2: +6.2%, 
P=0.004), and the piriform cortex (+19.2%, P=0.004). White matter structures were also 
affected and included the genu of the corpus callosum (+22.2%, P=0.00006), the soma of the 
corpus callosum (+16.1%, P=0.0003), and the internal capsule (+12.1%, P=0.0002). The 
lateral ventricles were the only brain regions exhibiting a decreased size (section 1: -36%, 
P=0.05; section 2: +54%, P=0.02).   
This was consistent in the females (n=8 per genotype; Fig.4.11B), where the total brain area 
was significantly increased across the three coronal sections (section 1: +13.8%, P=0.00001; 
section 2: +8.3%, P=0.0002; section 3: +7.9%, P=0.0003). Similar cortical regions and white 
matter structures were also significantly enlarged in female mice, for example, the 
somatosensory cortex (+6.9%, P=0.0001) and the soma of the corpus callosum (+27.3%, 
P=0.000017). The size of the hippocampus is the only brain structure not affected in Kptn-/- 
when compared to controls in both males and females.   
Taken together, the results indicate that Kptn depletion results in an increase in brain 
volume, with both white and grey matter affected in both sexes.





Figure 4.11 There is significant and global increase in size in the Kptn-/- brain, compared to controls. 
Images showing a representative heat map of p values of change in brain size (%) across three 
coronal sections – section 1 (left), section 2 (middle), and section 3 (right) - for male (A) and female 
(n=8 per genotype) (B) mice brains (n=8 per genotype), with red regions denoting areas with highest 
change in Kptn mutants (%) when compared to littermate wildtype controls. Below is the panel of 
colours and associated p value scores. 
  
4.2.2.2  Kptn mutants have a progressive macrocephaly 
We next investigated whether the macrocephaly observed in the Kptn-/- mice is present 
from birth (as was observed in the Amish patients) or is progressive (as with the Estonian 
siblings). To investigate this we performed morphological analysis on brains of postnatal day 
(P)0 mice (wildtype n=8, Kptn-/- n=9) using a quantitative histological approach with 53 
parameters of size and surface, similar to the analysis done on adult brains and with most 
parameters having an equivalent in the adult mice (Chapter 2, section 2.6; Table 4). 
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We observed no difference in 51 out of 53 parameters, including total brain area (Fig.4.12A). 
This indicates that macrocephaly phenotype in the Kptn-/- mouse model is not present at 
birth, and is, therefore, a progressive form, likely associated with postnatal development 
processes.  Out of the two parameters that were affected, there was 11% reduction in the 
area of the hippocampus in the mutants (P=0.04, Fig.4.12B) and a 9% increase in the 
internal capsule (P=0.03, Fig.4.12C), which suggests that some morphological anomalies 
originate from prenatal stages, but are restricted to the hippocampus and the internal 
capsule. 
Taken together, these data allowed us to discriminate between different forms of 
macrocephaly, concluding that Kptn deficiency is associated with progressive macrocephaly 
in the Kptn-/- mice. 
 





Figure 4.12 P0 mutant mice are not macrocephalic.  A. Total brain area shown for wildtype (WT) 
and Kptn-/- male P0 mice at Bregma +2.19mm and 3.51mm. In both instances, the total area was not 
significantly different between genotypes. B. The hippocampus total area is reduced by 11% in the 
Kptn-/- mice (P=0.04*). C. The internal capsule total area is increased by 9% in the Kptn-/- mice when 
compared to wildtype controls (P=0.03*). D. A representative image of the parameters in the P0 
brain morphology analysis, including primary somatosensory cortex (S1), secondary somatosensory 
cortex (S2), motor cortex (M1), retrosplenial granular cortex (RS), splenium of the corpus callosum 
(scc), habenula (Hb), thalamus (Thal), hippocampus (HP), total internal length of pyramidal layer 
(TILpy), amygdala (AM), hypothalamus (Hypo), internal capsid (ic), total brain area (TBA), fimbria (fi), 
third ventricle (3V), dorsal 3rd ventricle (D3V). E. Representative image of wildtype (WT) and Kptn-/- 
at Bregma 3.51 mm, with no phenotypic differences observed between genotypes (Nissl staining).  
 




4.2.2.3 Increased cell count and proliferation rate contribute to the adult macrocephaly 
phenotype in Kptn mutants 
To elucidate the cellular mechanisms behind the macrocephaly we investigated whether the 
macrocephaly observed in the adults could be explained by a larger number of cortical cells 
(assessed in males only, due to lack of sexual dimorphism), rather than cell size, as have 
been observed in some models of macrocephaly (Kwon et al., 2001). To answer this 
question we measured the following parameters in male mice (n=8 per genotype; Chapter 2, 
section 2.6) - cell count, cell area, cell circularity, cell solidity, and layer (region) area in each 
cortical layer (I - VI) of motor and somatosensory cortical regions (layer area: layer I: +21.1%, 
P=0.0018; layer II/III: +22.4%, P=0.012; layer IV: +29.9%, P=0.00054; layer V: +17.7%, 
P=0.013; layer VI: +17.4%, P=0.013) and cell count was increased in layers II to V (layer II/III: 
+21.7%, P=0.028; layer IV: +20.1%, P=0.008; layer V: +16.3%, P=0.028). There was a 19.4% 
increase in average cell count across the cortical layers and 21.8% increase in average layer 
(region) area in the mutants (Fig.4.13A-B). There was no significant increase in cell density 
or average cell area (a supporting parameter for cell size) (Fig.4.13A-B). There was no 
significant change in cell circularity and cell solidity, suggesting the rate of cell death is not 
affected. Taken together these results indicate that the increase in cell number in the brain 
contributes to the severe macrocephaly phenotype in adult   Kptn-/- mice.  
We next investigated whether there was an increase in the rate of proliferation (Chapter 2, 
section 2.6). Ki-67 protein is commonly used as a cellular marker for proliferation, and is 
present in all active phases of the cell cycle, but not in the quiescent (non-dividing cells). We 
performed a cell count of Ki-67 positive cells, and identified an average 11% increase in Ki-
67 positive cells in the dentate gyrus of the hippocampus of male adults (P=0.045), 
indicating an increase in the rate of proliferation in the hippocampus (Fig.4.13C).  
 




Figure 4.13 Kptn-/- mice have an increased cortical cell count and proliferation rate. A. Cell count 
and total cell area were measured in each cortical layer (I - VI) of motor and somatosensory cortical 
regions. All six cortical layers were increased in the mutants relative to the WTs (n=8 per genotype) 
(layer I: +21.1%, P=0.0018; layer II/III: +22.4%, P=0.012; layer IV: +29.9%, P=0.00054; layer V: +17.7%, 
P=0.013; layer VI: +17.4%, P=0.013) and cell count was increased in layers II to V (layer II/III: +21.7%, 
P=0.028; layer IV: +20.1%, P=0.008; layer V: +16.3%, P=0.028). The colours of the bars represent the 
significance level for each measurement (as shown by panel of colours and associated p value 
scores). Values are plotted as mean ± SEM. B. Representative images showing a larger number of 
cells in the Kptn-/- when compared to the control, without a change in density. C. There is an increase 
in Ki67 positive cells in the dentate gyrus of the hippocampus (P=0.045*), indicating an increase in 
proliferation in the hippocampus. Values are plotted as mean ± SEM.  
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4.2.3   Behavioural and cognitive consequences of Kptn deficiency 
Next, I determined whether the cognitive and behavioural phenotypes observed in the 
patients were phenocopied in this mouse model. Because there is no recorded sexual 
dimorphism in KPTN-syndrome patients, and no identified sexual dimorphism based on 
brain morphometric analysis, I conducted all subsequent experiments in male mice, unless 
otherwise stated, in order to reduce the number of animals used.  
 
4.2.3.1  Kptn-/- mice have increased locomotor activity and anxiety-like phenotypes 
To characterise the general behaviour of Kptn-/- mice, I assessed their overall locomotor 
capabilities, such as distance covered, time spent moving, and velocity travelled, compared 
to controls, using the open field test (Chapter 2, section 2.3.1). The Kptn mutant mice spent 
more time moving (mean difference: 82.16 sec, P ≤ 0.05, t=2.640 df=23, two-tailed Student’s 
t-test; Fig.4.14B) than controls and travelled a greater distance (mean difference: 1320cm, P 
= 0.0185, t=2.534 df=23, two-tailed Student’s t-test; Fig.4.14A). This is consistent with the 
hyperactivity phenotype observed in a subset of patients with KPTN-related syndrome 
(Baple et al., 2013). All other activity parameters were not significantly different between 
genotypes. 
To test for anxiety-related behaviours, a phenotype shared across all the patients; I used the 
light/dark box assay (Chapter 2, section 2.3.2). Kptn-/- mice spent significantly more time in 
the dark zone (mean difference: 190.2sec, P<0.0001 t=4.946 df=24, two-tailed Student’s t-
test; Fig.4.15A) and had a reduced frequency of visits to the light zone (mean difference: -
7.09, P= 0.0002, t=4.326 df=25, two-tailed Student’s t-test; Fig.4.15B), confirming a strong 
anxiety-like phenotype, which is concordant with the anxiety observed in the patients. It is 
important to note that the mutant mice still transitioned into the light zone, thus exploring 
both areas, but showing a significant increase in preference for the dark zone compared to 
controls. This excludes the possibility that this increase in preference is due to the lack of 
exploration. 





Figure 4.14 Kptn-/- mice display increased locomotor activity. The distance covered in an open field 
and time spent moving were plotted. A. Kptn-/- mice (red; n=12) covered significantly more distance 
(P=0.0185*) than wildtype controls (+/+) (blue; n=13) and B. spent more time moving (P=0.0146*). 
Values are plotted as mean ± SEM. 
 




Figure 4.15 Kptn homozygous mice have increased anxiety-like behaviour. A. Kptn-/- mice (red; 
n=14) spend significantly longer time in the dark zone (P< 0.0001****) of a light/dark box than 
wildtype (+/+) controls (blue; n=13), and B. have reduced frequency of visits to the light zone 
(P=0.0002***). Values are plotted as mean ± SEM. 
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4.2.3.2  Kptn-/- have a deficit in hippocampal-dependent memory  
All the KPTN-related syndrome patients were diagnosed with intellectual disability and 
global developmental delay, with variable severity. Since learning and memory are integral 
to cognition, to model the cognitive impairment observed in the patients, I tested the mice 
using several memory and learning assays (Sweatt, 2004).  
 
4.2.3.2.1 Social recognition 
First, I tested the mice using the social recognition assay (Chapter 2, section 2.3.4), which 
exploits in the innate preference of mice for investigating novel over familiar conspecifics 
and assesses olfactory-mediated hippocampus-dependent memory (Dias et al., 2016; 
Ferguson et al., 2001; Guan et al., 1993; Kogan et al., 2000; Sanchez-Andrade et al., 2005; 
Winslow and Insel, 2004). The Kptn-/- mutant mice did not differ from the wildtype controls 
in their levels of social approach behaviour, measured as time spent investigating the novel 
conspecific (stimulus A) on trial 1, implying the mice do not have a deficit in social 
interaction. Both wildtypes and Kptn-/- mice habituated to the stimulus over four trials, and 
significantly increased their investigation time on trial 5 (no significant interaction, genotype 
difference F (1, 17) = 1.004, P=0.3304; trial 4 vs trial 5 wildtype P <0.0001, mutants 
P=0.0023, post-hoc analysis after two-way ANOVA), indicating they were able to 
differentiate between the stimuli in trial 5 (stimulus B) and trial 4 (stimulus A), which is 
suggestive of an acquired memory for stimulus A (Fig.4.16A) and indicative of a functional 
olfactory system.   
During 24h memory test, the wildtype controls spent longer (investigating the unfamiliar 
stimuli on Day 2, whereas the Kptn mutants did not show a preference for the unfamiliar 
mouse when compared to controls, indicating a 24h memory impairment (wildtype: 
P=0.0002, t= 4.79 df=2; Mutant: P=0.985, t=0.0185 df=14, two-tailed multiple t-test with 
multiple comparison corrections; Fig.4.16B).  




Figure 4.16 24h memory impairment in Kptn-/- mice. A. Memory acquisition (Day 1). Both controls 
(n=11, +/+) and Kptn-/- mutant (n=8, Kptn-/-) (only females tested) recognize stimulus animal 
repeatedly presented to them over the course of four trials, as shown by a decline in the 
investigation time over trials 1-4. Both mutant and wildtype mice display an increase in the 
investigation time on trial 5 when presented with a novel stimulus animal (wildtype P <0.0001****, 
mutants P=0.0023**). B. 24h memory test (memory retention test). The controls, but not the 
mutant mice show a significant increase in time spent investigating the unfamiliar stimulus vs the 
familiar from Day 1), suggesting that Kptn-/- mice do not retain the memory of a familiar animal over 
24h (wildtype: P=0.0002***, Mutant: P= 0.985).  
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Taken together, Kptn-/- mice indicate likely deficits in hippocampus-dependent memory. To 
confirm this phenotype, I next tested the mice in a hippocampus-dependent spatial memory 
assay, the Barnes maze.    
 
4.2.3.2.2 Barnes maze 
Barnes maze is a dry alternative of the Morris water maze and relies on the inherent 
tendency of mice to want to escape an aversive environment (Chapter 2, section 2.3.7).  
Mice placed on a brightly lit open table surface with 20 holes around the periphery must use 
spatial cues to repeatedly locate an escape box beneath one of the holes, the target 
(Harrison et al., 2006; Harrison et al., 2009; Koopmans et al., 2003). 
  
4.2.3.2.2.1. Acquisition results 
During training, there was no difference between Kptn-/- and wildtype in the time taken to 
approach the escape box (measured by primary latency to approach) during both training 1 
(T1.1-T1.2) (no significant interaction, genotype difference: F (1, 207) = 0.1512, P=0.6978, 
two-way ANOVA) and training N2 (T2.1-2.3) (no significant interaction, genotype difference: 
F (1, 262) = 0.4383, P=0.5085, two-way ANOVA), indicating that both Kptn mutant and 
wildtype mice were able to locate the target zone with equivalent speed (Fig.4.17A). There 
was a significant overall reduction in the time taken to reach the escape box for both 
genotypes during training (F (4, 469) = 11.33, P<0.0001, two-way ANOVA) (Fig.4.17A).  
There was no detected difference in the total errors in wildtypes and mutants during 
Training 1 (T1.1-1.2; Chapter 2, section 2.3.7) (Fig.17B). However, during Training 2 (T2.1-
T2.3; Chapter 2, section 2.3.7) the Kptn mutant mice made overall significantly more errors 
(variable interaction P= 0.0157, genotype difference: F (1, 471) = 8.76, P = 0.0032; T2.2: 
mutant made on average 12.61 errors more than wildtypes (P<0.001), T2.3: Kptn mutant 
made on average 9.2 more errors than wildtypes (P<0.05); posthoc analysis after two-way 
ANOVA) (Fig.4.17B).  






Figure 4.17 Barnes maze memory acquisition results. A. Primary latency across all days of training 
(Training 1 (T1.1-1.2) and Training 2 (T2.1-2.3)) was measured for wildtypes (+/+) (n=16) and Kptn-/- 
(n=11). There was no genotype difference across all training days and a reduction in time taken to 
get to the escape box from T1.1 to T2.3. B. The total number of errors recorded before the mice 
went into the escape box, overtraining days (Training 1 (T1.1-1.2) and Training 2 (T2.1-2.3)) was 
plotted. There was no significant genotype difference in total errors made on T1.1-1.2, but there was 
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4.3.3.2.2.2 Memory retention results 
During 24h probe, the percentage of time spent around the target hole relative to other 
holes was calculated (Chapter 2, section 2.3.7). Both genotypes spent significantly longer 
around the target hole when compared to other holes (no significant interaction, genotype 
difference: F (1, 25) = 2.663, P=0.1153; genotype difference at target: P>0.05, post-hoc 
analysis after two-way ANOV; Fig.4.18A, Fig.4.19). However at 72h probe, the mutant mice 
spent 5% less time at the target zone than wildtype controls (significant interaction 
P=0.0326, genotype difference: F (1, 500) = 0.8423, P=0.3592; duration at hole P < 0.0001, 
post-hoc analysis after a two-way ANOVA; Fig.4.18C, Fig.4.19). The percentage difference in 
time spent at each hole between mutant and controls is also depicted spatially, showing the 
location of the target zones during 24h and 72h probe trials, and the difference between 
genotypes of the proportion of time spent at the target during both probe trials (Fig.4.19).  
There was a significant difference between the mean time spent in all holes vs target hole 
on 24h probe for both genotypes (P ≤ 0.001 for both genotypes, post-hoc analysis after two-
way ANOVA, Fig.4.18B), but the mutants did not have a significant difference between time 
spent at target vs non-target on 72h probe because of the overall reduction in time spent at 
target (controls: P ≤ 0.0001, mutants: P>0.05, post-hoc analysis after two-way ANOVA, 
Fig.4.18D). These results, therefore, indicate that Kptn mutants cannot retain spatial 
memory for 72h in this task.   
 




Figure 4.18 Kptn have a 72h memory impairment. A. The percentage of time male wildtype (+/+) 
(n=16) and Kptn-/- (n=11) mice spent each hole (1-20; with hole N1 being the target) of the Barnes 
maze during 24h probe trial was plotted. There was no difference in time spent near target hole 
(where during training there was an escape box). B. Mean percentage of time spent at target hole 
relative to all the other holes during 24h probe trial. Both genotypes spent significantly more time at 
target vs all other holes (P ≤ 0.0001***). C The percentage of time male wildtype (+/+) (n=16) and 
Kptn-/- (n=11) mice spent each hole (1-20; with hole N11 being the target) of the Barnes maze during 
72h probe trial was plotted. The controls spent a significantly more time (5.13% more) at the target 
(hole N=11) than the Kptn mutants (P≤ 0.001**). D. Mean percentage of time spent at target hole 
relative to all the other holes during 72h probe trial. The mutants did not have a significant 
difference between target vs non-target due to their reduced time at the target, while the wildtypes 
spent significantly more time at target vs all other holes (P ≤ 0.0001***).  Values are plotted as mean 
± SEM. 
 





Figure 4.19 A spatial representation of the time Kptn-/- mice spent at each hole during 24h and 72h 
probes relative to controls.  The two circles represent the spatial distribution of holes (labelled 1-20 
in black) in Barnes maze during 24h and 72h probes. The target hole is annotated by a red box in 
both instances (24h probe: hole N1; 72h probes: hole N11). The numbers in blue represent 
percentage of time difference between genotypes at each hole, with 0 being no difference and 
positive values meaning controls spend longer at the hole. There is no significant difference at target 
hole between genotypes on 24h probe and therefore, but the controls spend 5.13 % longer at target 
hole in 72h probe (P ≤ 0.01**).  
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The results from this assay testing hippocampus-dependent memory strongly support the 
hypothesis that the Kptn mutant mice have a deficit in hippocampus-dependent memory 
retention. 
 
4.2.3.3  Kptn-/- mutants do not have impairment in spatial memory of up to 2h  
I next tested the mice (n=12 for both genotypes) using the object discrimination paradigm, 
which incorporates object displacement (OD) and novel object recognition (NOR) testing 
(Chapter 2, section 2.3.3; pilots described in Chapter 3).  
There was no significant genotype difference observed in the preference of mice (n=7 
wildtype, n=9 Kptn-/-) for the moved object (P=0.9498, t=0.06405 df=14, two-tailed 
Student’s t-test) (Fig.4.20A). Both genotypes spent longer investigating the moved object in 
OD part of the paradigm than reference value mean of 50% chance (wildtype: mean: 74.67, 
P= 0.0242, t=2.995 df=6; Kptn mutants: mean: 75.42, P=0.0141, t=3.124 df=8; one-tailed t-
test). Therefore despite lower sample size relative to the estimated cohort size of n=12 
(power analysis, Chapter 2, section 2.3.3.3), both genotypes displayed sufficiently high 
preference score (%) to be able to detect a difference from the reference value of 50% (‘no 
preference’).  
Those mice that were not excluded from the OD phase, were then tested 24h later in NOR 
part of the paradigm. There was no significant genotype difference in their preference for 
the novel object (P=0.4875, t=0.7146 df=13, two-tailed Student’s t-test). Both genotypes 
spent significantly more with the novel object than the theoretical mean of 50% chance 
(wildtype: mean: 67.58, t=2.653 df=5; Kptn-/-: mean: 61.41, t=2.075 df=8; one-tailed t test) 
(Fig.4.20B).  
Overall, Kptn-/- did not exhibit 1-2h spatial memory impairment, nor an impairment in the 
NOR performance.    




Figure 4.20 Object discrimination paradigm, displaying no impairment in 1-2h spatial memory and 
NOR performance in the mutants.  A. Object displacement testing. The percentage of time spent 
(out of total investigation time of sample and displaced objects) with displaced object was plotted. 
Both genotypes (Kptn-/- n=9 and controls (+/+) n=7) had a significant preference for the displaced 
object, above 50% chance (dotted line). B. NOR testing phase. The percentage of time spent (out of 
total investigation of sample and novel objects) with novel objects was plotted. Both mutants (n=9) 
and wildtype (+/+) (n=5) had a significant preference for the novel object, above 50% chance (dotted 
line). Values are plotted as mean ± SEM. 
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4.2.3.4   Kptn-/- do not have an impaired perceptual non-hippocampal memory and 
learning 
To test whether the mutants have non-hippocampal dependent cognitive impairments, I 
used the touchscreen pairwise discrimination (PD) task, an operant conditioning task that is 
run using a touchscreen platform (Chapter 2, section 2.3.6; Chapter 3).  
N=12 per genotype were put through training, however only n=10 wildtype and n=8 Kptn-/- 
were able to learn the initial set of rules associated with the training phase. Two wildtypes 
and four mutants were excluded because they did not reach criteria within 25 day cut-off 
(Chapter 2, section 2.3.6). During the PD task, both genotypes started off at around 50% of 
correct trials in Session 1, which implies the mice had no bias for either of the images at the 
start of PD task. Both genotypes were able to reach the criteria 80% of correct trials for two 
consecutive days (F (1, 16) = 1.144, P=0.3007, two-way ANOVA; Fig.4.21), after a similar 
number of sessions (WT: 14.6 days, Kptn-/-: 11.25 days, P=0.2093, t=1.162 df=16, two-tailed 
Student’s t-test; Fig.4.22).  
To ensure that the mice did indeed learn, the images were swapped (CS- image became the 
CS+ and vice versa) after the last PD task session and the percentage of correct trials was 
recorded for a subset of the mice (wildtype n=9, Kptn-/- n=4).  As expected, the percentage 
of correct trials dropped significantly below 50% for both genotypes (genotype difference: 
(F (1, 11) = 0.02269, P=0.8830, two-way ANOVA)) between the last day of pairwise 
discrimination (session 25) and the first day of images being swapped from CS+ to CS- 
(session 1, with an arrow) (F (6, 66) = 68.19, P<0.0001, two-way ANOVA), (Fig.4.21). The 
percentage of correct trials increased with subsequent sessions, reaching the 50% correct at 







Figure 4.21 Kptn mutants do not display a difference in performance in the hippocampus-
independent pairwise discrimination task. Percentage of correct trials (when CS+ image was nose-
poked) out of the total trials done per session were plotted for Kptn-/- (n=8) and wildtype (n=10) 
mice. There is no significant difference in genotype between learning in the pairwise discrimination 
(P=0.3007). Once the mice reached criteria (80% correct trials; blue dotted line), the mean of 
percentage of correct trials over their last two days was taken and used in the overall mean for the 
subsequent sessions. Therefore, each session has an equal number of mice, even though some mice 
finished the assay faster than other. Mice (wildtype n=9, Kptn-/- n=4) showed significant decrease in 
the percentage of correct trials completed, below 50% chance (black dotted line), between the last 
day of pairwise discrimination (session 25) and the first day of images being swapped from CS+ to 
CS- (session 1, with an arrow) (P<0.0001), but there was no genotype difference in percentage of 








Figure 4.22 There was no detected genotype difference of days needed to reach criteria in 
pairwise discrimination task. The number of sessions (each session is one day) it took for Kptn-/- 
(n=8) and wildtypes (+/+) (n=10) to get 80% of trials correct on two consecutive days was plotted. No 
genotype difference was observed (P=0.2093). Values are plotted as mean ± SEM. 
 
4.2.4   Kptn deficient transcriptome  
In order to assess postnatal consequences of Kptn deficiency on a molecular level and 
explore affected mechanisms in different brain regions, I carried out gene expression 
analysis on four separate brain regions from male Kptn mutant and wildtype mice (n=6 per 
genotype) (Chapter 2, section 2.7). The regions analysed, in collaboration with Fernando 
Riveros-McKay at the Sanger Institute, were hippocampus, striatum, prefrontal cortex, and 
cerebellum. These structures are of particular interest due to the cognitive testing results 
and morphometric analysis I performed. Although no behavioural or cognitive assays 
specifically tested cerebellar function in Kptn-/- mice, this region was collected to provide 




Genotypes were confirmed for each tissue by examining the counts of reads for Kptn across 
Kptn-/- and wildtype controls (Fig.4.23). In all of the four tissues, normalised read counts for 
Kptn clustered by genotype as expected (Fig.4.23). 
 
 
Figure 4.23 Normalised read counts for Kptn in wildtype (+/+) and Kptn-/- in cerebellum, prefrontal 
cortex, hippocampus, striatum. The genotype of the samples was confirmed by observing clustering 
of normalised Kptn counts by genotype in each of the four tissues collected: A. cerebellum, B. 




A comparison between mutant and wildtype samples revealed that within each tissue, there 
are numerous differently expressed (DE) genes. Using a threshold of 5% FDR, we identified 
578 DE genes in the cerebellum (out of which 326 were unique to the tissue), 776 DE genes 
in prefrontal cortex (PFC) (out of which 396 were unique to the tissue), 1315 DE genes in 
hippocampus (out of which 841 were unique to the tissue), and 3896 DE genes in the 
striatum (out of which 3232 were unique to the tissue) (Fig.4.24A). Only nine of these DE 
genes overlapped between all the tissues, with Kptn being one of them (Fig.4.24A). These 
nine common DE genes are enriched in seven KEGG pathways including antigen processing 
and presentation, allograft rejection, type I diabetes mellitus, autoimmune thyroid disease, 
salivary secretion, PPAR signalling pathway, viral myocarditis, and graft-versus-host disease. 
Among the upregulated DE genes, of which there are 262 in the cerebellum, 606 in the 
hippocampus, 1776 in the striatum, and 439 in PFC (Fig.4.24B, D-G), there are only 3 that 
overlap all tissue (Fig.4.24B). Regarding the downregulated DE genes, there are 199 in the 
cerebellum, 709 in the hippocampus, 2120 in the striatum, 337 in the PFC (Fig.4.24C, D-G), 
and only four overlaps between all tissues (Fig.4.24C). Interestingly, when analysing the 
subset of DE genes in the hippocampus that are upregulated, negative regulation of mTOR 
signalling was the only significantly associated biological pathway (Fig.4.25D). It was also 
one out of 284 biological pathway GO terms enriched in PFC (Fig.4.25B). 
In order to identify the biological and functional enrichment within the DE genes, I 
performed a pathway and GO enrichment analysis of DE genes in each tissue, using as 
background all genes expressed in the particular tissue being analysed (Chapter 2, section 
2.7.3). There was an over-representation of only 2 KEGG pathways – one in the 
hippocampus (‘ribosome’) and one in the cerebellum (‘graft-versus-host disease’) (Table 6). 





Table 6  KEGG pathway results of DE genes for different brain tissues in Kptn-/-.  
 
Tissues KEGG term Number of 
genes 






8 18 0.444 
Prefrontal 
Cortex 
- - - - 
Hippocampus Ribosome 84 125 0.672 
Striatum - - - - 
 
Enriched gene ontology categories included terms related to neuronal and central nervous 
system development, negative regulation of mTOR signalling, regulation of neurogenesis, 
proliferation, immune system, cell-cell signalling, adhesion, negative regulation of cell 
death, behaviour, actin cytoskeleton, synapse transmission, ion transport, translation and 
ribosome. Due to the recently described role of KPTN as a negative regulator of mTOR 
pathway, I tested whether the DE genes were enriched for mTOR signalling in the four 
tissues. Only PFC and hippocampus had an enrichment of mTOR regulation as one of the GO 
terms (Fig.4.25). No other tissues had mTOR signalling enrichment, suggestive that aberrant 
mTOR signalling is associated with these tissues.  
Through this preliminary analysis of the RNAseq results from mutant Kptn mouse brains, 
there is a significant signal of aberrant mTOR signalling in specific tissues.  These data are in 










Figure 4.24 Kptn-/- mice have altered gene expression profiles in all brain tissues examined. A. 
Differentially expressed genes in all the tissues: 578 DE genes in the cerebellum (C) (326 unique to 
the tissue), 776 DE genes in prefrontal cortex (P) (396 unique to the tissue), 1315 DE genes in 
hippocampus (Hipp) (841 unique to the tissue), and 3896 DE genes in the striatum (S) (3232 unique 
to the tissue). B. Differentially expressed genes upregulated in Kptn-/- brain tissues. Among the total 
upregulated DE genes: 262 are in the cerebellum (C), 606 in the hippocampus (Hipp), 1776 in the 
striatum (S), and 439 in prefrontal cortex (P). C. Differentially expressed genes downregulated in 
Kptn-/- brain tissues. Among the total downregulated DE genes: there are 199 in the cerebellum (C), 
709 in the hippocampus (Hipp), 2120 in the striatum (S), 337 in the prefrontal cortex (P). D-G. Plots 
of differential gene expression between Kptn-/- and wildtype in D. cerebellum, E. hippocampus, F. 
striatum, G. prefrontal cortex. The x-axis is the log10 average expression of all samples (normalised 
counts); the y-axis is DESeq2’s shrinkage estimation of log2 fold changes between genotypes. Each 
gene is represented as a dot; significantly differentially expressed genes (Benjamini-Hochberg  
adjusted p-value< 0.05) are highlighted in red. Orange numbers indicate total upregulated genes per 


















Figure 4.25 Biological pathway GO terms significantly enriched in the differentially expressed 
genes in Kptn-/- compared to reference set of total genes expressed in the tissue. All the 
significantly enriched biological pathways associated with the differentially expressed genes from 
the Kptn-/- brain tissues plotted as a proportion of the total number of genes associated with that 
pathway. Due to a high number of biological pathways associated with cerebellum (A) and 
prefrontal cortex (B), the terms are displayed as numbers (with pathways listed in Table 7), while the 





Table 7. Biological pathways enriched in Kptn-/- cerebellum (cereb.) and prefrontal cortex 
(PFC), with the number labels (N) used in Fig.4.25. 
Tissue N Biological pathway 
Cereb. 1 antigen processing and presentation of exogenous peptide antigen via MHC class I 
2 clustering of voltage-gated potassium channels 
3 antigen processing and presentation of exogenous peptide antigen via MHC class II 
4 regulation of systemic arterial blood pressure by baroreceptor feedback 
5 antigen processing and presentation of exogenous peptide antigen 
6 establishment or maintenance of transmembrane electrochemical gradient 
7 sodium ion export 
8 sodium ion export from cell 
9 neuronal ion channel clustering 
10 cellular potassium ion homeostasis 
11 cellular sodium ion homeostasis 
12 antigen processing and presentation of exogenous antigen 
13 antigen processing and presentation of peptide antigen via MHC class II 
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC 
class II 
15 antigen processing and presentation of peptide antigen 
16 regulation of the force of heart contraction 




18 antigen processing and presentation of peptide antigen via MHC class I 
19 humoral immune response mediated by circulating immunoglobulin 
20 calcineurin-mediated signaling 
21 calcineurin-NFAT signaling cascade 
22 sodium ion homeostasis 
23 antigen processing and presentation 
24 regulation of sodium ion transport 
25 regulation of sodium ion transmembrane transport 
26 import into cell 
27 immunoglobulin mediated immune response 
28 B cell mediated immunity 
29 positive regulation of adaptive immune response 
30 sodium ion transmembrane transport 
31 signal release from synapse 
32 neurotransmitter secretion 
33 neurotransmitter transport 
34 presynaptic process involved in chemical synaptic transmission 
35 regulation of metal ion transport 
36 regulation of neurotransmitter levels 
37 sodium ion transport 
38  homophilic cell adhesion via plasma membrane adhesion molecules 




40 synapse assembly 
41 calcium ion transmembrane transport 
42  regulation of cation transmembrane transport 
43  adaptive immune response based on somatic recombination of immune receptors 
built from immunoglobulin superfamily domains 
44 adult behavior 
45 lymphocyte mediated immunity 
46 calcium ion transport 
47 cell-cell adhesion via plasma-membrane adhesion molecules 
48 adaptive immune response 
49 positive regulation of immune response 
50 divalent inorganic cation transport 
51 divalent metal ion transport 
52 activation of immune response 
53 regulation of ion transmembrane transport 
54 synapse organization 
55 regulation of transmembrane transport 
56 innate immune response 
57 regulation of membrane potential 
58 cellular metal ion homeostasis 
59 regulation of ion transport 




61 metal ion homeostasis 
62 metal ion transport 
63 synaptic signaling 
64 trans-synaptic signaling 
65 anterograde trans-synaptic signaling 
66 chemical synaptic transmission 
67  cell-cell adhesion 
68 cellular cation homeostasis 
69 cellular ion homeostasis 
70 cation homeostasis 
71 cell adhesion 
72 immune response 
73 biological adhesion 
74 defense response 
75 cation transport 
76 ion transmembrane transport 
77 regulation of immune system process 
78 neuron development 
79 neuron projection development 
80 ion transport 
81 response to external stimulus 




83 neuron differentiation 
84 regulation of transport 
85 regulation of response to stimulus 
86 cell communication 
87 signaling 
88 single organism signaling 
89 multicellular organismal process 
90 single-multicellular organism process 
PFC 1 antigen processing and presentation of endogenous peptide antigen via MHC class I 
via ER pathway 
2 antigen processing and presentation of endogenous peptide antigen via MHC class I 
via ER pathway, TAP-dependent 
3 D-aspartate transport 
4 D-aspartate import 
5 canonical Wnt signaling pathway involved in osteoblast differentiation 
6 antigen processing and presentation of exogenous peptide antigen via MHC class II 
7 antigen processing and presentation of exogenous peptide antigen 
8 antigen processing and presentation of endogenous peptide antigen via MHC class I 
9 antigen processing and presentation of exogenous antigen 
10 T cell mediated cytotoxicity 
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC 
class II 




13 basement membrane organization 
14 antigen processing and presentation of peptide antigen 
15 antigen processing and presentation of peptide antigen via MHC class I 
16 positive regulation of adenylate cyclase activity 
17 epithelial cell morphogenesis 
18 membrane repolarization 
19 positive regulation of cAMP biosynthetic process 
20 positive regulation of lyase activity 
21 negative regulation of TOR signaling 
22 positive regulation of cAMP metabolic process 
23 regulation of adenylate cyclase activity 
24 leukocyte mediated cytotoxicity 
25 embryo implantation 
26 cell killing 
27 positive regulation of cyclic nucleotide biosynthetic process 
28 actin-mediated cell contraction 
29 regulation of phospholipid metabolic process 
30 membrane depolarization 
31 antigen processing and presentation 
32 regulation of potassium ion transport 
33 cAMP biosynthetic process 




35 response to cAMP 
36 regulation of cAMP metabolic process 
37 cAMP metabolic process 
38 regulation of nucleotide biosynthetic process 
39 regulation of purine nucleotide biosynthetic process 
40 cyclic purine nucleotide metabolic process 
41 cyclic nucleotide biosynthetic process 
42 response to corticosteroid 
43 response to purine-containing compound 
44 lymphocyte mediated immunity 
45 response to organophosphorus 
46 circadian rhythm 
47 transforming growth factor beta receptor signaling pathway 
48 response to glucocorticoid 
49 extracellular structure organization 
50 extracellular matrix organization 
51 adaptive immune response based on somatic recombination of immune receptors 
built from immunoglobulin superfamily domains 
52 cyclic nucleotide metabolic process 
53 response to transforming growth factor beta 
54 cellular response to transforming growth factor beta stimulus 




56 single-organism behavior 
57 regulation of blood circulation 
58 regulation of metal ion transport 
59 angiogenesis 
60 muscle system process 
61 response to decreased oxygen levels 
62 regulation of angiogenesis 
63 muscle contraction 
64 response to hypoxia 
65 adaptive immune response 
66 leukocyte mediated immunity 
67 response to oxygen levels 
68 regulation of transporter activity 
69 leukocyte migration 
70 cellular carbohydrate metabolic process 
71 rhythmic process 
72 positive regulation of cell migration 
73 positive regulation of cell motility 
74 response to steroid hormone 
75 transmembrane receptor protein serine/threonine kinase signaling pathway 
76 response to drug 




78 positive regulation of locomotion 
79 positive regulation of cellular component movement 
80 behavior 
81 response to hormone 
82 signal release 
83 response to peptide hormone 
84 blood vessel morphogenesis 
85 response to inorganic substance 
86 response to nutrient levels 
87 circulatory system process 
88 response to peptide 
89 divalent inorganic cation transport 
90 regulation of cell motility 
91 regulation of cell migration 
92 divalent metal ion transport 
93 regulation of cellular component movement 
94 positive regulation of immune response 
95 blood vessel development 
96 response to organic cyclic compound 
97 anterograde trans-synaptic signaling 
98 chemical synaptic transmission 




100 synaptic signaling 
101 trans-synaptic signaling 
102 vasculature development 
103 regulation of ion transport 
104 G-protein coupled receptor signaling pathway 
105 cardiovascular system development 
106 positive regulation of immune system process 
107 response to organonitrogen compound 
108 metal ion transport 
109 response to nitrogen compound 
110 response to endogenous stimulus 
111 anatomical structure formation involved in morphogenesis 
112 positive regulation of cell differentiation 
113 immune response 
114 positive regulation of phosphorus metabolic process 
115 positive regulation of phosphate metabolic process 
116 response to lipid 
117 cellular response to endogenous stimulus 
118 defense response 
119 brain development 
120 negative regulation of cell death 




122 system process 
123 regulation of immune system process 
124 circulatory system development 
125 secretion 
126 cell adhesion 
127 response to abiotic stimulus 
128 positive regulation of multicellular organismal process 
129 response to external stimulus 
130 regulation of programmed cell death 
131 localization of cell 
132 regulation of multicellular organismal process 
133 positive regulation of developmental process 
134 regulation of localization 
135 cell motility 
136 cell migration 
137 regulation of cell differentiation 
138 response to oxygen-containing compound 
139 response to organic substance 
140 positive regulation of response to stimulus 
141 regulation of apoptotic process 
142 regulation of cell death 




144 cellular response to chemical stimulus 
145 cell-cell signaling 
146 cellular response to organic substance 
147 regulation of transport 
148 movement of cell or subcellular component 
149 regulation of phosphorus metabolic process 
150 regulation of phosphate metabolic process 
151 immune system process 
152 regulation of developmental process 
153 regulation of multicellular organismal development 
154 signaling 
155 single organism signaling 
156 nervous system development 
157 cell communication 
158 regulation of response to stimulus 
159 cell surface receptor signaling pathway 
160 regulation of molecular function 
161 regulation of cell communication 
162 regulation of signaling 
163 cell differentiation 
164 regulation of biological quality 




166 system development 
167 animal organ development 
168 cellular developmental process 
169 multicellular organismal process 
170 response to stress 
171 positive regulation of biological process 
172 signal transduction 
173 response to stimulus 
174 developmental process 
175 anatomical structure development 
176 single-organism developmental process 
177 positive regulation of cellular process 
178 multicellular organism development 
179 cellular response to stimulus 
180 biological regulation 





4.3  Discussion and future directions 
By using a series of behavioural and cognitive tests, testing overlapping behavioural and 
cognitive domains, combined with morphometric brain analyses, I successfully recapitulated 
in the Kptn-/- mice the main phenotypes observed in the patients with KPTN-related 
disorder, namely macrocephaly, anxiety, hyperactivity, and cognitive impairment. 
Moreover, I gained further insight into the underlying processes affected by Kptn deficiency. 
  
4.3.1  Kptn-/- mice exhibit behavioural abnormalities and hippocampus-
dependent memory impairment 
To test for behavioural abnormalities associated with the disorder, I tested the mice in the 
open field under dim rather than bright light (stressor), in order to capture the general 
activity and locomotion of mice in a less stressful environment (dim light). Under dim light, 
the Kptn mutant mice spent more time moving and covered a larger overall distance than 
the controls, suggestive of hyperactivity-like phenotype, which parallels the hyperactivity 
phenotype observed in a subset of patients with KPTN-related disorder. When tested in the 
light/dark assay, the mice spent longer in the dark zone than Ktpn-/- mutants. Moreover, 
taking into account that Kptn-/- have increased activity, the fact that they spent significantly 
longer in the dark zone, which is a smaller area than the light zone, implies that the 
performance of the mutants in this test is due to increased anxiety and not due to other 
confounding effects such as increased overall activity.   
The results of several cognitive assays strongly point to hippocampal function being affected 
in Kptn-/- adult mice. Kptn-/- mice displayed impaired performance in cognitive tasks that rely 
on hippocampal function, such as the Barnes maze and social recognition assay, while there 
was no difference in performance between genotypes in pairwise discrimination task, which 
is hippocampus-independent task. Because the male wildtype controls did not habituate 
correctly to the initial stimuli in acquisition phase, I was not able to analyse males in the SOR 
assay. However, no sexual dimorphism has been reported in the patients, nor was there 
sexual dimorphism in our brain morphology data.  For these reasons, I chose to test the 




showed no significant bias for either familiar or unfamiliar stimuli. In subsequent 
experiments, I used only males in order to reduce number of animals used.  
In the Barnes maze, testing spatial memory, both genotypes successfully completed initial 
training sessions (T1-2) taking the same time to approach the escape hole, without a 
difference in total errors made. On 24h probe, Kptn-/- mice spent an equivalent time near 
the target zone as the wildtypes, indicating no deficit in memory of the location of the 
target. However, Kptn-/- showed impaired memory retention when tested after 72h (during 
72h probe session), indicating that spatial, hippocampus-dependent memory is affected in 
the mutant Kptn mice.  
When the escape box was moved in second part of training (training 2), Kptn-/- identified the 
escape box with an equivalent speed (primary latency) to the wildtypes, but made 
significantly more errors, measured as frequency of visits to other holes, before going into 
the escape box (which terminates the session). The fact that the Kptn-/- mice displayed a 
primary latency reduction, equivalent to wildtypes, over this training period, as well as a 
significant reduction from the first day of initial training to last day of training N2, implies 
Kptn-/- mice learned where the escape box is. The difference in total errors could be 
indicative of the Kptn-/- mice locating the target, but not going into the escape box straight 
away. Therefore, as a result, despite having learned the association between spatial cues 
and the escape location and identifying it, the total errors may be reflective on an increased 
exploratory behaviour in the mice during training N2 or reduced motivation to go into the 
escape box as soon as it is found. The performance in training N2 requires an inhibition of 
previously learned information and the ability to learn the new location.  Performance in 
this learning task is associated with cognitive flexibility and is dependent on orbitofrontal 
region of prefrontal cortex (OFC) (Brigman et al. 2013; Chudasama and Robbins, 2003).  It, 
therefore, could be possible that Kptn deficiency affects cognitive flexibility. Unfortunately, 
reversal was not done after pairwise discrimination task to be able to confirm this.  
When interpreting the Barnes maze results, it is important to be mindful of potential non-
cognitive factors that may affect the results of this assay, such as anxiety and activity levels 




memory impairment but are affected by the mutant’s greater responsiveness to stress due 
to their increased anxiety and overall locomotion.  Studies have shown that stress and 
anxiety have varying effects on hippocampus function depending on the task under 
consideration, as well as the duration of stress (Hölscher, 1999; Luine et al., 1996; Miyakawa 
et al., 2001). Stress has been shown to negatively affect hippocampus-dependent 
performance in the water maze (Hölscher, 1999; Harrison et al., 2009). Interestingly, 
however, Harrison et al. (2009) have shown that spatial memory is inversely correlated with 
corticosterone levels in the water maze, but not Barnes maze, suggesting the Morris water 
maze performance is more affected by stress than the Barnes maze. Moreover, the Barnes 
maze has been shown to be less anxiogenic than the water maze (Harrison et al., 2009). It is 
therefore unlikely that my results are purely non-cognitive, especially since the results are 
consistent across two assays (Barnes maze and social recognition). 
After identifying Kptn-/- hippocampus-dependent memory impairment phenotypes with 
social recognition and Barnes maze assays, I tested the animals with the object 
discrimination paradigm that combines object displacement (OD) and novel object 
recognition (NOR) assays, which I piloted in Chapter 3. Both genotypes performed well in 
the paradigm, and I was unable to detect impairment in the mutants in both the OD part of 
the assay nor the NOR part.  There are several likely reasons for this:  Firstly, the lack of 
phenotype in the OD part of the paradigm, which assesses spatial hippocampus-dependent 
memory, indicates that the mutant mice do not have 1h spatial memory impairment. This 
suggests that the memory defect seen in Kptn mice is sensitive to the interval time between 
acquisition and training, in agreement with the results from SOR and the Barnes maze. 
During piloting (Chapter 3), in order to optimise the paradigm to be suited for a more high-
throughput approach, I shortened the time between acquisition training and testing from 
24h to 1-2h. Testing the Kptn-/- mice with a longer time interval should confirm whether this 
assumption. Secondly, although the critical roles of the PFC and parahippocampal regions in 
the NOR task have been well established, there is controversy, due to the great variety in 
testing methodology between studies, regarding the association of the hippocampus in the 
NOR task (Bussey et al., 1999; Brown and Aggleton 2001; Banks et al. 2012; Hammond et al., 




that have shown that hippocampus involvement in this assay is reliant on complex 
environmental conditions with spatial and contextual cues, which was not the case in my 
paradigm (Winters et al. 2004; Forwood et al. 2005). Lastly, in this OD/NOR paradigm I 
excluded a number of animals from the analysis because of their suboptimal overall 
investigation of the objects (Chapter 2, section 3.2.3) Because of the high dropout rate of 
the mice, I decided not to incorporate it as part of the cognitive screen for characterizing 
multiple novel DD mouse lines (described in Chapter 5).   
The pairwise discrimination (PD) task (Chapter 2, section 2.3.6; Chapter 3) assesses reward-
based associative learning, associated with the dorsal striatum (Brigman et al. 2013; 
Hamilton and Brigman 2015). Both Kptn mutant and wildtypes completed a series of 
procedural training stages, confirming there were no visual, motor, or motivational issues in 
these mice tested in the platform.  When tested in the PD task, both genotypes were able to 
complete the PD criteria of 80% correct nose-pokes of the CS+ stimuli, in 60 minutes, over 
two consecutive days, suggestive of no memory and learning impairment in both genotypes. 
Learning was confirmed by swapping CS+ and CS- images (new CS+ image was previously 
not associated with the reward). Both genotypes significantly dropped in their performance 
in this case, indicating a strong association to the original CS+. The results from PD are 
suggestive of intact striatum and hippocampal-independent learning in the mutants, 
however care must be taken when interpreting the results as it is possible that subtle 
differences were missed due to lower number of animals tested in the PD task than the 
estimated sample size (Chapter 2, section 2.3.6; Chapter 3, section 3.3.2).  
 
4.3.2  Kptn deficiency contributes to a progressive global macrocephaly 
phenotype  
A consistent phenotype across all patients was macrocephaly.  Interestingly, the age of 
onset of this phenotype varied between the Amish (9 probands, all macrocephalic at birth) 
and the Estonian cohorts (2 siblings, born with normal head parameters and display 
macrocephaly in adulthood). Our analysis revealed that Kptn-/- mice display severe 




histological morphometrics), but are not macrocephalic at birth (P0).  This indicates that the 
deficit in Kptn causes progressive macrocephaly in our mouse model.  Importantly, P0 stage 
in the mice is equivalent of that of gestation week 23–32 in the humans (pre-birth), as 
discussed in Chapter 1. This may imply that the progressive form of macrocephaly in the 
mouse has comparable relative timing to the Amish patients, who are born macrocephalic. 
In order to elucidate this further, several postnatal mouse time points should be collected 
and the brain morphology analysed in a similar manner as was done with P0 brains. If the 
mice display macrocephaly at P7-10, which is equivalent to infant stage in humans, then this 
finding would be in accordance with the Estonian siblings who have progressive 
macrocephaly. 
Observing phenotypic manifestations of neurodevelopmental disorders postnatally is not 
uncommon. For example, both autism and Rett syndrome are associated with normal initial 
development and an onset of pathology occurring at later postnatal stages, associated with 
aberrant cell growth, synaptic maturation, connectivity, and stabilization (Zoghbi, 2003; 
Rubenstein, 2010). Aberrant increase in brain volume is most commonly associated with 
autism spectrum disorder (ASD), where the brain volume and head circumference of 
patients’ increases during early postnatal stages and subsequently decelerates at later 
stages (Piven et al., 1995; Carper et al., 2006; Amaral et al., 2008). Since KPTN is involved 
with actin cytoskeleton, it would be important to look at whether axonal projections and 
overall connectivity is affected in the mutants during development. This could be done by 
performing neural outgrowth assays at different embryonic ages to assess KPTN 
involvement in neuromorphogenesis (Radio & Mund, 2008). In adult mice, our results 
indicate that the mutants have global macrocephaly, with most brain regions significantly 
enlarged, and both grey and white matters affected. Interestingly, only two structures were 
not enlarged in the mutant adult brain – the hippocampus and the ventricular zone. The 
hippocampus was the same size as the wildtypes, and the ventricular zones were reduced. 
In the P0 brains on the contrary, none of the parameters were affected in the mutants, with 
the exception of an observed reduction in the hippocampus and an increase in the internal 




The reduction of the ventricular size in the adult mutants suggests a potential compensation 
mechanism of the cavities to accommodate the enlarged size of the overall brain. The 
finding of a normal sized hippocampus in the adult Kptn-/- mice is somewhat unexpected, 
given my results pointing to cognitive deficits involving hippocampus-dependent processes. 
The hippocampus plays a role in the multi-modal sensory integration system in the CNS, by 
being both upstream and downstream of cortical areas of the brain (Sweatt, 2004). Since 
the hippocampus sends projections to the cortex and receives information from the various 
cortical areas, having the cortex enlarged while the hippocampus remains unchanged in size 
may lead to aberrant cognitive pathways. It has been shown that hippocampus is 
significantly reduced in people with mild cognitive impairment (MCI) when compared to 
normal cognition controls (Schuff et al., 2001). Therefore, even though the hippocampus is 
not reduced in size in adult Kptn-/- mice relative to the controls, the reduced size ratio of the 
hippocampus to cortex may affect the cognitive processes, similarly that a reduction of 
hippocampal size in a normal sized brain would have.  Moreover, Kptn mutants display a 
reduction of hippocampus size when compared to controls at birth (P0), while other brain 
structures apart from internal capsule remain within normal size range. This suggests that 
the abnormalities in the hippocampus originate prenatally, potentially causing a delay in its 
development, which in turn is associated with aberrant function in adulthood despite the 
normal size of the hippocampus in the adult brain of Kptn mutant mice.  
Our data suggest that the increase in internal capsule starts prenatally. Internal capsule is a 
white matter structure linking cerebral cortex with other parts of the brain, with a role in 
influencing higher cognitive function (Rousset et al., 2006). The abnormal signal intensity in 
the internal capsule from MRI studies in infants has been shown to be a good predictor of 
aberrant neurodevelopmental outcomes (Rutherford et al., 1998). Moreover, damage in 
white matter structures, such as internal capsule, have been associated with cognitive 





4.3.3  Kptn deficient transcriptome 
Combining the results from morphometric brain analyses and cognitive testing, an 
interesting pattern emerges, associated with the hippocampus. Firstly, several independent 
cognitive tests identified hippocampus-dependent memory impairment in the Kptn-/-, but no 
memory impairment was identified when Kptn-/- were tested in hippocampus-independent 
cognitive tasks.  Secondly, based on morphometric analyses hippocampus has a significantly 
reduced size in Kptn-/- at P0 relative to the wildtypes, implying a pre-natal developmental 
defect. However, in adult Kptn-/- mice, hippocampus and ventricle zones are the only brain 
structures not enlarged. Therefore, to shed more light on the effect of Kptn deficiency on 
the postnatally and detect potential mechanisms that may be contributing to the adult 
phenotypes described, I analysed the transcriptome of hippocampus, striatum, prefrontal 
cortex and cerebellum in Kptn-/- adult mice. The four brain structures were chosen for 
transcriptomic analysis due to the morphometric and cognitive phenotyping data, with the 
first three neuroanatomical structures associated with the cognitive testing described 
earlier in this chapter and all the structures apart from the hippocampus are enlarged in the 
Kptn-/- adults based on our morphometric data.  
The transcriptome of all four neuroanatomical structures analysed were affected by Kptn 
deficiency (compared to the expression levels of wildtype controls), with many differently 
expressed (DE) genes identified in each tissue. The largest number of significantly 
differentially expressed genes was in the striatum, where 3896 genes were differentially 
expressed, followed by hippocampus with an affected expression in 1315 genes. Based on 
the gene set enrichment analysis, the DE genes identified are enriched in many pathways, 
including those associated with neuronal development, brain function, and behaviour.  
Interestingly, mTORC1 signalling was enriched in the DE genes only in the hippocampus and 
prefrontal cortex.  Moreover, ‘ribosome’ was the only significantly enriched KEGG pathway 
associated with the DE genes in the hippocampus, with 85 DE genes associated with 
ribosome function (68% of the total proportion of functional genes associated with this 
KEGG pathway). As outlined here, mTOR signalling is an important regulator of ribosomal 
biogenesis and has a role in gene transcription regulation in part through the activation of 




2011; Yokogami et al., 2000). Therefore, the enrichment of DE genes associated with 
ribosome function may be an indication of an increased activity of the mTORC1 in the 
hippocampus, which could be one of the contributing factors to the functional deficit 
detected in the hippocampus. This is in accordance with recent finding by Wolfson et al. 
(2017) of the role of KPTN as a negative regulator of mTORC1 signalling, as part of a 
KICSTOR complex, which suggests Kptn deficiency should lead to mTORC1 signalling 
hyperactivity in the brain. This was previously confirmed in another protein of the KICSTOR 
complex, Szt2, where deficiency in Szt2 was associated with an increase in mTORC1 
signalling in the brain (Peng et al., 2017; Frankel et al., 2009). To my knowledge, no study to 
date has tested mTOR activity levels in Kptn-/- mice.   
Interestingly, when gene enrichment was analysed for upregulated DE genes, there was 
enrichment for negative regulation of mTORC1 in the hippocampus and prefrontal cortex. In 
the hippocampus, this was the only pathway enriched in the upregulated DE genes. This 
could suggest that the loss of negative regulation of mTORC1 in these structures, due to 
deficiency in Kptn, could potentially lead to upregulation of other mTOR negative regulators 
in these brain regions, as part of the feedback loop mechanism. However, despite this 
potential compensatory mechanism, the full function of hippocampus was not rescued, as 
demonstrated by the cognitive results in the Kptn-/-. Increase in mTOR signalling due to loss-
of-function of negative regulators, such as Pten and Tc1, have been previously associated 
with increased neuron soma size and macrocephaly (Ehninger et al., 2008; Kwon et al., 
2003). Therefore, it is possible that an increase of activity of mTORC1 signalling in the Kptn-/- 
brain could be contributing to the macrocephaly phenotype in this model as well. One 
hypothesis could be that the compensatory mechanism of increasing expression of other 
negative mTOR regulators could be one of the processes that are responsible for the lack of 
volume change in the adult hippocampus relative to the other brain structures. 
Distinguishing this hypothesis from one in which cell death counteracts the overgrowth 
phenotypes will be the subject of further study in the lab. 
In order to confirm the involvement of mTOR signaling in Kptn deficient brain and to assess 
the distribution of mTOR activity between different brain regions, the activity of mTOR 




phosphorylation levels of the mTOR downstream targets, such as S6K and 4E-BP, between 
controls and mutants, by western blotting (Sharma et al., 2010; Way et al. 2012). If this 
confirms the dysregulation of the mTORC1 pathway, it opens an exciting opportunity for 
therapeutic intervention, by targeting the hyperactive pathway with rapamycin, a clinically 
approved drug, to rescue some of the phenotypes associated with the disease.  
 
4.3.4  Future directions 
4.3.4.1  Phenotypic rescue with rapamycin treatment 
Rapamycin has been extensively and successfully used to target many of the mTORC1 
components, leading to increased lifespan and rescuing of cognitive deficits in 
neurodevelopmental and neurodegenerative mouse models (Ehninger et al., 2008; Harrison 
et al., 2009; Johnson et al., 2013; Spilman et al., 2010). Tsc2+/- mice showed learning deficits 
in three hippocampus-dependent tasks (Morris water maze, eight-arm radial maze, context 
discrimination) and had hyperactive mTOR signalling in the hippocampus, suggesting that 
enhanced mTOR signalling leads to these deficits. Suppression of the aberrant signalling 
with rapamycin in these mice, rescued the cognitive deficits associated with this mouse 
model (Ehninger et al., 2008). Moreover, rapamycin treatment reduced brain weight (Tsc1) 
and reversed neuronal soma enlargement (Pten) in the conditional mouse models, with 
minimal effects on normal brain growth and function in wildtype mice (Ehninger et al., 
2008; Kwon et al., 2003).   
Therefore, once hyperactivity of the mTOR pathway in Kptn-/- confirms my hypothesis that 
treating Kptn-/- mutant mice with rapamycin from birth could rescue either the 
macrocephaly, some aspects of behavioural and cognitive impairments identified in the 
adults, or possibly both. Cognitive rescue could be tested in the adults using the light/dark 
and social recognition assays, supported by morphometric and transcriptomic brain 
analysis. Furthermore, by identifying the postnatal stage at which the progressive 
macrocephaly is first manifested in the Kptn-/- and performing rapamycin treatment after 




defects, and assess if these are independent.  If these treatments show promise, it will be 
crucial to consider how this might be moved into the clinic to potentially treat patients with 
KPTN-related syndrome. 
 
4.3.4.2  Macrocephaly mechanism 
An important question to answer is at what postnatal stage the macrocephaly phenotype 
first appears. Our morphometric data indicate that the Kptn-/- mice are born with normal 
growth parameters and are severely macrocephalic in adulthood.  These data, in the context 
of the recently identified role of KPTN as a negative regulator mTORC1 pathway, which is 
involved in cell growth and cell cycle progression, support the hypothesis that Kptn may be 
involved in the regulation of brain growth during a critical growth window (Szulc et al., 
2015; Zhang et al., 2005). As outlined in Chapter 1, the peak brain growth spurt in mice is at 
P7-P10, with brain reaching 95% of its volume by P20 (Bockhorst et al., 2008; Keshavan et 
al., 2002). Measuring the brain volume before this growth window (P7-P20) and after should 
elucidate when the mice become significantly macrocephalic. One can then analyse 
proliferation and apoptosis rates at this stage of initial macrocephaly manifestations to 
elucidate the mechanisms responsible for the increased growth. One possibility is that the 
deficiency in Kptn is causing a reduction in apoptosis at the peak of brain growth, leading to 
an abnormal increase in brain size. Alternatively, Kptn mutants may experience a longer 
period of brain growth beyond the normal plateau around P20 in wildtype mice.  
In the adult Kptn mutant mice, we were able to detect increased number of proliferating 
cells in the hippocampus, increased cell counts in the cortex, and no increase in apoptosis in 
the cortex. This suggests that increased proliferation rates could be contributing to the 
macrocephaly phenotype. However, because these assays were performed only in adults, 
likely after the overgrowth has occurred, the observations on cell cycle and apoptosis may 
not be relevant to the underlying mechanism acting during the acquisition of the 
phenotype.  It will, therefore, be critically important to analyse changes during the brain 




4.3.4.3  Elucidating the roles of neurogenesis in the adult 
The increased proliferation rate identified in the hippocampus of Kptn-/- mice could be 
suggestive of an increased rate of adult neurogenesis in the hippocampus. Adult 
neurogenesis is a process through which new neurons are generated from a pool of 
progenitor cells, and is believed to be restricted to the hippocampus (Hill et al., 2015; Sahay 
et al., 2011). However, some controversial evidence points to the presence of neurogenesis 
in other areas of the brain such as the neocortex and striatum (Gould et al., 2007; Lledo et 
al., 2006; Bernier et al., 2002). Adult neurogenesis persists throughout life and the rate of 
proliferation, maturation, and survival of the progenitors is affected by environmental cues 
such as exercise, antidepressants, stress, and age (Hill et al., 2015; Ishikawa et al., 2016; 
Kitamura and Inokuchi, 2014; Sahay et al., 2011).  
Co-staining the adult Kptn-/- mouse brain sections with cell-type specific markers and 
markers of proliferation will identify the cell types that are undergoing cell division. If adult 
Kptn-/- mice have increased neurogenesis in the hippocampus in adults, it may further 
explain why mutant mice have specific impairment in the hippocampus-dependent and not 
hippocampus-independent tasks. The role of neurogenesis in cognition is complex. On the 
one hand, studies outline the importance of neurogenesis in neural circuit plasticity and 
report positive effects of neurogenesis on learning and cognitive plasticity (Sahay et al., 
2011). Neurogenesis has been implicated in enhanced pattern separation, and reduced 
rates have been associated with age-dependent decline and neurodegenerative disorders 
(Aimone et al., 2014; Bishop et al., 2010; Chen et al., 2008; Zhao et al., 2008). On the other 
hand, increased neurogenesis in hippocampus has also been linked to loss of hippocampus-
dependent recent memories, but not remote (long-term) and hippocampus-independent 
memories (Epp et al, 2016; Ishikawa et al., 2016; Kitamura et al., 2009).  
Further cognitive tests associated with cognitive flexibility, such as the five-choice serial-
reaction test and operant reversal learning, could be used to elucidate this further (Bussey 
et al. 2012; Semenova, 2012). The five-choice serial-reaction test is similar to the human 
continuous performance tasks and tests attention, motor impulsivity, decision-making 




4.3.5  Concluding remarks 
KPTN-syndrome, a novel developmental disorder, was identified in homozygous and 
compound heterozygous patients with loss-of-function mutations in the KPTN gene.  Here I 
report that Kptn-/- mice phenocopy the main behavioural and cognitive features of the 
human condition namely anxiety, cognitive impairment, and macrocephaly, thus 
successfully characterising a novel developmental disorder associated with intellectual 
disability. Through the developmental and molecular experiments done in this thesis work, I 
gained preliminary insights into the underlying mechanisms associated with the disorder, 
but further work needs to be done to fully elucidate the roles of KPTN in the brain. The work 
outlined here, in the light of recent insight into KPTN role in the mTOR pathway, offers 




Chapter 5. Behavioural and Cognitive Neurodevelopmental 
Disorder screen 
5.1 Introduction 
5.1.1  Decipher Developmental Disorders (DDD) study 
As discussed in Chapter 1, many neurodevelopmental disorders have a genetic cause, yet 
few affected children receive a genetic diagnosis (Fitzgerald et al., 2015; Wright et al., 2015). 
Successful diagnosis is further challenged by disorders that are not well characterised, have 
highly variable manifestations, and are hard to distinguish from other disorders 
phenotypically. Due to the clinical and genetic heterogeneity of neurodevelopmental 
disorders, there is a growing appreciation that using unbiased genome-wide approaches, 
such as genomic microarrays and next-generation sequencing (whole genome and exome), 
can dramatically improve diagnosis of neurodevelopmental disorders (Fitzgerald et al., 
2015; Firth et al., 2011; Vries et al., 2005; Wright et al., 2015).  It has been estimated that 
the per-generation mutation rate in humans is between 7.6 × 10−9 and 2.2 × 10−8, such that, 
on average, a newborn child has 50 to 100 de novo mutations in their genome (Lynch et al., 
2010; Roach et al., 2010; Vissers et al., 2010). Mutations occurring spontaneously in the 
germline persist in the population despite serious phenotypic consequences, such as 
intellectual disability (ID) and reduced fecundity, (Uher, 2009). Because ID negatively affects 
reproductive fitness, sporadic forms are more severe than the familial the more severe 
forms of are mainly sporadic, while the familial forms are milder (Vissers et al., 2016).  
Deciphering Developmental Disorders (DDD) is a large-scale study that uses parent/child trio 
exome sequencing to identify causative mutations in the genomes of children with 
undiagnosed developmental disorders (Wright et al., 2015; Fitzgerald et al., 2015; McRae et 
al., 2017). The study uses a genotype-driven genome-wide diagnostic approach for 
identification of groups of patients with similar pathogenic variants from a large number of 
patients with diverse DDs (Wright et al., 2015; Fitzgerald et al., 2015; McRae et al., 2017).  
Moreover, this approach has the potential of expanding the phenotypic range of known DD 
conditions, by genetically characterizing patients lacking the clinical features used for 




The DDD study began in 2011 and had recruited 13,600 patients from all over UK and 
Ireland, through UK National Health Service (NHS) and Republic of Ireland genetics services 
by 2017. Children with severe undiagnosed DD and their parents were recruited, in order to 
maximise the chances of capturing highly penetrant monogenic conditions (Wright et al., 
2015; Fitzgerald et al., 2015; McRae et al., 2017). Growth measurements, relevant family 
history, developmental milestones were recorded, pertinent pregnancy and neonatal 
parameters, and the detailed clinical phenotypes were noted using Human Phenotype 
Ontology terms.  The median age of children assessed in the study was around 5.5 years old 
(Fitzgerald et al., 2015).  The most prevalent phenotypes (of the first 1,133 children 
analysed) were intellectual disability or developmental delay (87%), cranial abnormalities 
(30%), seizures (24%), and congenital heart defects (11%) (Fitzgerald et al., 2015). The 
genetic ancestry of the recruited patients is predominantly (90%) of Northwest European 
ancestry (Fitzgerald et al., 2015). Overall the disorders in the affected patients were 
genetically and phenotypically heterogeneous.  
De novo mutations (DNM) have been reported as a major cause of neurodevelopmental 
disorders by multiple studies, although the reported diagnostic yield varies between studies 
due to experimental design, while recessive inherited mutations are enriched in populations 
with frequent parental consanguinity (de Ligt et al., 2012; Firth et al., 2011; Hamdan et al., 
2014; Musante and Ropers, 2014; Najmabadi et al., 2011; Rauch et al., 2012; Vissers et al., 
2010; Wright et al., 2015). In the DDD cohort, de novo variants have the highest diagnostic 
yield, and it was estimated that 42% of individuals in the cohort carry pathogenic DNMs in 
the coding sequences, with relatively equal representation of loss-of-function mutations and 






5.1.2  Systemic behavioural testing paradigms 
Although next-generation sequencing approaches play a critical role in identifying disease-
associated mutations, animal and cellular modelling are essential to verify the candidate 
mutation, validate novel candidate genes, and elucidate pathophysiological mechanisms. 
Mouse models are a critical resource for modelling human disease and dissecting gene 
function. To fully understand the neurophysiological and neuroanatomical implications of a 
disorder, it is critical to apply a broad set of behavioural and cognitive tests to assess 
overlapping behavioural domains when modelling a new mouse model (Rogers et al., 1999; 
Tarantino et al., 2000). As outlined in previous chapters, rodent behaviour is susceptible to 
environmental influence, background strain, sex, and the overall experimental design.  
These present a particularly difficult challenge, not only to achieve sufficient sensitivity and 
consistency but also to maintain inter-operator and inter-lab reproducibility (McGoniglea 
and Rugger, 2014). Studies have tried to dissect these problems by assessing the 
contribution of different strains on behavioural outputs and/or test mice in different 
paradigms to explore the effect of differences in environment and experimental history on 
experimental outcomes (Contet et al., 2001; McIlwain et al., 2001; Rogers et al., 1997; 
Rogers et al., 1999; Tarantino et al., 2000; Võikar et al., 2001; Võikar et al., 2004). In line 
with this, there is a delicate balance to be reached between on the one hand, allowing for 
flexibility of experimental design, for example to tailor a study to fit a particular model in 
question, and on the other hand striving for a level of standardisation of methodology, to 
allow for comparisons across laboratories and studies, and to maximise reproducibility. 
Accurate and reproducible phenotype assessment is thus “the jewel in the crown of genetic 
manipulation” (Rogers et al., 1997).   
In the late 1990s, the SHIRPA testing protocol was established by a multicentre consortium 
to screen mouse models in a systematic way using a wide range of behavioural and 
functional tests (Rogers et al., 1997; Rogers et al., 1999). More recently the Mouse Genetics 
Project (MGP) and the European Mouse Disease Clinic (EUMODIC) were established (late 




and analysis of mouse knockout lines, provided valuable information on effective design of 
phenotyping platforms and overall optimal operation of such big initiatives, and provided 
resources for over 900 lines (Ayadi et al., 2012; White et al., 2013). Since then, new 
initiatives have been set up by the International Mouse Phenotyping Consortium (IMPC), 
including a new adult pipeline, aiming to characterize new knockout mouse strains and 
creating a genome-wide gene function catalogue (Meehan et al., 2017). These approaches 
aim to avoid inter-study discrepancies by testing multiple mouse lines without the inherent 
variation that would exist if these models were studied separately (Bucan and Abel, 2002; 
Fuchs et al., 2012; Laughlin et al., 2012; Marston et al., 2001; Wakana et al., 2009). These 
paradigms are powerful yet logistically challenging, as they are reliant on the ability to scale 
up phenotypic testing and ensure the tests are both rapid and sensitive to detect different 
behavioural and cognitive repertoires in multiple mouse lines.  
 
5.1.3  The approach and aims 
Although there are several efforts, outlined above, to characterize multiple mouse knockout 
lines, there is a relative lack of specialised high-throughput behavioural and cognitive 
approaches focusing on intellectual disability and other neurodevelopmental disorders. In 
this Chapter, I will describe a mouse phenotyping paradigm, designed to support a large, 
specialised functional screen that I applied to systematically characterise an initial four 
novel neurodevelopmental disorders associated with intellectual disability, identified by the 
DDD project. The four loss-of-function mouse lines under investigation, Arid1b Setd5, 
Setd1a, Zmynd11, have mutations in genes encoding chromatin remodelling factors (CRFs) 
(Fitzgerald et al., 2015). Due to the druggable nature of CRFs and their involvement in many 
types of cancer, there is a high level of investment for developing drugs targeting of making 
them an attractive set of proteins to work on (Filippakopoulos et al., 2010; Helin and 
Dhanak, 2013; Huether et al., 2014). 
Since I was able to successfully recapitulate the main patient phenotypes in the homozygous 
loss-of-function Kptn mouse model (Chapter 4), my next aim was to assess whether the 




neurodevelopmental disorders associated with intellectual disability. The phenotyping was 
not intended to be an exhaustive characterisation of each mutant line. The strategy had 
three critical criteria: (1) It was required to operate in a standardised and relatively high-
throughput manner, ensuring the testing paradigm doesn’t last longer than 4-6 weeks to 
enable multiple lines to be tested a year, with (2) sufficient breadth to detect a variety of 
cognitive and behavioural defects, and (3) have the sensitivity to capture phenotypic 
differences between disorders under investigation. For this I employed the most robust 
techniques from the Kptn study, as well as an additional assay testing for features 
commonly associated with autism spectrum disorders (ASD). This paradigm will henceforth 
be referred to as BCND (Behavioural and Cognitive Neurodevelopmental Disorder) screen.   
This pilot project lay the groundwork for a larger five-year project at the Sanger Institute, 
aimed at characterising a range of novel neurodevelopmental disorders arising from 
mutations identified in the DDD and Prenatal Assessment of Genomes and Exomes (PAGE) 
projects. The plans for the project include generation and phenotypic characterization of 
approximately 40 mouse lines, prioritising CRFs. Gene expression profiling of several brain 
regions from each line is also being carried out, as well as the generation and 
characterization of human induced pluripotent stem cell (hiPSC) lines harbouring the same 
mutations as the mouse models. This will aid biological validation of the causality of the 
mutations under investigation, provide insight into the underlying mechanisms for each 
disorder, as well as provide a large-scale platform for comparison between multiple 
neurodevelopmental disorders. When a set of robust pathological consequences is 
identified in a mutant mouse line, the possibility of reversing these phenotypes will be 
assessed, through inducible reversion of mutant alleles to wild-type. This proof of 
reversibility is a critical step towards devising therapeutic strategies.  
The strategy for BCND was to contribute to the refinement and piloting of the experimental 





5.1.4  Candidate genes  
5.1.4.1  Epigenetic modifications – histone lysine methylation and acetylation  
As described in Chapter 1, more than 700 genes have been associated with ID and related 
cognitive disorders (Vissers et al., 2016). Despite the genetic heterogeneity, it is becoming 
apparent that ID can be dissociated into distinct modules of genes, functioning as part of a 
common pathway or complex and associated with interrelated phenotypes (van Bokhoven, 
2011). Transcriptional regulators and chromatin remodelling factors (CRFs) have been 
shown to be enriched in neurodevelopmental disorders (Hamdan et al., 2014; Kleefstra et 
al., 2012; Kleefstra et al., 2014; McCarthy et al., 2014; Ronan et al., 2013; van Bokhoven, 
2011; Vogel-Ciernia and Wood, 2014).   
Epigenetic modifications are responsible for creating differences in tissue and cell type-
specific gene expression (van Bokhoven, 2011). Chromatin modifiers have been shown to 
play crucial roles in brain development, as well as being involved in numerous types of 
cancer, suggesting a potential overlap between cognitive impairment and carcinogenesis 
(Vissers et al., 2016). The timing of the de novo mutations in CRFs is critical in directing 
whether the mutations will cause intellectual disability if they occur early in development, 
or cancer, if they occur later in life (Vissers et al., 2016). 
The DNA and histone modifications, such as methylation and acetylation, regulate patterns 
of gene expression. DNA methylation leads to more stable long-term modifications of DNA 
accessibility, whereas histone modifications are more flexible and shorter term, causing 
changes in chromatin structure (Handy et al., 2012). There are dedicated proteins which 
function as writers, erasers, and readers of epigenetic tags, as well as proteins that act as 
chromatin remodelers (Fahrner and Bjornsson, 2014). Writers are responsible for placing 
the markers on particular regions of the genome and histone tails, which are recognised and 
interpreted by readers and counterbalanced by erasers which favour the opposite 
chromatin state to the writers. Chromatin remodelers usually act as part of larger protein 
complexes and are responsible for modifying chromatin architecture and thus 




Histone acetylation at lysine residues in H3 and H4 tails promotes open chromatin structure 
and therefore most often associated with transcriptional activation, even though the open 
chromatin state may also give access to transcriptional repressors (Shogren-Knaak et al., 
2006;). The reverse process of histone deacetylation is associated with inactive chromatin 
state (Nan et al., 1998). Histone deacetylase enzymes are themselves subject to regulation 
by acetylation, phosphorylation, and sumoylation, which in turn can affect their function, 
distribution, and protein-protein associations (Mellert and McMahon, 2009).  
Histone lysine methylation is a more complex than acetylation because methylation sites 
can be associated both with transcriptionally permissive (euchromatin) and repressive 
chromatin (heterochromatin) (Martin et al., 2005).  Moreover, lysine residues can be mono, 
di, or tri-methylated. Most histone lysine methyltransferases have Su(var)3-9, Enhancer of 
Zeste, Trithorax (SET) homology domain. SET domain containing proteins are broadly 
subdivided into seven subfamilies based on their structure - SUV39, SET1, SET2, EZ, RIZ, 
SMYD, and SUV4-20 families (as well as a few orphan members such as SET7/9 and SET8) 
(Dillon et al., 2005). SET1 methyltransferase members promote active chromatin state by 
methylating H3K4, whereas other methyltransferases can methylate several histone targets. 
Some of the methyl transferases also contain additional domains that allow them to bind to 
methylated DNA and other proteins.  
Initially it was proposed that the only mechanism for removal of histone methylation is 
histone turnover, however, subsequently multiple histone demethylases have been 
identified that demethylate histone lysine methyl groups (Shi et al., 2004). Histone 
methylation is nevertheless less dynamic than acetylation and has been implicated in 
cellular memory of transcriptional states (Völkel and Angrand, 2007).    
 
5.1.4.2  ARID1B (BAF250B and ELD/OSA1) 
AT-rich interaction domain-containing protein 1B (ARID1B) (also known as BAF250B and 
ELD/OSA1), encodes a protein with four isoforms and is part of the SWI/SNF chromatin 




(Flores-Alcantar et al., 2011). ARID1B directly binds double-stranded DNA, and has been 
implicated in cell-cycle activation and progression (Flores-Alcantar et al., 2011; Yan et 
al.,2008). Knockdown and haploinsufficiency of ARID1B have been shown to delay cell cycle 
re-entry (Nagl et al., 2005; Sim et al., 2014).  
ARID1B is ubiquitously expressed in most tissues.  In the adult brain, it is predominantly 
expressed in neuronal cell bodies in the cortex, with moderate expression in neurons and 
glial cells in the hippocampus, and is most highly expressed in the Purkinje cells in the 
cerebellum (Uhlén et al., 2015). Although ARID1B is predominantly expressed in 
differentiated cells, it has also been implicated to have a role in the developing brain 
(Flores-Alcantar et al., 2011).    
Deficits in ARID1B have been identified as a frequent cause of ID (Fitzgerald et al., 2015 
Hoyer et al., 2012). Moreover, haploinsufficiency in ARID1B have been associated with 
abnormalities in corpus callosum, developmental delay and speech impairment, as well as 
implicated in autism spectrum disorder and as a major cause of Coffin-Siris syndrome  
(Backx et al., 2011, 167; Halgren et al., 2011; O'Roak et al., 2012; Santen et al., 2012; 
Tsurusaki et al., 2012; Vals et al., 2014). Two studies, published during the writing of this 
thesis, reported that Arid1b+/- mice display anxiety-like behaviour, social deficits, and growth 
impairment (Celen et al., 2017; Shibutani et al., 2017). Celen et al. also demonstrated that 
growth hormone treatment rescued the growth impairment and motor issues (Celen et al., 
2017).  
 
5.1.4.3  SETD5 
SET Domain-Containing Protein 5 (SETD5) is a ubiquitously expressed gene, with high levels 
of expression in the brain (Grozeva et al., 2014). It is conserved among mammalian species 
and is involved in histone modification and transcriptional regulation. Recent studies have 
identified a number of loss-of-function mutations, de novo as well as some familial cases, in 
SETD5 in patients with ID, implicating SETD5 variants as a relatively frequent  (0.67-0.7%) 




al., 2016; Stur et al., 2017). Moreover, SETD5 is in the critical genomic region for 3p25 
microdeletion syndrome, a rare spectrum disorder caused by deletions within the short arm 
of chromosome 3 (Grozeva et al., 2014; Peltekova et al., 2012). The patients with de novo 
SETD5 mutations show phenotypic similarity to those with deletions in the 3p25 region, 
suggesting that SETD5 haploinsufficiency may be at the core of the phenotype in the 
microdeletion syndrome (Grozeva et al., 2014; Kuechler et al., 2015).  
SETD5 was proposed to a ‘writer’ histone lysine methyltransferase due to the presence of 
SET domain and putative methyl lysine-recognising plant homeodomain (Grozeva et al., 
2014; Kuechler et al., 2015). However functional work in mice did not confirm this, and 
instead, Setd5 was suggested to lack the PHD domain and thus methyltransferase activity. 
The Setd5 mutant mice were shown to be homozygous lethal and no viable null embryos 
were observed after E10.5 (Osipovic et al., 2016). Of note, there was no difference observed 
between heterozygous and wildtype embryos. Setd5 thus has been reported to be critical 
for embryo development, cell cycle progression, and chromatin modification (Osipovic et al., 
2016). Osipovic et al. proposed that Setd5 regulates gene expression through the co-
transcriptional regulation of histone acetylation, by interacting with PAF1 and NCoR 
complexes. Moreover, the study has identified ROSA26 as a bidirectional transcript pair of 
Setd5. The authors propose that unaltered transcription in ROSA26 direction may aid in 
maintaining a consistent level of Setd5 expression.  
 
5.1.4.4  SETD1A (KMT2F) 
SET Domain Containing 1A (SETD1A), also known as KMT2F, encodes a catalytic subunit of 
the histone lysine methyltransferase protein complex, Set/COMPASS (complex protein 
associated with Set1). The complex mediates mono-, di-, and trimethylation methylation of 
histone H3 at Lysine 4 (H3K4) and thus associated with active chromatin structure that is 
permissive to transcription (Lee and Skalnik, 2008; Schneider et al., 2003).  
There is increasing evidence for a role of chromatin modifiers in psychiatric and 




studies have implicated SETD1A in schizophrenia (Singh et al., 2016; Takata et al., 2014). 
Interestingly, many of the individuals with schizophrenia identified in these studies, 
heterozygous for SETD1A loss-of-function variants, have learning difficulties or 
developmental delay. It is yet to be elucidated whether SETD1A is specifically responsible 
for the cognitive phenotype in the disorder.  The individuals in the DDD cohort were all 
below the typical age of onset for schizophrenia, so it remains possible that some could 
develop psychiatric co-morbidities.   
 
4.1.4.5  ZMYND11 (BS69) 
Zinc finger MYND domain-containing protein 11 (ZMYND11, also known as BS69), is localised 
to the nucleus, ubiquitously expressed, and has an inhibitory role in muscle and neuron 
differentiation (Velasco et al., 2006; Yu et al., 2009). It was first identified as a 
transcriptional suppressor that interacts with the transactivation domain (conserved region 
3) of the 289R adenovirus type 5 E1A protein, involved in cell cycle (Hateboer et al., 1995). 
More recently, it was demonstrated that ZMYND11 is a chromatin ‘reader’, specific to the 
H3.3 variant of histone 3 and that it recognises the tri-methylated histone at Lys-36 
(H3K36me3) but does not bind other H3 subtypes (Wen et al., 2014; Wen et al., 2014).  H3.3 
is enriched in transcribed regions and H3K36me3 is associated with an increase in mRNA 
expression levels. Therefore ZMYND11 activity co-localizes with highly expressed genes. It 
has been proposed that ZMYND11 acts as a transcriptional co-repressor with NCoR complex 
through its MYND domain (Masselink and Bernards, 2000).  It is thought to be recruited 
when sufficient levels of H3.3K36me3 have accumulated, after several initial rounds of 
transcription, and is responsible for the fine-tuning of gene expression (Wen et al., 2014). 
Expression of E1A inhibits repression mediated by ZMYND11, therefore modulating its 
function (Masselink and Bernards, 2000). 
Several cases of a 10p15.3 microdeletion, with ZMYND11 mapped within the region, have 
been reported with patients with the following clinical features: cognitive, behavioural, and 
developmental difficulties, speech and motor delay, dysmorphism and brain anomalies, 




show phenotypes similar to the microdeletion cases suggesting that the haploinsufficiency 
in ZMYND11 contributes to these clinical features and that ZMYND11 mutations are 
causative of intellectual disability (Coe et al., 2014; Cobben et al., 2014; DeScipio et al., 
2012; McRae et al., 2016).  ZMYND11 truncating mutations have also been associated with 
autistic traits, aggression, and complex neuropsychiatric features (Coe et al., 2014; Vissers et 
al., 2016). A recent genome-wide association study (GWAS) of behavioural, physiological 
and gene expression phenotypes in a commercially available Carworth Farms White outbred 
mouse population identified an association between anxiety-like behaviour and Zmynd11,  
implicating Zmynd11 in anxiety-like behaviour (Parker et al., 2016). 
 
5.2 Results  
5.2.1  There is high variability in phenotypes within each subset of DDD patients. 
From the recent 10,000 patient DDD dataset, 25 probands have mutations in SETD5 gene, 
60 in ARID1B, 11 in SETD1A, and 6 in ZMYND11 (DDD study, unpublished work) (Fig.1). 
ARID1B is the most significantly mutated gene in the DDD dataset, with 11 independent 
loss-of-function mutations identified (Fitzgerald et al., 2015). Either due to the mutational 
spectrum, the influence of environmental and genetic heterogeneity of the affected 
individuals, or both, there is a large variability of clinical phenotypes within each set of 
affected DDD patients, despite all carrying mutations in the same gene.  Because of the 
large number of phenotypes associated with each disorder (254 in the ARID1B cohort, 116 
phenotypes in SETD5 cohort, 73 in the SETD1A cohort, 40 in ZMYND11 cohort), as well as 
many phenotypes described once per cohort, I filtered for phenotypes with occurrence of 
more than one proband per disorder for the SETD5, SETD1A, and ZMYND11 cohorts 
(Fig.5.1). For display purposes, filtering of more than two probands was applied for ARID1B 
cohort due to large number of phenotypes (Fig.5.1C). All the affected individuals were 
haploinsufficient for putative loss-of-function mutations in genes encoding chromatin 
modifiers. There was only one case of reported consanguinity (in the ARID1B cohort). Most 
parents in the trios were unaffected except one parent in the ARID1B cohort and both 




The most prevalent phenotypes across all the four disorders can be broken down into 
several broad groups (Fig.5.1). The majority of patients in the four disorders have global 
developmental delay, a term that encompasses both intellectual disability (ID) (ascribed to 
patients over the age of 18 who can be diagnosed using an IQ test) and cognitive 
impairment in children (diagnosed as a delay in achieving developmental milestones). The 
second most frequent set of phenotypes involves delay in speech and language. Craniofacial 
deformities, including defects of eyes/ears/face/head, are also common among the patients 
although these are not always consistent within each disorder. For example, in the SETD1A 
cohort, one patient was macrocephalic, while another was microcephalic. Motor issues, 
such as motor development delay and ataxia, and/or autistic features have been identified 
in several patients in each cohort. Aggression was the most common behavioural 



















Figure 5.1 Distribution of phenotypes and their occurrences in four novel monogenic disorders 
identified in the DDD study, associated with mutations in (A) SETD5 (N=25 probands), (B) SETD1A 
(N=11 probands), (C) ARID1B (N=60 probands), and (D) ZMYND11 (N=6 probands). Phenotypes 
with occurrence (%) in more than one proband, out of the total (displayed in the upper right corner) 
per disorder have been plotted for all cohorts, except ARID1B where filtering of more than two 
probands was applied due to the large number of phenotypes associated with this disorder. Those 
phenotypes with the highest occurrence (%) per disorder are displayed first in darker colours, with 





5.2.2  BCND screen design 
A series of tests were used, covering multiple behavioural domains. Less invasive assays, 
such as that testing locomotion and activity were run first to decrease the chance of 
behavioural outputs being affected by prior test history (McIlwain et al., 2001). This was 
followed by cognitive tests, which require more handling procedures prior to testing (Võikar 
et al., 2004). The assays used in BCND, listed in Table 8, were designed to test the most 
common overlapping phenotypes observed in patients under investigation, with a particular 
focus on cognitive impairment because the main consistent phenotype shared by patients in 
all the four disorders is global developmental delay (Fig.5.1). 
The most robust assays from Kptn work were used in BCND. The efficiency of an assay was 
judged based on three factors: 
1. The length of the protocol. Those that lasted up to a week were used, in order for 
the overall testing paradigm per mouse line to last 4 weeks.  
2. The robustness of the wildtype data, without which conclusive comparisons with 
mutant mice cannot be made.   
3. The ability of the assay to detect subtle behavioural and cognitive deficits.  
Because all the affected individuals were heterozygous for mutations in the genes under 
investigation, I tested heterozygous mice and littermate controls (n=10-15 per line per 
genotype). Testing began at 10-12 weeks of age, lasted 3-4 weeks, and culminated in the 
collection of brain samples (hippocampus, prefrontal cortex, striatum, and cerebellum) from 
n=6 of each genotype, as well as skulls from n=6 per genotype (Fig.5.2). The brain and skull 
samples were collected for RNA sequencing and micro CT imaging, respectively, for future 








Figure 5.2 BCND testing schedule flowchart. Sequence of tests in BCND screen are outlined and the 
duration of each assay, culminating in tissue collection (skulls for micro-CT imaging and brain 
samples for RNA sequencing).  
 
Assays Kptn BCND Reasons for inclusion/exclusion 
Open Field Y Y  
Light/dark box Y Y  
Social recognition 
(SOR) 
Y Y  
Barnes maze Y Y  




Y N Too many mice were excluded in the Kptn analysis to 
be viable for a screen (Chapter 4) 
Pairwise 
Discrimination 
Y N The assay duration is  too long (>1 months, including 





5.2.3  Behavioural abnormalities 
The mice were first tested using the open field (OF) assay under bright light (Chapter 2, 
section 2.3.1). The time spent moving, time in the centre, frequency of visits to the centre, 
velocity, and total distance covered was measured (Fig.5.3; Fig.5.4). Out of the four lines, 
only Setd1a mutants displayed a behavioural phenotype in this assay (Fig.5.3A). The 
Setd1a+/- mice spent longer moving than their littermate controls (mean difference: 
55.41sec, P=0.0121, t=2.684 df=28, two-tailed Student’s t-test), suggestive of an increased 
exploratory behaviour (Fig.5.3A). There was no significant difference between Setd1a 
mutants and controls in the overall distance covered, velocity of movement (Fig.5.4A). 
Setd1a+/- mice did not spend longer in the centre compared to littermate controls, an index 
of anxiety, but visited the centre more frequently than the controls (mean difference: 7.53, 
P=0.0221, t=2.422 df=28, two-tailed Student’s t-test) (Fig.5.3, Fig.5.4). None of the mutants 
from the other lines had significant differences relative to their littermate controls in any of 
the OF parameters (Fig.5.3, Fig.5.4). The data for percentage of time spent in the centre 
failed the D'Agostino & Pearson normality test for all the lines (Setd1a+/-: P=0.0437; Arid1b+/-
: P=0.0003; Setd5+/+: P=0.0021; Zmynd11+/+: P=0.0094), therefore the two-tailed Mann 











Figure 5.3 BCND open field results, part 1. The frequency of visits to the centre and time spent 
moving for four mouse lines is displayed. A. Setd1a mutants and wildtypes (+/+) littermate controls 
(n=15 per genotype). Setd1a mutant mice made more visits to the centre (P=0.0221*) and spent 
more time moving overall (P=0.0121*).  B. Arid1b mutants (n=11) and wildtypes (+/+) littermate 
controls (n=12) had no significant difference in the frequency of visits (P= 0.2344) and time spent 
moving (P=0.7191). C. Setd5 mutant (n=12) and wildtypes (+/+) littermate controls (n=24) had no 
significant difference in the frequency of visits (P= 0.2525) and time spent moving (P= 0.1055). D. 
Zmynd11 mutants (n=12) and wildtypes (+/+) littermate controls (n=14) had no significant difference 










Figure 5.4 BCND open field results, part 2. Non-significant results in (i) time spent in the centre as 
proportion of total investigation time (%), (ii) total distance covered, and (iii) speed while moving 
(velocity) between mutants and littermate controls for the four lines is plotted. A. Setd1a line. 
Centre: P= 0.0555; distance: P=0.12; velocity: P=0.76. B. Arid1b line. Centre:  P=0.44; velocity: 
P=0.95. C. Setd5. Centre: P=0.42; distance: P=0.41; velocity: P= 0.76. D. Zmynd11 line. Centre: 




To assess a possible anxiety-like phenotype, Setd1a+/- mice were tested in the light/dark 
assay (Chapter 2, section 2.3.2). The transition frequencies to the light zone, as well as time 
spent in the light zone, were measured in mutants and controls. The light/dark assay was 
established in our laboratory midway through the testing of the lines; I was therefore only 
able to run this assay on naïve mice from two lines - Setd1a and Zmynd11 (Fig.5.5). There 
was no significant difference, in mutants compared to controls, detected in both lines of 
transitions from dark zone to light zone (Setd1a: P=0.79, t=0.2740 df=23; Zmynd11: P=0.22, 
t=1.253 df=21; Two-tailed  Student’s t-test) or in time spent in the light zone (Setd1a: 
P=0.59, t=0.5475 df=23; Zmynd11: P=0.43, t=0.7963 df=21; two-tailed  Student’s t-test), 
implying a lack of anxiety-like behaviour (Fig.5.5). This also suggests that the increased 
frequency of visits observed in Setd1a+/- mice may be a consequence of increased 







Figure 5.5 BCND light/dark assay results.  Frequency of visits to the light zone and time spent in the 
light zone were plotted for mutants and their littermate controls (+/+). A. Setd1a: Freq visits: P=0.79; 






Because of the prevalence of autistic phenotypes in DDD patients overall and ARID1B (10%), 
SETD5 (12%), SETD1A (9%) - I used the three-chamber sociability assay (Chapter 2, section 
2.3.5; Fig.5.1). The time spent in the mouse and object zone and the preference for the 
mouse zone (%) was recorded (Fig.5.6). To ensure the investigation times are comparable 
between genotypes, overall investigation time was assessed (investigating both mouse zone 
and object zone). Setd5+/- mice spent significantly more time investigating both zones than 
their littermate controls (mean difference: 48.2sec, P=0.0068, t=3.036 df=19, two-tailed 
Student’s t-test), while in Arid1b mice the variance of the two genotypes differed 
significantly (F test P=0.0392), but the means were not significantly different (mean 
difference: -0.13 secs, P=0.64, t=0.7909 df=20, two-tailed Student’s t-test) (Fig.5.6A-B). 
There was no significant difference in overall investigation time between mutant and 
wildtypes in Setd1a (P=0.902, t=0.1234 df=26, two-tailed Student’s t-test) (Fig.5.6C).   
In order to account for the differences in overall investigation, I calculated the time spent 
investigating the mouse zone as a proportion of total investigation time. In Arid1b mice, 
there was a significant genotype difference in the preference for mouse zone, with an 
increase of 13% investigation of mouse zone by Arid1b+/- compared to the controls 
(P=0.0198, t=2.532 df=20, two-tailed Student’s t-test) (Fig.5.6A). There was no genotype 
difference in Setd5 and Setd1a mice in the preference for the mouse zone (Setd5: P= 0.95, 
t=0.06875 df=19, two-tailed Student’s t-test; Setd1a: P=0.51, t=0.6715 df=27, two-tailed 









Figure 5.6 BCND sociability results.  The overall duration spent near mouse and object zones for the 
mutants (red) and wildtype controls (blue) are displayed on the left in seconds and the preference 
for the mouse zone is displayed on the right as a preference score from 0-1, with 0.5 indicating no 
preference. A. Arid1b left graph: there was no genotype difference in the means of Arid1b overall 
investigation time but there was a significant difference in variance (F test: P=0.039). Arid1b right 
graph: there was a significant difference between genotypes (P=0.0198*), with an increase of 13% 
investigation of mouse zone in Arid1b+/- compared to littermate controls. B. Setd5 left graph: the 
Setd5 mutants had a significantly greater total investigation time of both holders (P=0.0068**).  
Setd5 right graph: There was no significant genotype difference in preference for the mouse zone 
(P= 0.95). C. Setd1a left graph: There was no significant difference in overall investigation times 
between genotypes (P= 0.9027). Setd1a right graph: There was no significant genotype difference in 
the preference for the mouse zone (P=0.51).  
 
5.2.4  Cognitive impairment  
Next, I assessed cognitive impairment in the mice, by using two cognitive assays – social 
recognition (Chapter 2, section 2.3.4) and the Barnes maze (Chapter 2, section 2.3.7), both 
testing overlapping cognitive domains associated with hippocampus-dependent learning.  
 
5.2.4.1 Olfactory-mediated memory  
Social recognition (SOR) assay (Chapter 2, section 2.3.4), is reliant on the inherent 
preference of mice to investigate an unfamiliar conspecific longer than a familiar mouse. To 
ensure mice do not have a bias for either of the stimuli before acquisition of memory, I 
tested naïve wildtype mice (n=12) of the same background strain for the presence of 
inherent preferences and did not observe any stimulus bias. The mice did not spend a 
significantly different time investigating either of the stimuli (mean difference: 5.1sec, P= 





Figure 5.7 No inherent stimulus bias was detected. Mice naïve to the assay did not show a 
preference for either of the two stimulus animals presented (P=0.57).  
 
I therefore proceeded with SOR assessment. On Day 1, there was an overall difference in 
investigation time across trials and no genotype difference for Setd1a line (trials: F (4, 68) = 
12.13, P<0.0001; genotype: F (1, 17) = 1.165, P=0.2955; two-way ANOVA), Arid1b line: trials: 
F (4, 44) = 6.494, P=0.0003; genotype: F (1, 11) = 2.784, P=0.1234; two-way ANOVA), 
Zmynd11 line: F (4, 106) = 11.76, P<0.0001; genotype: F (1, 106) = 1.269, P= 0.2624; two-
way ANOVA) (Fig5.8). Setd5 mice displayed a trial difference on Day 1, but also a genotype 
difference, with an increase in overall investigation time (trials: F (4, 112) = 14.81, P<0.0001; 
genotype: F (1, 112) = 10.28, P=0.0018; two-way ANOVA) (Fig.5.8B). On trial 5, for Setd1a, 
Setd5, Zmynd11 lines, both genotypes showed increased investigation of the novel stimulus 
when comparing the investigation during trial 4 and trial 5 (Setd1a: wildtypes: P<0.001, 
mutants: P<0.05; Setd5: wildtypes: P<0.001, mutant: P<0.01; Zmynd11: wildtypes: P<0.001, 
mutants: P<0.05;  post-hoc analysis after two-way ANOVA). Arid1b controls (n=6) did not 
display a significant difference in the post hoc analysis between trial 4 and 5, but did show a 
reduction in investigation between trial 3 and 5 (P<0.05) and trial 2 and 5 (P<0.05), while 
Arid1b+/- (n=7) did not display an overall difference across trials (two-way ANOVA), but there 
was a significant increase in trial 5 vs trial 4 when these were compared separately 
(wildtype: P= 0.0208, t=3.330 df=5; Mutant:P= 0.0157, t=3.334 df=6; two-tailed Student’s t-






Figure 5.8 BCND results for Day 1 of SOR.  Investigation time is plotted for wildtypes (+/+; blue) and 
mutants (red) for each of the four mouse lines. A. Setd1a line. There was a significant difference 
between trial 1 and 4 (wildtype: P<0.001***, Mutant: P<0.05*) and trial 4 and 5 (wildtype: 
P<0.001***, Mutant: P<0.05*). B. Setd5 line. There was a significant difference between trial 1 and 4 
only in the wildtypes (P<0.001***), but trial 4 and 5 in both genotypes (wildtype: P<0.001***, 
Mutant: P<0.001**). C. There was a significant difference between trial 1 and 4 (wildtype: P<0.01**, 
Mutant: P<0.05*) and trial 4 and 5 (wildtype: P<0.001***, Mutant: P<0.01**). C. Zmynd11 line. 
There was a significant difference between trial 1 and 4 (wildtype: P<0.01**, Mutant: P<0.05*) and 
trial 4 and 5 (wildtype: P<0.001***, Mutant: P<0.05*). D. Arid1b line. There was a significant 
difference between trial 4 and 5 (with Student’s t-test) (wildtype: P= 0.0208; Mutant: P= 0.0157). 




On Day 2, there was no difference in overall investigation time of the two stimuli between 
genotypes in any of the lines (Setd1a: P=0.09, t=1.785 df=19, Two-tailed  Student’s t-test; 
Setd5: P=0.6405, Two-tailed  Mann Whitney test; Zmynd11: P=0.88, t=0.1554 df=20, Two-
tailed  Student’s t-test; Arid1b: P=0.58 , t=0.5664 df=11, Two-tailed  Student’s t-test). 
(Fig.5.9A-D). The Setd5 data failed the normality test (wildtype P<0.0001, mutants P=0.0003) 
and therefore the difference in investigation time was analysed with a Mann-Whitney test.  
The wildtypes in all the lines were able to distinguish between unfamiliar and familiar 
stimuli and therefore spent significantly longer with the unfamiliar mouse (Setd1a: P= 
0.0078, t= 4.37891 df= 18.0; Setd5: P= 0.00022, t= 4.28034 df= 26.0; Mutant P= 0.033; 
Zmynd11: P= 0.014, t= 2.6401 df= 26.0; Arid1b: P= 0.016, t=2.87621 df=10.0, two-tailed 
multiple t-test with Holm-Sidak method corrections) (Fig.5.10A-D). The performance in the 
memory test varied in the mutants of the four lines. Setd1a+/- and Setd5+/- mice were able to 
distinguish between familiar and unfamiliar, and therefore spent significantly longer with 
the unfamiliar (Setd1a+/-: mean difference: 15.1sec, P= 0.00036, t= 2.95575 df= 20.0; Setd5+/-
:mean difference: 15.8sec, P= 0.033; , t= 2.29697 df= 20.0; two-tailed multiple t-test with 
Holm-Sidak method corrections), while Arid1b+/- and Zmynd11+/- did not spend significantly 
longer with either of the stimuli (Zmynd11+/- : P= 0.86, t= 0.182443 df= 16; Arid1b+/- P= 
0.399698, t= 0.873185 df= 12; two-tailed multiple t-test with multiple comparison 






Figure 5.9 Total investigation time on Day 2 of social recognition. Total investigation time of 
familiar and unfamiliar stimuli by wildtypes (+/+) and mutants in four mouse lines is shown. There 
was no genotype difference between total investigation times in all four lines. A. Setd1a line 
(P=0.09), B. Setd5 line (P=0.6405). C. Zmynd11 line (P=0.88). D. Arid1b line (P=0.58). Values are 





Figure 5.10  Day 2 SOR 24h memory test results. The investigation time of familiar (turquoise) and 
the unfamiliar (orange) stimuli by wildtype (+/+) and mutant mice from four mouse lines is shown. A. 
Setd1a line. Both genotypes spent longer investigating the unfamiliar mouse (wildtype: P= 0.0078**; 
Mutant P= 0.00036***). B. Setd5 line. Both genotypes spent longer investigating the unfamiliar 
mouse (wildtype P= 0.00022***; Mutant P= 0.033*).  C. Zmynd11 line. The wildtypes spent longer 
with the unfamiliar stimuli than the familiar (P= 0.014*), whereas the mutants did not show a 
significant difference in time spent next to either stimulus. D. Arid1b line. The wiltdypes spent longer 
with the unfamiliar stimuli than the familiar (P= 0.016*), whereas the mutants did not show a 






5.2.4.2 Spatial memory  
I then assessed spatial memory of the mice using the Barnes maze (Chapter 2, section 2.3.7; 
and as described in Chapter 4). Learning during training was assessed by measuring primary 
latency to reach the target and a total number of errors recorded before the mice went 
inside the escape box. Training was plotted either as an average performance per training 
day (Fig.5.11(i-ii)) or as a breakdown of all trials for each training day (Fig.5.11(iii)). Memory 
was tested during 24h and 72h probe trials, as the duration of time the mice spent at the 
target.   
In Zmynd11 and Setd1a lines, there was no genotype difference in the primary latency 
(Training 1: Zmynd11: F (1, 44) = 1.388, P=0.2450; Setd1a: F (1, 58) = 0.009076, P=0.9244; 
two-way ANOVA. Training 2: Setd1a: F (1, 89) = 1.123, P=0.2921, two-way ANOVA) and total 
errors made (Training 1: Zmynd11: F (1, 44) = 1.264, P=0.2670; Setd1a: F (1, 58) = 0.4114, 
P=0.5238; two-way ANOVA. Training 2: Setd1a: F (1, 89) = 0.3736, P=0.5426, two-way 
ANOVA) (Fig.5.11A,C).  
There was no significant difference in total errors made by Arid1b or Setd5 mutants when 
compared to the littermate wildtype controls during training (Arid1b: training N1: F (1, 62) = 
2.11, P=0.1514; training N2: F (1, 93) = 2.55, P=0.1137, two-way ANOVA. Setd5 training N1: F 
(1, 42) = 0.6573, P=0.4221, two-way ANOVA) (Fig.5.11B,D). However, Arid1b+/- and Setd5+/- 
mice were slower during Training N1, as measured by the primary latency to approach the 
target zone. There was an overall genotype difference in primary latency in Arid1b line (F (1, 
26) = 14.68, P=0.0007, two-way ANOVA) (Fig.5.11Di). Even though Arid1b+/- mice were not 
different to controls during the first trial (T1.1_1), by the last trial (T1.1_4) of T1.1 (Day 1 of 
TrainingN1) the mutants took significantly longer to approach the target hole than the 
controls as measured by primary latency (P<0.001, post-hoc analysis after two-way ANOVA) 
(Fig.5.11Diii). However, on the next day of training (T1.2) the mutants were able to perform 
as well as the controls throughout T1.2, as well as during training when the location of the 
target was reversed (T2.1-T2.3). There was no genotype difference in primary latency (F (1, 




way ANOVA) in the Arid1b cohort during Training N2 (Fig.5.11D). For Setd5 line, there was 
no overall genotype difference in the average primary latency training (F (1, 42) = 3.424, 
P=0.0713, two-way ANOVA; Fig.5.11Bi). There was an overall genotype difference in primary 
latency when the breakdown of trials was analysed (F (1, 168) = 4.751, P=0.0307, two-way 
ANOVA), but no significant genotype difference in primary latency between individual trials 
(P>0.05, post-hoc analysis of trial comparisons after two-way ANOVA) (Fig.5.11Biii).  
There was a significant overall difference in the investigation (%) of the 20 holes on 24h 
probe trial (Setd1a line: F (19, 580) = 22.13, P<0.0001; Setd5: F (19, 420) = 2.127, P=0.004; 
Arid1b: F (19, 570) = 12.94, P<0.0001; Zmynd11: F (19, 418) = 10.72, P<0.0001; two-way 
ANOVA), but no genotype difference in investigation of the target (hole N1) (P >0.9999 for 
all four mouse lines; post-hoc analysis after two-way ANOVA) (Fig.5.12A-D).  
During the 72h probe, Setd1a mutant mice spent the same amount of time near the target 
as the controls, however Setd1a+/- also spent significantly longer around the holes on either 
side of the target when compared to the controls (hole 10: P=0.0171, hole 12: 0.0399, 
target: P= 0.9998, post-hoc analysis after two-way ANOVA), with a greater standard error 
around the mean time spent near those holes (Fig.5.13A). This is indicative of a reduced 
specificity of memory, with mutants remembering the overall area where the zone is but 
show uncertainty as to the exact whereabouts by investigating the neighbouring holes 
significantly longer than wildtype mice. For the other two lines, Arid1b and Zmynd11, there 
was a significant overall difference between time (%) spent at the 20 holes during the 72h 
probe trial (Arid1b: F (19, 570) = 12.94, P<0.0001; Zmynd11: F (19, 420) = 5.012, P<0.0001), 






















Figure 5.11 BCND Barnes maze training. A. Setd1a line. Ai) Average primary latency per training day 
during training N1 (T1.1-1.2) and training N2 (T2.1-2.3), Aii) Average errors per training day during 
training N1 (T1.1-1.2) and training N2 (T2.1-2.3), Aiii) Total errors made per trial over all training 
days. There was no significant genotype difference in primary latency of approach to target and total 
errors made. B. Setd5 line. Bi) Average primary latency per training day during raining N1 (T1.1-1.2), 
Bii) Average errors per training day during raining N1 (T1.1-1.2), Biii) Primary latency to approach 
target zone per trial over all training days. There was an overall genotype difference in primary 
latency per trial (P=0.0307). C. Zmynd11 line. Ci) Average primary latency per training day during 
training N1 (T1.1-1.2) and training N2 (T2.1-2.3), Cii) Average errors per training day during training 
N1 (T1.1-1.2) and training N2 (T2.1-2.3), Ciii) Total errors made per trial over all the training days. 
There was no significant genotype difference in primary latency of approach to target and total 
errors made. D. Arid1b line. Di) Average primary latency per training day during training N1 (T1.1-
1.2) and training N2 (T2.1-2.3). There was an overall difference in the primary latency between 
genotypes and training days (genotype: P=0.0007, two way ANOVA), with a significant genotype 
difference on day 1 (T1) (P<0.001***). Dii) There was no genotype difference in the average errors 
per training day during training N1 (T1.1-1.2) and training N2 (T2.1-2.3), Diii) There was a significant 
genotype difference in primary latency in trial 4 of day one (T1.1_4) (P<0.001***). Values are plotted 







Figure 5.12 BCND 24h probe results. The percentage of time spent at each hole for controls (+/+; 
blue) and mutants (red) is plotted. For all four mouse lines there was a significant overall difference 
between % of time spent at the 20 holes, but no genotype difference in the investigation of the 
target (hole N1). A. Setd1a line, B. Setd5 line, C. Arid1b line, D. Zmynd11 line. Values are plotted as 









Figure 5.13 BCND Barnes maze 72h probe results.  The percentage of time spent at each hole for 
controls (+/+; blue) and mutants (red) is plotted, with the target at hole N11. A. Setd1a line. There 
was a significant genotype difference in the percentage of time spent at hole 10 and 12 
(neighbouring holes to target), but no significant genotype difference at the target (hole 10: 
P=0.0171, hole 12: 0.0399, target: P= 0.9998). B. Zmynd11 line. There was a significant overall 
difference between the percentage of time spent at the 20 holes, but no genotype difference in 
investigation. C. Arid1b line. There was a significant overall difference between the percentage of 
time spent at the 20 holes, but no genotype difference in investigation.  Values are plotted as mean 
± SEM. 
 
5.2.5  Summary BCND results  
The combined results across all four lines, as well as results from the previous testing of 
Kptn mice, are outlined in Table 9 (orange cells represent no phenotype, green cells 
represent the presence of phenotype, and white cells signify that the particular test was not 
done (ND) on that mouse line). By testing the same set of mice across a battery of tests, 
assessing several cognitive and behavioural domains, and screening multiple mouse models 
of novel distinct neurodevelopmental disorders in the same comparable manner using the 
BCDN screening paradigm, I was able to detect unique behavioural phenotypes for each 
loss-of-function mouse model investigated. However, recapitulating the full spectrum of 
phenotypes, as achieved in the Kptn mouse model, was challenging. This could be due to 






Table 9 Summary of BCND results compared to Kptn work.   
 
 
5.3 Discussion and future perspectives 
In this chapter, I describe the design of a behavioural and cognitive screening paradigm, 
BCND screen, which was used to characterize four loss-of-function mouse lines, each with a 
mutation in a gene, recently identified by Decipher Developmental Disorders (DDD) project, 
encoding a chromatin remodelling factor. Each of the four conditions modelled is associated 
with a variety of phenotypes that are variable between and within each disorder. By 
controlling environmental and genetic backgrounds in the mice, I can dissect the function of 
the candidate genes in a more focused manner than could be done in the patients. Because 
the patients in all four disorders are haploinsufficient, the four DDD mouse lines 
characterised here are dosage reduced for the genes under investigation. However, unlike 
with homozygous null models as Kptn, modelling haploinsufficient conditions is challenging 
as dosage sensitivity may vary between species. It is nevertheless preferable to use 
heterozygous mice when modelling heterozygous patients, in order to better recapitulate 





5.3.1  Behavioural impairments  
It is important to perform a careful assessment of all sensory function to all mouse lines 
entering the Behavioural and Cognitive Neurodevelopmental Disorder (BCND) screen, as 
sensory impairments may interfere with the performance of the mice and bias the results. 
All mouse lines underwent a systematic primary screening, assessing a broad range of 
physiological and neurological traits, as part of the Wellcome Trust Sanger Institute's Mouse 
Genetics Project (MGP), prior to being tested in the BCND screen (White et al., 2013). In 
addition, many assays used in the BCND screen, such as social recognition, have specifically 
inbuilt criteria that would flag relevant impairments in sensory domains. For example, in 
social recognition, mice that had olfactory or social deficits would not reach relevant criteria 
on Day 1 and would be removed from testing. Nonetheless, subtle sensory defects could 
have been missed out.  
Tasks that assess the overall behaviour of the mouse provide important information on the 
locomotor abilities and activity levels, which should be considered in the subsequent 
cognitive tests, as they may act as confounding factors. Setd1a+/- mice were the only mutant 
line to exhibit phenotypes on the first two initial behavioural tests – open field and 
light/dark assay. Setd1a+/- mice spent a long time moving in an open field and visited the 
centre more times, but did not spend a long time in the centre, when compared to their 
littermate controls. Besides, Setd1a+/- did not display behaviours in the light/dark assay that 
are associated with a reduced anxiety-like state, such as an increased transition to the light 
zone and longer time spent in the centre. Taken together the results are suggestive of an 
increased exploration and activity phenotype in Setd1a+/-. No anxiety was detected in any of 
the lines, which is consistent with the lack of anxiety phenotypes in the patients. 
Three mouse lines (Setd1a, Setd5, and Arid1b) were assessed for autistic-like phenotypes 
because the haploinsufficiency of SETD1A, ARID1B, and SETD5 were associated on average 
with autistic features in 10% of the patients. Autism spectrum disorder (ASD) is a 
neurodevelopmental spectrum disorder diagnosed by social and communication deficits, as 
well as repetitive behaviours (American Psychiatric Association, 2013).  ASD varies in 




complex task (Moy et al., 2004; Shibutani et al., 2017).  Mice are social species and their 
social behaviours have been extensively studied (Silverman et al., 2010; Winslow and Insel, 
2002). The sociability test assesses social deficits in mice and is reliant on the innate 
preference of mice to spend time in investigating a novel conspecific rather an inanimate 
object (Moy et al., 2004; Silverman et al., 2010). Mice with social deficits will have lower 
levels of social approach behaviour than the controls. Heterozygous Setd1a and Setd5 mice 
showed a preference for the mouse and not the object, suggestive of no detectable social 
deficit in these mouse lines. When the preference for the mouse zone was analysed in 
Arid1b line, the Arid1b+/- displayed an increased preference score for the mouse zone when 
compared to their littermate controls, implying no autistic-like phenotype in Arid1b+/-. In 
fact, there was an increase in preference for the mouse zone in the Arid1b+/- mice. Social 
deficit phenotypes were reported in two other recent studies testing heterozygous Arid1b 
mice. However, there were differences between behaviours reported by the two studies 
(Celen et al., 2017; Shibutani et al., 2017).  Shibutani et al. found milder behavioural 
abnormalities, and reduced social interaction only in a home-cage environment and not 
when tested using the sociability assay (Shibutani et al., 2017). The reported differences 
between mouse models with mutations in Arid1b may be reflective of the range of 
mutations and phenotypes associated with ARID1B pathologies (Celen et al., 2017; Yu et al., 
2015; Shibutani et al., 2017).  
 
5.3.2  Cognitive impairments  
5.3.2.1 Olfactory-mediated memory for conspecific 
In the social recognition (SOR) assay, the experimental design relies on the fact that the 
behaviour of test mouse towards a conspecific will change depending on whether the test 
mouse has the memory of prior interaction with the conspecific. Naïve mice presented with 
two stimuli investigate both mice without showing a particular preference for either. 
Conversely, as the test mice increase their exposure to a particular stimulus (Day 1, trial 1-4) 
they display a reduced interest in that stimulus over time. This is therefore a way to confirm 




the test animals have an intact olfactory system and do not have severe short-term memory 
impairment of up to 10 min. The mutant mice in each line displayed habituation to the 
stimulus over four trials and an increased investigation on trial 5 when a novel mouse was 
introduced.  On Day 2 of social recognition, Setd1a+/- and Setd5+/- mice were able to 
distinguish between familiar stimulus (from Day 1) and an unfamiliar stimulus, displaying a 
preference for the unfamiliar, indicating the haploinsufficiency in these mice is not resulting 
in a deficit in 24h memory retention in this assay. Zmynd11+/- and Arid1b+/- mice spent on 
average an equivalent amount of time investigating both familiar and unfamiliar stimuli, 
without showing a significant preference for either of the stimuli, which implies a social 
recognition memory deficit. However, due to the lower number of Arid1b mice tested in 
social recognition than the estimated sample size (power analysis, Chapter 2, section 
2.3.4.4), care must be taken when interpreting the results. Further studies with a larger 
sample size (n=9) would be necessary to confidently assess that Arid1b mutants show no 
evidence of learning. 
Moreover, since Arid1b+/- mice had an indication of a mild social deficit in the sociability 
assay, this could affect the overall preference of the mutants to investigate novel 
conspecifics, which SOR assay is reliant upon (Dias et al., 2016; Moy et al., 2004; Sanchez-
Andrade et al., 2005). Because diminished interest in novelty and avoidance of unfamiliar 
social entities has been described in some autistic individuals, social novelty preference test 
is widely used in autistic-like mouse models (American Psychiatric Association, 2013.; Moy 
et al, 2004; Moy et al, 2009; Shibutani et al., 2017; Silverman et al., 2010). Therefore, it is 
possible that the lack of preference for the unfamiliar over familiar is not due to lack of 
memory, but rather due to a deficit in the normal novelty-seeking behaviour of wildtype 
mice. In order to dissociate memory impairment from a social deficit, additional tests would 
need to be run, such as social novelty preference test, which can be run immediately after 
sociability, ensuring mice would still have the memory of the conspecific they were exposed 
to in sociability assay (Moy et al., 2004).   
At first, the discrepancy between the results of SOR and Barnes may appear contradictory, 
as both assays are known to be dependent on hippocampal function. However, the two 




The Barnes maze is a specialised spatial memory test and is primarily reliant on a functional 
hippocampus, while social recognition is an olfactory-mediated memory test and is 
additionally reliant on accessory olfactory systems, amygdala, and hypothalamus (Kogan et 
al., 2000; O’Leary et al., 2011). Furthermore, Barnes maze assay has the power to detect a 
larger spectrum of behaviours than the SOR assay, allowing uncovering subtle deficits which 
would not be possible by the SOR alone. 
 
5.3.2.2 Spatial memory  
Using the spatial memory test (Barnes maze), I found deficits in learning during training and 
72h memory retention in individual mutant lines. Arid1b and Setd5 mutants were slower 
during initial training (training N1), but did not display deficits in 24h memory retention, 
when subsequently tested during a 4-min probe trial, suggestive of a subtle learning deficit 
in Arid1b+/- and Setd5+/- mice. However, once Arid1b mutants acquire a strategy to find the 
target near the end of initial training, they no longer show learning deficits, during training 
N2, when the target location was moved. Setd1a and Zmynd11 mutant mice performed as 
well as the controls in training and neither displayed deficits in the performance during the 
24h probe. Of note, Zmynd11 mice did not undergo training N2, but rather were re-trained 
briefly with the same target location after the 24h probe and then tested for 72h memory 
retention during the 72h probe. Although this made Zmynd11 data not directly comparable 
to the other lines tested, the approach was useful in assessing whether a shorter protocol 
for memory retention in the Barnes maze could be used in future work, with the larger 
project in mind. Removing training N2 (the change in target location) allows for a cleaner 
comparison between 24h and 72h probe trials, without the potentially confounding effect 
of a change in training between the two memory tests (assessing different length of recall). 
It may, therefore, make sense, in future work, to schedule one day of training after the 24h 
probe and then test the mice 72h later. Other studies have addressed this by keeping both 
initial and reversal training the same length, and either kept a consistent interval between 
each probe trial or tested memory only after reversal training (O’Leary and Brown, 2009; 




Out of three lines tested on the 72h probe, Setd1a mutants were the only ones to display a 
phenotype. The mutant mice did not spend any less time around the target zone, but they 
did spend longer investigating the adjacent holes on either side of the target. This may 
indicate a component of uncertainty for the specific location of the escape box, but an 
intact memory of a larger region, including the target zone. The results are unlikely to be 
due to non-cognitive factors, such as hyperactivity, because during the 24h probe both 
genotypes spent equivalent time near the target hole without an observed difference near 
the adjacent holes. 
 
5.3.3  Concluding remarks and future perspectives 
In summary, I designed a specialised behavioural and cognitive screen, BCND, and used it to 
test four DDD mouse models. The approach taken with the BCND screen allowed for the 
identification of specific phenotypic repertoires for each mouse line, allowing for 
comparisons to be made between several novel developmental disorders (Table 9). For 
example, in the Barnes maze I detected slower acquisition learning in Arid1b+/- and Setd5+/-, 
but no memory deficit during probe sessions, while Setd1a+/- had a reduced specificity of 
spatial memory retention in the 72h probe which is suggestive of a mild memory deficit 
(Table 9). Moreover, the lessons learned about the practicalities and challenges of running 
such a screen helped shape the larger five-year project in Hurles group at the Sanger 
Institute.  
In order to develop therapies for rare diseases it is important to focus on those disorders 
where postnatal intervention can have a reasonable prospect of improving the patient’s 
condition, and where the pathogenicity of the disorder is not confined to a developmental 
time point. Although the four disorders modelled here have a broad array of different 
manifestations, if well targeted, elevating even a small subset of these could have a 
potentially significant benefit on the patient’s quality of life.  The conditional reversion 
approach in mice offers a good model for assessing whether reactivating postnatal gene 
expression can rescue some of the functional burden associated with the disorder. For this, 




approach has been successfully applied to the treatment of Rett syndrome (Buchovecky et 
al., 2013; Cobb et al., 2010; Guy et al., 2007). Moreover, postnatal reversal of a mutated 
Shank3 gene, associated with autism, successfully rescued the social deficits and neuronal 
function in the adult mice (Mei et al., 2016).  Encouragingly, in this thesis work, I was able to 
detect phenotypes in all of the mouse models characterised. The most promising for 
behavioural and cognitive rescue are Setd1a+/-and Arid1b+/- mice, because they display the 
largest repertoire of cognitive and social deficits.  A recent study has successfully rescued 
growth parameters in Arid1b+/- mutant mice and patients (Celen et al., 2017). 
Demonstrating a rescue of cognitive impairment would be a very powerful addition to the 
body of work implicating Arid1b as a promising therapeutic target for patients with ARID1B 




Chapter 6. Concluding discussion and future perspectives 
6.1 Concluding remarks  
Research focusing on the genetics of intellectual disability (ID) and other 
neurodevelopmental disorders has greatly expanded our understanding of the normal 
development of the brain and the fundamental mechanisms associated with cognition 
(Kaufman et al., 2010). In addition, advances in sequencing technology have facilitated an 
increase in diagnostic yield and enabled a higher discovery rate of rare and novel causes of 
ID. With a large number of novel neurodevelopmental disorders identified by genome-wide 
genotype-driven diagnostic efforts, there is an increasing demand for understanding the 
causal mechanisms underpinning these newly identified pathologies. In my thesis work, I 
focused on studying five such monogenic disorders associated with intellectual disability, by 
employing a multi-phase multi-model approach.  
To characterise the five mouse models, I have established and refined a series of 
behavioural and cognitive assays, described in Chapter 3, aimed at detecting phenotypic 
abnormalities in the mice.  By developing a robust phenotyping strategy, I then successfully 
characterised all five mouse models, capturing a spectrum of phenotypes reflective of those 
observed in patients. Combining this with morphometric, developmental, and molecular 
analyses I successfully characterised the Kptn mouse model in greater depth, described in 
Chapter 4, recapitulating all the main endophenotypes associated with a KPTN-related 
syndrome. Moreover, I gained further insight on the underlying pathogenic mechanisms 
associated with the disorder, opening the possibility of a treatment that could rescue some 
aspects of behavioural and cognitive impairments identified in the adults.  
Adapting the testing paradigm used with Kptn mice, I designed a specialised behavioural 
and cognitive neurodevelopmental screen (BCND), described in Chapter 5, which I used to 
broadly characterize Arid1b, Setd1a, Setd5, and Zmynd11 mutant mouse lines, modelling 
the four haploinsufficiency disorders. This approach allowed for identification of specific 
phenotypes for each of the four mouse lines, providing a platform for comparison between 




year project, which is starting in Hurles group at the Sanger Institute, aimed at 
characterising a larger number of human neurodevelopmental disorders. 
 
6.2 Characterizing intellectual disability in mice 
The strength of an animal model of disease can be measured by the degree to which it 
parallels the human condition, enabling the study of pathology in greater depth.  This is of 
particular importance for newly identified disorders, with unknown associated pathogenic 
mechanisms. Cognition involves multiple components, including various forms of learning, 
attention, decision-making, cognitive flexibility, and future planning (Nithianantharajah and 
Grant, 2013). These cognitive domains are homologous in mice and humans, with conserved 
underlying genetic and neuroanatomical mechanisms (Nithianantharajah et al., 2013). 
Therefore, in my thesis work, I have used inbred laboratory mice to dissect gene function 
associated with the human condition, while controlling for other environmental and genetic 
factors.  The mouse models thus facilitate the study of the primary causative role of the 
genes under investigation and their specific contribution to the phenotypes associated with 
the human condition, without the confounding effects of other factors. This is especially 
useful for disorders that have multiple associated mutations and variable phenotypes across 
patients, such as the ones described in Chapter 5 (ARID1B, SETD1A, SETD5, and ZMYND11 
haploinsufficiencies), as the mouse models provide a more simplified framework for 
investigating the direct gene-phenotype relationships than is possible in the humans. 
Many disease-causing mutations identified in the human genome cause 
haploinsufficiencies, yet heterozygous mice are less frequently characterised in knockout 
models compared to homozygous mice (Peça et al., 2011; Schmeisser et al., 2012; White et 
al., 2013). Although homozygous null alleles typically present the strongest phenotypic 
output and provide insight into the absolute requirement for a protein, they are not always 
reflective of the consequences of the human genotypes being modelled. It is therefore 
important to use the appropriate genotype of the mouse when modelling specific human 
disorders (Bakker et al., 1994; Cuthbert et al., 2007). In my thesis work, I have used 




with loss-of-function mutations in KPTN, as well as using heterozygous mice (Arid1b+/-, 
Setd1a+/-, Setd5+/-, Zmynd11+/-) for modelling disorders in which patients are heterozygous. 
Although the genotypes under investigation were chosen to best parallel the human 
condition and minimize animals used, testing heterozygous alongside the homozygous Kptn 
mutants can shed light on the dosage effect Kptn may have on the phenotype, as well as 
assess if there are any abnormalities detectable in the carriers, and should be explored in 
future studies. Likewise, testing the homozygous mutants for the latter four disorders would 
enable the assessment of the essential functions of the proteins. However, due to the 
essential function of chromatin remodelers, most of these disorders are homozygous lethal. 
This was, in fact, the case for Arid1b, Zmynd11, Setd5, and Setd1a mouse lines.  
The range of mutations modelled in this thesis work, including inherited recessive and de 
novo dominant variants, facilitated the exploration of multiple causes of human 
neurodevelopmental disorders and intellectual disability in one study. For the heterozygous 
de novo disorders, I purposefully chose from a larger set for which clear evidence exists that 
the consequence of the mutations is very likely loss of function. This was often revealed by 
the presence of multiple affected individuals in the human cohorts carrying truncating 
premature stop codons. Because of this prior patient information, I felt that it was best to 
analyse the loss-of-function phenotypes in mouse models as a first approach to 
understanding these disorders. Further work linking different genotypes to a varied 
phenotypic outcome (so-called genotype-phenotype correlations) will entail engineering 
patient-specific missense mutations, with further phenotype testing. The advancements in 
CRISPR technology makes this a feasible proposition (Doudna and Charpentier, 2014). As a 
separate case, for the modelling of the KPTN-syndrome, further work will be required to 
determine whether the in-frame duplication variant identified in patients produces any 
functional protein, displaying hypomorphic, gain-of-function, or potentially neomorphic 
activity. These are valuable analyses that will further enrich the first-pass characterisation 
that we have undertaken. Moreover, additional considerations should be made to validate 
whether the loss-of-function mutations truly result in no protein product in the mouse lines. 
In the Kptn mouse model (Chapter 4, section 4.2.1), the Kptn expression levels were 




Similar assessments should be carried out for other mutant lines. However, efforts were 
made to ensure true loss-of-function alleles were generated using sophisticated targeting 
strategies (Chapter 2, section 2.1) (Skarnes et al., 2011; Testa et al., 2004; White et al., 
2013).  
The assessment of behavioural and cognitive deficits in rodent models of 
neurodevelopmental disorders is typically carried out on adult mice, after the maturation of 
the central nervous system (CNS) (Bakker et al., 1994; Guy et al., 2001). A limitation of 
characterising only adult mice, however, carries a risk of missing the effects of mutations on 
the development of the function of the CNS. Because developmental disorders have an 
onset during development, the assessment of neonatal, pre-weaning, and adolescent mice 
can identify age-dependent behavioural, cognitive, and motor deficits, as well as providing 
potential therapeutic targets in phases of development where an intervention can lead to a 
higher chance of recovery (Altafaj et al., 2001). Multiple tests have been established to 
assess mice at various postnatal stages (Branchi and Ricceri, 2002). For example, testing 
homing and passive avoidance learning allow for the detection of cognitive deficits in pups 
in the first two weeks of postnatal life, while more complex tasks such as spatial learning 
have been applied to post-weaning age animals (Alleva & Calamandrei 1986; Chapillonet al. 
1995; Ricceri et al. 2000). It would be informative to explore Kptn deficiency on disease 
progression during development, using this approach. As discussed in Chapter 4, Kptn 
deficiency causes progressive macrocephaly (not present at birth) and cognitive deficits in 
the adult Kptn-/- mice. Once we determine the timing of the onset of macrocephaly in the 
Kptn-/- mice, the cognitive abilities of the Kptn mutant mice could be tested before and after 
this period, in order to clarify the relationship between the onsets of macrocephaly and 
cognitive development, and the contribution of the macrocephaly phenotype, if any, to the 
cognitive impairment observed in adults.  
Another domain that would be a valuable addition to the testing repertoire for modelling 
neurodevelopmental disorders is ultrasonic vocalisation, characterised by frequencies 
ranging between 30 and 90 kHz (Branchi et al., 2001; Scattoni et al., 2009). Ultrasonic 
vocalization rate follows an ontogenetic profile, increasing in the first postnatal week 




second postnatal week and can quantitatively analysed with minimal handling of the pup 
(Branchi et al., 2001; Scattoni et al., 2009). Ultrasonic vocalization pattern analysis has 
therefore been applied to study several neurodevelopmental models, including Rett 
syndrome and Down syndrome mouse models (Holtzman et al., 1996; Picker et al., 2006).  
Mecp2 null male and heterozygous female mutants (Rett syndrome model) exhibited an 
increase in ultrasonic vocalization as a response to social isolation, beginning at P5, while 
Ts65Dn mice (Down syndrome model) displayed delayed ultrasonic profile by four days 
(Holtzman et al., 1996; Picker et al., 2006). Moreover, it has been shown that mouse 
ultrasonic vocalization shares a common molecular mechanism with human speech and has 
been used to model speech-language disorders (Fujita et al., 2008). Ultrasonic vocalization 
can, therefore, be applied to model the speech and language delay detected in the DDD 
patients (Chapter 5). Speech and language delay is the second most frequent set of 
phenotypes in the four disorders under investigation in this thesis (Chapter 5), but has not 
been assessed in this thesis work and can, therefore, be an interesting future avenue to 
explore. Of note, care must be taken when different strains are tested, as considerable 
differences have been reported between different mouse strains (Hennessy et al., 1980; 
Roubertoux et al., 1996; Thornton et al., 2005).  
 
6.3 Translational power of mouse modelling  
An advantage of the current project design comes from access to clinical data and patients, 
through clinical collaborations, allowing for a two-way information flow, in which the mouse 
modelling is informed by clinical work and equally clinical work can be shaped by the 
research outcomes of mouse modelling. The initial clinical characterization of the 
undiagnosed patients is reliant on a broad set of clinical phenotype-driven observations. The 
patients then receive a genetic diagnosis, which clusters them into distinct conditions based 
on their genetic architecture. The phenotypes are then compiled for each condition and 
these are the set of phenotypes used to model these newly identified conditions in mice. 
Due to ease of genetic and environmental manipulations in mice, it is possible to perform 




clinical characterisation. For example, the patients with loss-of-function mutations in KPTN, 
described in Chapter 4, were diagnosed with global developmental delay and intellectual 
disability. I identified hippocampal-dependent memory deficits in Kptn-/- mice, but no 
difference in the performance of Kptn-/- when compared to wildtype controls in 
hippocampus-independent tasks. This provides an important insight into the effect of loss-
of-function of Kptn on cognitive output, implicating the hippocampus as an affected brain 
region. These results can then guide further hypothesis-driven examination of the patients. 
Translational research of such nature, shaped by the work in rodents, includes the Pavlovian 
fear conditioning paradigm that facilitated mapping of fear circuitry in rodents being 
adapted for human studies to test fear inhibition (Jovanovic et al., 2005; Myers and Davis, 
2004). 
To draw meaningful comparisons between species it is important to ensure that equivalent 
cognitive domains are tested.  The ideal way to achieve this is to test both mice and humans 
in the same manner. This can be achieved using automated touchscreen methods for 
rodents and the Cambridge Neuropsychological Test Automated Battery (CANTAB) 
touchscreen-based technology for patients (Bussey et al., 2012; Fray et al, 1996; Gur et al., 
2001). Equivalent tasks include delayed matching to sample task, testing working memory, 
and five-choice serial-reaction task, testing cognitive flexibility (Mar et al., 2013; Aggleton et 
al., 1988; Bussey et al., 2002; Égerházi et al., 2007; Falconer et al., 2010; Semenova, 2012).  
Kptn-/- mice did not display deficits in a visual pairwise discrimination task, run on the 
touchscreen. It would be of value to test the patients in the CANTAB equivalent task, intra-
extradimensional set-shifting, to assess whether they too perform normally. Similarly, 
determining whether patients have a spatial memory deficit, as was identified in the Kptn 
mutant mice, would allow for a more in-depth understanding of the impaired cognitive 
processes in the patients and allow for potentially better management of their symptoms. 
This could be assessed using a visuospatial learning and a touchscreen-based learning task in 
both mice (object-location paired associates learning task) and humans (paired-association 
learning task). The results outlined from the Kptn mouse model have been relayed to the 
clinicians working with the KPTN-related syndrome patients to encourage additional testing 




patients would heighten the relevance of this animal model, justifying further work. A 
similar approach was taken by Nithianantharajah et al. (2013), who tested Dlg2-/- mice, 
using visual discrimination acquisition and cognitive flexibility, and DLG2 deficient patients 
on the equivalent task, intra-extradimensional set-shifting, using the touchscreen platform. 
Those authors showed that the patients displayed significantly more errors than healthy 
control subjects in the task, consistent with the phenotype of Dlg2-/- mice, highlighting the 
conserved gene-phenotype relationship between the two species (Nithianantharajah et al., 
2013).  
 
6.4 The use of phenotyping screens as a modelling approach 
Although touchscreen technology proved to be a valuable tool when modelling the Kptn-/- 
mice (Chapter 4), the duration of the assays using this platform was incompatible with the 
requirements of screening paradigm, termed in my thesis as the Behavioural and Cognitive 
Neurodevelopmental Disorder (BCND) screen, in which each mouse line had to be tested in 
4-6 weeks (Chapter 5). However, touchscreen technologies can be a powerful method for 
hypothesis-driven secondary phenotyping for those models. Moreover, other technologies, 
such as the automated IntelliCage system (NewBehaviour), can be used as part of the initial 
screening paradigm instead (Krackow et al., 2010). This technology allows for automated 
cognitive and behavioural testing of individual mice in an undisturbed group environment, 
and contains operant testing areas in the corners of the cage, enabling testing in the home-
cage environment (Endo et al., 2011; Krackow et al., 2010; Mechan et al., 2009). This 
technology, therefore, maximises animal welfare, minimizes the human disturbance during 
testing, and allows for a high level of standardization. Furthermore, the testing can be done 
during active hours of the mouse, and not those artificially imposed by the working hours of 
the investigator. This technology can, therefore, be a powerful addition to the repertoire of 
tests in BCND. Since IntelliCage requires minimal human input, a second cohort can be run 
in parallel to the one being tested in the battery of tests outlined in Chapter 5, enriching the 
overall data collected. This method is less translatable to human testing than the 




otherwise be missed or confounded by other factors arising from a more stressful and 
artificial testing environment.  
The power of using inbred strains of mice allows for isogenic animals of completely identical 
genetic makeup to be analysed, leading to a strong reduction in variance compared to 
outbred populations. This also allows to determine the degree of phenotypic variability in 
the absence of any contribution from genetic background, a common confounder in human 
studies. However, it is important to recognise that any choice of inbred mouse strain for 
performing phenotypic tests may lead to the identification of strain-specific effects of gene 
mutations (Homanics et al., 1999; Keane et al., 2011). This must be taken into account when 
interpreting the findings in our studies, and in any comparisons between animal models and 
their human patient counterparts. Establishing and testing disease models on alternative 
inbred strains may help explain the contribution of genetic background to phenotypic 
presentation, but given the effort, expense, and additional use of animals required, may not 
be justified in most cases.   
The advent of human induced pluripotent stem cell (iPCS) in 2006, which are reprogrammed 
somatic cells that are induced into pluripotent state with embryonic stem cell-like 
properties, can provide a complementary approach for studying human disease and the 
associated biochemical and cellular processes (Takahashi and Yamanaka, 2006; Takahashi et 
al, 2007; Yu et al., 2007). hiPSC can be differentiated to various cell types, retaining the 
unique genetic signatures of the person they are derived from, allowing to study 
idiosyncratic patient-derived human neurons and their development. Therefore, a patient-
derived iPSC strategy can be used not only to study the pathogenic pathways of all the 
conditions discussed in my thesis work but also to generate and characterize multiple iPSC 
lines reflective of the mutational spectrum in the patients in parallel. This could be 
particularly beneficial for frequently mutated genes, such as ARID1B that is associated with 
11 independent loss-of-function mutations and over 200 phenotypes in 60 patients 
described here (DDD study, unpublished work).  
Many neurodevelopmental diseases have been modelled using the iPSC technology, 




molecular processes identified previously by mouse modelling and post-mortem human 
brain studies (Ananiev et al., 2011; Kim et al., 2011; Sheridan et al., 2011). However, these 
models had a one cell type approach, which poorly recapitulates the cellular complexity of 
the human condition. Subsequently, techniques have been established for co-culturing of 
more than one cell type derived from iPSCs, and more recently, 3-dimensional iPSC-derived 
organoids have been developed that enable the study of cell-cell interactions in more detail 
(Lancaster and Knoblich, 2014; Marchetto et al., 2008; McCracken et al., 2014). Although 
these technologies cannot recapitulate all the complexity of the brain, they provide a 
unique opportunity to dissect relevant processes associated with human condition using a 
human-derived tissue. A combinational approach, including animal modelling, genetics, and 
hypothesis-driven iPSC work can provide a comprehensive perspective on the disease being 
modelled. iPSC work will be conducted for the disorders discussed in this thesis, as part of 
the wider study. 
Behaviour-centric phenotyping, which has been extensively used in my thesis work, is one 
way of identifying the effect of underlying mutations on the final output of the central 
nervous system. However, this can be complemented with other non-behaviour based 
approaches. The central nervous system (CNS) contains a large variety of cell types, each 
with a unique gene expression profile. Gene expression profiles are reflective of the cellular 
diversity in the brain and can be used to detect changes in cellular states (Lein et al., 2007). 
Whole genome expression profiling, therefore, can be used as a genome-wide functional 
analysis tool and has been used successfully to classify tumours by their expression profiles 
(Golub et al., 1999; Perou et al., 1999). Obtaining expression repertoires for multiple 
different mutant models should allow for the identification of co-regulated transcript 
groups and potential functional connections between different disorders. This concept of 
functional discovery using a compendium of gene expression data has been used in 
mammalian cells and has provided functional annotation of small molecules and genes in 
yeast (Hughes et al., 2000; Lamb et al., 2006). Such an approach could be extended to 
molecular phenotyping of neurodevelopmental disorders, which could facilitate the 
identification of shared pathogenic pathways and modules in these disorders and identify 




transcriptome-driven approach. Firstly, the heterogeneity of cell populations within and 
between brain regions and their interconnectivity may require single cell and system level 
expression profiling, to resolve the complexity. Secondly, although transcriptomic provides 
great insight into disease states, the link between gene expression and protein levels is not 
always straightforward (Anderson and Seilhamer, 1997; Greenbaum et al., 2003). Therefore, 
an ideal strategy would involve both transcriptomic and proteomic profiling of several brain 
regions across multiple mouse and human cellular models.  
 
6.5 Treatment possibilities for intellectual disability  
One of the research areas lacking sufficient research is in the area of treatment of 
neurodevelopmental disorders and intellectual disability. Treatment for ID falls into three 
main categories: (1) treatment centred on elevating the comorbidities associated with the 
disorder with the aim of improving the patient’s functioning and life skills, such as 
pharmacologic treatment of behavioural disorders associated with fragile X syndrome 
(Lozano et al., 2015; Hagerman and Polussa, 2015); (2) treatment focused on early 
behavioural and cognitive intervention, appropriate education, and psychological support, 
which can improve the condition especially in milder cases of ID; (3) treatment that targets 
the underlying causes of ID, with the aim of mitigating the consequences of the disease, as 
has been done with dietary restriction of phenylalanine in phenylketonuria patients 
(Potocnik and Widhalm, 2013).  
The latter category of treatment is most desirable as it has the potential to ‘cure’ the 
condition or prevent the disease from manifesting itself in the first place, but is also much 
harder to achieve due to the genetic complexity of the disorders, often limited knowledge 
of the underlying mechanisms, and confounding effects of comorbidities.  A promising 
development in this area comes from the notion that it is possible to harness plasticity in 
the adult brain in order to improve cognitive function associated with developmental 
disorders in adulthood. Many mutations that cause developmental disorders affect genes 
that are expressed throughout life, and not only restricted to development. High level of 




in development where the structure and function of the brain is most malleable to change 
(Hubel and Wiesel, 1970). For example, the acquisition of language in humans has been 
shown to be constrained by specific ontological windows (Lenneberg, 1967). However, 
subsequent studies have shown that the adult brain retains features of developmental 
plasticity, for example, the structural changes in spines, axons, and dendrites observed in 
the adult cortex, and this plasticity can be manipulated by altering levels of cortical 
inhibition (Hensch et al., 1998; Florence et al., 1998; Trachtenberg et al., 2002; Tailby et al., 
2005; Sawtell et al., 2003; Sale et al., 2007) Increased levels of intracortical inhibition have 
been  shown to alter the plasticity in the adult brain to the levels observed during 
development (Spolidoro et al., 2008). Moreover, McGraw et al. have demonstrated that an 
inducible model of Rett syndrome recapitulates the constitutive mutant allele phenotypes in 
the adult mice, implying the pathogenicity of the mutation is not confined to a critical 
period in development (McGraw et al., 2011). Taken together, these findings highlight the 
potential possibility of rescuing the cognitive impairments associated with the disease, by 
reversing the causative molecular deficits of the disorder in the adult brain.   
The behavioural results from BCND provide an important initial characterization of these 
models. However, I would argue that on their own, the behavioural and cognitive 
phenotypes identified are not as informative as those from the Kptn mouse model. The 
patients with loss-of-function mutations in KPTN had a consistent set of phenotypes, 
facilitating testing for similar deficits in the Kptn mice, which is one of the reasons why this 
line was characterised more thoroughly. The other four disorders, with haploinsufficiencies 
in ARID1B, SETD1A, SETD5, ZMYND11, had variable phenotypes within each disorder. 
Therefore, because this variability in the four disorders made it challenging to parallel all the 
human phenotypes in the four mouse lines, the focus of the testing was to identify robust 
phenotypes in the mice which could be used when designing reversal experiments.   
Conditional mouse models offer a unique opportunity to test whether the phenotypic 
consequences of mutations could be rescued postnatally. However, most studies have 
focused on conditionally inducing a mutant allele, rather than reverting a mutant allele to 
wildtype (McGraw et al., 2011). The latter approach has been shown to successfully rescue 




MECP2 model of Rett syndrome and has led to the identification of novel therapeutic 
targets for treatment of Rett syndrome (Buchovecky et al., 2013; McGraw et al., 2011). 
Therefore, the repertoire of behavioural phenotypes in the four mouse lines Arid1b, Setd1a, 
Setd5, Zmynd11, detected by the BCND screen, and the potential of all the mouse lines 
under investigation to be conditionally reversed to wildtype, provides a strong foundation 
for future reversion work and facilitate treatment development.  
As discussed in Chapter 4, KPTN has recently been associated with a role as a negative 
regulator in mechanistic target of rapamycin (mTOR) signalling by Wolfson et al., (2017). 
This finding, in addition to the detected upregulation of differentially expressed genes 
associated with the mTOR pathway in the brain of Kptn-/- mice, and the hippocampus-
dependent memory deficit observed in Kptn-/- from behavioural testing, together imply a 
potential mTOR signalling-induced brain defect due to loss of Kptn function, which could be 
targeted with rapamycin, a clinically approved drug. Studies targeting other negative 
regulators of mTOR that are involved in brain development, such as Pten, Tsc1, Tsc2, have 
shown that postnatal rapamycin treatment can rescue the neurological symptoms caused 
by the loss-of-function of these regulators (Ehninger et al., 2008; Harrison et al., 2009; Kwon 
et al., 2003; Shin et al., 2017). Moreover, pharmacological mTOR inhibitors have shown 
clinical benefits in neurological disorders, such as tuberous sclerosis, and there are ongoing 
clinical trials in epilepsy, autism, and dementia, making mTOR related treatment for KPTN-
related syndrome a strong candidate for a successful bench to clinic translation.  
An interesting possible link between the five genes is their associated roles in carcinogenesis 
and brain development. Mutations in chromatin remodelling factors (CRFs) that happen 
later in life have been extensively associated with multiple types of cancer (Helin et al., 
2013; Vissers et al., 2016). Aberrant mTOR signalling has also been linked to many cancer 
types, and the recently identified role of KPTN as a mTOR negative regulator points to the 
possible involvement of KPTN in cancer, as has been shown with other negative mTOR 
regulators discussed above, such as PTEN, TC1, and TC2 (Johannessen et al., 2005; 
Johannessen et al., 2008; Shuch et al., 2013). It remains to be seen whether the children 
with KPTN-related syndrome develop any of these comorbidities. However, the potential 




carcinogenesis, which have been extensively studied over decades, could be used to 
facilitate the development of more effective therapies for both. 
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